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Abstract
Many psychotropic drugs have not been properly tested in clinical trials for efficacy 
and safety in children and adolescents. The increasing use of psychotropic drugs in 
young people is better established in North America; however, it is unclear to what 
extent these studies are applicable to UK practice.
Using data fi*om the UK General Practice Research Database (GPRD), an overall 
prevalence of psychotropic drug prescribing trend was initially carried out involving 
children and adolescents, aged 0-18 years, between January 1992 and December 2000. 
Upward prevalence of prescribing was observed in stimulants (aged 3-18 years), 
antidepressants (aged 13-18 years) and anticonvulsants (aged 6-18 years). Following 
this finding, two drug utilisation studies on stimulants and anticonvulsants were 
carried out. The use of antidepressants was not included, as its prescribing pattern had 
already been published elsewhere.
An increasing prescribing of stimulants was attributable to methylphenidate use. This 
was coincident with the change of methylphenidate licence status in 1995. The 
prevalence of methylphenidate prescribing significantly increased hom 0.01 per 1000 
patients (95%CI 0.004-0.02) in 1992 to 2.13 per 1000 patients (95%CI 1.92-2.36) in 
2000. The age-specific prevalence was highest between the aged 10-12 years. The 
most commonly diagnosis associated with its prescription was behavioural disorders. 
As some patients were taking methylphenidate as needed and some individuals may 
have stopped taking it during school holiday, this was problematic to measure 
methylphenidate exposure using a computerised database. Consequently, it was not 
possible to conduct further safety studies for methylphenidate use.
The second drug utilisation study on anticonvulsants has shown the incidence of 
prescribing remain stabled fi*om 1.40 per 1000 person-years (95%CI 1.41-1.57) to
1.05 per 1000 person-years (95%CI 0.90-1.22) throughout study period. The rate was 
highest in younger children aged 0-2 years. The use of conventional anticonvulsants 
appeared to decline whilst the use of newer anticonvulsants constantly increased. The 
majority of subjects prescribed anticonvulsant had a diagnosis of epilepsy.
A small proportion of anticonvulsant-treated subjects died during the study period. As 
sudden unexpected death in epilepsy (SUDEP) is a phenomenon which is not fully 
understood at this time, hence, a descriptive case series study was conducted to assess 
the causes of death. Unfortunately, this was not a successful approach due to the 
incomplete information recorded in the database. In addition, we did not utilise GPRD 
verification service to obtain additional information. As a result, this study did not 
provide any compelling evidence.
Due to the concern of an increasing use of lamotrigine (newer anticonvulsant) and the 
limited evidence of risk cutaneous reactions associated with anticonvulsants in 
paediatric population, a case-control study was subsequently conducted to investigate 
the association of severe cutaneous reactions (Stevens-Johnson syndrome, toxic 
epidermal necrolysis, erythema multiforme, exfoliative dermatitis) and 
anticonvulsants use. There was no evidence to show an increased risk of severe 
cutaneous reaction associated with anticonvulsant use (odd ratio: 0.93; 95%CI 0.48- 
2.05), several risks factors were found significantly associated with these conditions. 
It is suggested to use case-crossover study design to reassure our findings.
Ill
This thesis has illustrated strengths and limitations of using a computerised primary 
care database in the field of paediatric psychiatric research. It has provided an in- 
depth understanding of psychotropic drug prescribing patterns in young people in UK 
practice. Comparing it with published studies from North America, there is variation 
of prescribing trends between countries. It is suggested that GP questionnaire should 
be utilised in order to obtain additional information to confirm diagnosis and 
treatment. To collaborate with other countries in order to document psychotropic drug 
use in paediatric population at the multinational level is needed. Considerable 
research is still required to ensure that psychotropic drugs can be used appropriately 
in clinical practice.
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Chapter 1 Introduction
1.1 Drug use in children and adolescents
Children and adolescents are often excluded ftom clinical trials and, as a result, many 
marketed drugs have not been adequately studied in this population. The absence of efficacy 
and safety information in the paediatric population has been recognised for several years 
(Gadow 1991; Cote et ah 1996; Impicciatore & Choonara 1999; t Jong et al. 2002a). In 1968, 
Shirkey used the term ‘therapeutic orphans ’ to describe the fact that most drugs approved by 
the U.S. Food and Drug Administration (FDA) were not licensed for use in infants and 
children. This situation has not yet improved. In 1995, for example, a comprehensive review 
article by Kauffman indicated that about 80% of drugs approved by the FDA over the past 30 
years were not authorised for use in the paediatric population. This concern has also arisen in 
the United Kingdom (UK). Wilton and colleagues (1999) examined the use of newly 
marketed drugs in children and adolescents (aged 2-17) ft-om Prescription-Event Monitoring 
(PEM), a national non-interventional observational technique to monitor events which are 
associated with newly marketed drugs. There were 63 drugs introduced into the UK market 
between 1987 and 1997, of which 44 drugs were being prescribed to 9,081 children and 
15,256 adolescents; antibiotics and anticonvulsants were the most used drug groups. Of 9,081 
children, 37% (n=3,383) were given drugs for epilepsy treatment and 1,000 of these children 
(30%) received anticonvulsants that had not been licensed for use in children in the study 
period. For example, 50% of 1,419 lamotrigine heated children were given the drug before it 
was licensed to use in children (off-label use).
There are several reasons for excluding children and adolescents from clinical trials. The 
primary reason is that pharmaceutical industries generally have viewed children as a market 
that would only bring small financial benefits (Shirkey 1968; Cote et a l 1996; Sanz 1998;
1
Conroy et a l  2000; Sutcliffe 2003; Rose 2005). Ethical concerns mean that it is also difficult 
to recruit sufficient numbers of children to participate in clinical trials. Although children can 
assent with parents’ assistance, it is still difficult for them to fully understand the potential 
risk and other considerations compared to adults in similar situations. All these reasons lead 
to the pharmaceutical industry being reluctant to seek a product licence in this vulnerable 
population. Consequently, ‘off-label’ and ‘unlicensed’ prescribing to children occurs. 
Although off-label or unlicensed prescribing patterns in children should not imply improper, 
to extrapolate data from adult studies to children to determine efficacy and safety could 
possibly produce unknown consequences.
‘Children are not small adults’ (Shirkey 1968). Children are a heterogeneous group in terms 
of physiology, cognition, and motor function. In addition, pharmacokinetics and 
pharmacodynamics differ between children and adults; this even varies within different age 
groups in children (Cote et al. 1996; Simeon 1997; Moore 1998; Conroy et a l 2000). 
Evidence has revealed the physiological differences in children and adults, including a 
smaller proportion of body fat, lower renal excretion, and immature hepatic microsomal 
enzymes (Ritter et a l 1999). It can therefore be expected that drug responses such as efficacy 
and safety in children would be different from those in adults. Firstly, this could result in a 
failure of the treatment (under-treatment). An example of this would be that faster absorption 
rates have been reported for phénobarbital, carbamazepine in children, as a result, the serum 
drug concentration variation is larger and may lead to unwanted adverse effects or poor 
seizure control (Gilman et a l  2003). Secondly, it could result in over-treatment; leading to an 
increased risk of toxicity. The absorption rate in infant skin, for example, is higher than that 
in adults so the absorption of locally applied corticosteroids may be increased and may cause 
unexpected toxicity. Thirdly, as mentioned above, due to differences in physiology, it is not
reliable to extrapolate safety information from adult studies. It has been expressed that safety 
profiles in children differ from those in adults (Choonara 2002). Aspirin, for example, is safe 
for adult use but can cause Reye’s syndrome in younger children (Starko et a l 1980). Other 
instances such as neonatal deaths as a result of chloramphenicol-induced ‘gray baby’ 
syndrome (Sutherland et a l 1959). Over the past few years, several drugs have caused severe 
adverse drug reactions in children, so safety warning has been added to leaflet or the drug 
withdrawn from the market. Table 1.1 demonstrates some selected drugs presented in 
chronological order which have been reported to cause toxicities in children.
Table 1.1 Selected published adverse drug reactions (ADRs) in children.
Authors Year Drug Adverse drug reactions
Sutherland 1959 Chloramphenicol Grey baby syndrome
Donat et al 1979 Sodium valproate Hepatic failure
Starko et al 1980 Aspirin Reye’s syndrome
Gershanik a/. 1982 Benzyl alcohol Gaspine syndrome
MHRA report 1997 Lamotrigine Serious skin reaction
MHRA report 2000 Cisapride Cardiovascular effects
Parke et al 2001 Propofol Metabolic acidosis, hyperlipaemia, and hepatomegaly
MHRA report 2004 Paroxetine Suicidal behaviour
In general, drugs need to be frilly examined particularly before a product licence is granted. 
In the UK, ‘The Medicines Act 1968’ required all drugs to have been tested before market 
launch (Office of Public Sector Information). Each drug needs to have ‘marketing 
authorisation’ (previously known as ‘product licence’) granted from the Licensing Authority; 
Medicines and Healthcare products Regulatory Agency (MHRA) an executive agency of the 
Department of Health. Efficacy, safety and quality are all examined, since the active 
ingredients, formulation, conditions to be treated, solubility, potency, and balance of risk and 
benefit are all considered during the process of licence status. For those marketed drugs that 
have not been tested in the paediatric population, the information stated on the leaflet would
be ‘not licensed fo r me in children’ or ‘child under 16 years not recommended’. Given the 
limited information, physicians sometimes prescribe a drug to children and adolescents 
without clear knowledge of the efficacy, appropriate dosage, and safety in this population (’t 
Jong et a l 2002).
1.2 Off-label and unlicensed use
First it is necessary to clarify the terms off-label and unlicensed use. The definition developed 
by Turner et al. (1997) is adopted by most studies. According to Turner’s definition, ‘off- 
label’ is to prescribe a licensed drug outside the terms of the product, including indication, 
age, and contraindication etc. For example: clonidine is licensed only for the treatment of 
hypertension but is commonly prescribed for children with hyperactivity in clinical practice. 
The term ‘unlicensed’ is defined as:
• Medicines used prior to the granting of a license.
• Medicines that are licensed but the particular formulation is manufactured under a 
special manufacturing license.
• Medicines that are not licensed but are produced under a special manufacturing 
license.
• Use of chemicals as medicines.
• Modifications to a licensed medicine.
• Imported medicines.
A common example of unlicensed prescribing in children is to crush a tablet in order to make 
a suspension for use in children (Conroy er (?/. 1999; Banner 2002).
As noted above, the study of Wilton et al. (1999) indicated that ‘off-label’ use in children and 
adolescents is prevalent in the UK. Several studies have investigated the extent of off-label 
and unlicensed prescribing in children and adolescents. (Turner et al. 1996; Turner et al.
1998; Conroy et a l 1999; Chaulumeau et «/.,2000; Conroy et al. 2000; McIntyre et al 2000; 
’t Jong et a l 2001; Bucheler et a l 2002; Schirm et a l 2002; ’t Jong et a l 2002; Serreau et al. 
2005). A summary from these published studies presents in Table 1.2. Of these, only one 
study has exclusively examined one particular drug class. Serreau et a l (2005) carried out a 
prospective study in a psychiatric ward with children aged 3-15. Of 295 prescriptions issued 
to 162 patients they found about 48% (142/295) of prescriptions were either off-label or 
unlicensed, the most common of which were antidepressants, followed by antipsychotics and 
stimulants. Another issue of this widespread off-label and unlicensed prescribing is the lack 
of appropriate formulations and dosage (Nunn & Williams 2005), in particular appropriate 
formulations for infants and young children such as liquid dosage forms (Nahata 1999). A 
study from the Netherlands reported that a large proportion of young children received 
inappropriate oral formulations for treatment (Schirm et al. 2003). However, several factors 
need to be considered. The different drug references, settings, and samples (e.g. age groups) 
could all lead to variation between studies. In addition, the licensed status may have changed 
over time, so that the drug is no longer being used off-label or without a license. Therefore, it 
is difficult to compare these studies directly.
A hospital-based prospective study by Turner et a l (1999) examined adverse drug reactions 
(ADRs) records from five wards at Alder Hey Children’s Hospital between 1995 and 1996. 
Of 1,046 patients, a total of 4,455 prescriptions had been issued. There were 112 ADRs were 
associated with 2,881 licensed prescription (3.9%) and 95 (6%) of the 1,574 prescriptions 
were associated with off-label or unlicensed. The percentage of unlicensed and off-label 
drugs has shown a significantly associated with increased risk of an ADR (Mann-Whitney 
test p<0.0001). This indicated that children are at greater risk when they are being given off- 
label or unlicensed treatment.
Off-label and unlicensed prescribing patterns in children are widespread, this has been 
recognised as a global health care issue. Several new regulatory initiatives have been 
proposed to improve the current situation in the USA and Europe. This will discuss in more 
detail in the next section. The subsequent section reviews the recent initiatives, proposed 
regulations, draft guidelines, or press releases in both the USA and European Union (EU).
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1.3 Regulatoiy aspects
As discussed above, the lack of licensing and labelling of medicines for use in the paediatric 
population has been of continuinig concrn for many years. In the USA and European Union 
(EU), several initiatives have been implemented to tackle this situation.
USA developments
The U.S. Food and Drug Administration (FDA) has taken the lead in introducing several new 
initiatives to improve the situation. These include changing drug approval process policy, 
establishing new legislation and providing incentives to the pharmaceutical industry to cany 
out clinical trials in children. Listed below are thiee statutes regarding clinical research in the 
paediatric population that were amended to the 1938 Federal Food, Drugs and Cosmetics Act 
(FFDCA) (Fox 2005):
• the Food and Drug Modernization Act 1997 (FDAMA),
• the Best Pharmaceuticals for Children Act 2002 (BPCA),
• The Pediatric Research Equity Act 2003 (PREA).
Within FDAMA, the manufacturer could seek six months patent extension for conducting 
studies leading to paediatric labelling. This Act also provides financial incentives to conduct 
clinical trials in children. At the same time, a ‘Pediatric Priority List ’ was drawn up which 
identified a total number of 493 drugs as having a high priority for the use in the paediatric 
population. This action was meant to focus on drugs that were frequently used for children 
where the labelling information was insufficient, and manufacturers were required to carry 
out clinical trials in order to provide sufficient information on efficacy and safety in the 
paediatric population. This list is updated annually to remove drugs that now have paediatric 
labelling and to add new drugs (2001b).
In 2002, the Best Pharmaceuticals for Children Act 2002 (BPCA) came into force. Under this 
provision, any new drug that is expected to be prescribed to children and adolescents under 
the age of 18 years needs to be studied regarding the efficacy and safety for this population as 
part of the requirements for the FDA approval process. The BPCA requires the FDA to issue 
an annual list of drugs for which paediatric information is needed. In addition, the FDA is 
required to set up an Office of Pediatric Therapeutics in order to manage and facilitate the 
activities which are relevant to paediatric medical practice. In 2003, ‘The US Pediatric 
Research Equity Act (PREA)’ was released. It clearly points out that in order ‘to assess safety 
and effectiveness in all relevant paediatric sub-populations’, the manufacturers need to 
submit paediatric assessment data when submitting the New Drug Application (NDA). The 
proposition of paediatiic research on a voluntary basis is also encouraged under this 
provision.
In order to assess the impact of these regulations, the FDA compiles reports on their website. 
These reports cover various topics including efficacy-safety, pharmacokinetics-safety, 
pharmacokinetic-pharmacodynamic, and safety. Such reports are updated every six months. 
By implementing these new regulations, the FDA now progressively works to ensure that 
drug use in the paediatric population is safe, effective and of high quality. Furthermore, the 
National Institutes of Health has revised policy guidelines to encourage more research to be 
carried out in children and adolescents; the National Institute of Mental Health (NIMH) has 
already set up 7 research units for paediatric psychophaimacology where the efficacy and 
safety of the commonly used drugs for mental disorders are investigated (Jensen 1998).
Within the US governmental imperative, the evidence has shown an increased rate of clinical 
trials in children in the USA. Sammons and Choonara (2005) in examining the clinical trials
in children from Medline, indicated that clinical trials in the paediatric population have 
become more frequent over the 7 year study period (1996-2002), the rate was at a peak 
between 1996 and 1999. The authors noted this coincided with the new regulations in the 
USA. However, during the study period, the number of clinical trials in children remained 
constant in the EU; this means that the development of regulatory initiatives to encourage the 
conduct of clinical trials in the paediatric population has lagged behind in the EU.
European Union (EU) developments
There are approximately 75 million children aged 0-16 years in Europe, but more than 50% 
of drugs have not been authorised for their use (European Commission 2006). European 
countries have become aware of the absence of information relating to the use of drugs in 
children, together with the need to strengthen regulations in relation to the paediatric 
population.
In 1998, the European Commission at the EMEA (European Agency for the Evaluation of 
Medicinal Products) together with ICH (International Conference on Harmonisation) first 
agreed to support clinical friais in children. The ICH guideline (ICH Topic E l l )  under the 
title ‘Clinical investigation of medicinal products in the paediatric population’ was adopted as 
a European guideline, and it came into force in 2001. This guideline provides a broad view on 
the use of drugs in the paediatric population. The issues under this guideline are outlined as:
• Considerations when initiating a paediatric programme for a medicinal product,
• Timing of initiation of paediatric studies during medicinal product development,
• Types of studies (pharmacokinetic, pharmacokinetic/pharmacodynamic (PK/PD), 
efficacy, safety,
• Age categories, ethics of paediatric clinical investigation.
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Other specific considerations regarding the performance of clinical trials in children are 
issued separately, such as clinical safety data management (ICH Topic E2), and dose- 
response information to support drug registration (ICH Topic E4). In 2002, the European 
Commission released a consultation paper on 'Better Medicines fo r  Children- proposed 
regulatoiy actions in paediatiic medicinal products \  which addressed the issue of inadequate 
clinical trials in the paediatric population. This was the initial step taken by the European 
Commission followed the EMEA to resolve the issue of drug use in children and it aimed to 
build up a framework that could facilitate an improved situation (http://pharmacos.eudra.orgk 
In this paper, it was noted that about 50% to 90% of medical products used in children have 
not yet been evaluated. This initiative of ‘Better Medicines fo r Children ’ is still ongoing at 
this time. Six objectives were proposed as new EU regulatory initiatives:
• Increasing the availability of authorised medicinal products which are suitably 
adapted to the needs of children of different age groups,
• Ensuring that pharmacovigilance mechanisms are adapted to meet the challenges of 
possible long-term use in specific cases,
• Facilitating the avoidance of unnecessary studies through the publication of details of 
clinical trials already initiated and better exchange of information,
• Establishment of a list of priorities for research on existing authorised medicinal 
products in accordance with public health needs and which may include priority in 
different therapeutic classes,
• Developing European excellence in the field of research, development and assessment 
of clinical trials through a specific and dedicated committee within the EMEA and 
through a European paediatric network for performing paediatric studies.
• Ensuring that the highest ethical criteria are met.
Several ways of approaching these objectives were described in the paper, in particular the 
provision of more funding into paediatric research. To describe these approaches is beyond 
the scope of this thesis so no detailed discussion will be included. Although this is the first
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initiative in Europe, many of these approaches are similar to those in the U.S. Recently, the 
European Commission has drawn up ‘the Regulation on Medicinal Products for Paediatric 
Use’; this legislation came into effect in late 2006. In addition to this, the EU Parliament 
approved a new regulation to extend the patent by six months as an incentive to encourage 
the pharmaceutical industi y to provide drugs for use in children for the treatment of diseases 
such as cancer, AIDS, or psychiatric disorders (European Commission 2006). Under these 
regulation initiatives, the situation is deemed to have improved. It indicated that over 60 
labels of new paediatric information have been added to establish (Watson 2004).
Apart from the regulation efforts, more research in paediatric population is being carried out. 
In 1998, the European Network for Drug Investigation in Children (ENDIC) was established. 
Its intention was to set out more research in order to provide information on drug use in 
children (Bonati et a l 1999). The following year, the UK Royal College of Paediatrics and 
Child Health published a reference formulary Medicines for Children’, with the aim of 
providing clear information for health carers (i.e. paediatricians, pharmacists, and general 
practitioners) who prescribe, dispense or administer drugs to children. In July 2000, the UK 
Committee on Safety of Medicines (CSM) Paediatric Medicines Working Group (PMWG) 
was set up to advise the UK Licensing Authority with regard to regulatory issues and 
unlicensed drug use in children (MHRA 2006). In 2005, the first edition of the ‘BNF for 
Children’ was released as a joint publication of the British Medical Association (BMA), the 
Royal Pharmaceutical Society of Great Britain (RPSGB), the Royal College of Paediatrics 
and Child Health (RCPCH), and the Neonatal and Paediatric Pharmacists Group (NPPG). 
This book provides detailed information on use of drugs in neonates, infants, children and 
adolescents, and the information is updated annually (BNF for children 2005). In 2001, the 
Department of Health Standing Medical Advisory Committee also recommended that the
12
records of paediatric prescriptions should be kept for further research works (Department of 
Health).
13
1.4 Issues leading to this study
The development of regulations can oblige the pharmaceutical industry to study their 
products in the paediatric population. It also stimulates more research in this population 
through networking and creating flinding as a practical way forward. Although many efforts 
have been made, there is still much to be done. Evidence of this gap in research is clear from 
the FDA-mandated Written Request for pediatric studies, which shows that 
neuropharmacological products are the most frequently requested group (Table 1.3).
Manufacturers are not required to conduct a paediatric study in response to a Written 
Request, but this report shows the number of Written Requests and proposed pediatric studies 
for psychotropic drugs is high. Many drugs such as antibiotics, drugs acting on the respiratory 
system (e.g. anti-asthma drugs), drugs acting on the central nervous system (CNS), and 
vaccines, are being commonly prescribed to children and adolescents. However, many studies 
have documented a dramatic increase in the prescription of psychotropic drugs to children 
and adolescents in recent years (Zito et al. 2000; Zito et al. 2002; Zito et al. 2003; Schirm et 
al. 2001; Hugtenburg 2004; Fegert et al. 2006). In the FDA ‘Pediatric Priority List’, several 
psychotropic drugs appeared at the top of list. This reflects an urgent need for understanding 
on efficacy and safety in this drug group’s use in the paediatric population.
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Table 1.3 Paediatric assessments by FDA Center for Drug Evaluation and Research 
reviewing division, {source: FDA, 5.30.2006)
Review division Proposed Pediatric Study Written Requests*
Requests Received issued
Cardio-renal drug products 46 32
Neuropharmacological drug products 62 44
Psychiatry 3 0
Oncology drug products 30 35
Medical imaging and hematology drug products 7 1
Anesthetic, analgesia and rheumatology drug products 44 26
Gastro-intestinal and coagulation drug products 42 23
Metabolic and endocrine drug products 88 42
Anti-infective and ophthalmology drug products 23 32
Anti-viral drug products 27 28
Dermatologie and dental drug products 35 16
Non-prescription drug products 8 5
Pulmonary and allergy drug products 22 18
Reproductive and urologie drug products 12 5
Special pathogen and transplant drug products 18 13
Total 467 320
’ Written request; a legal document written by die FDA to inanufactuers requesting studies in tlie paediatiic population on a 
voluntary basis.
Similarly, a growth of psychotropic drug use in children and adolescents in the UK has been 
reported (Wong et al. 2003), but to what extent these drugs are used in this population 
remains unclear. This issue has gained national publicity especially the use of 
methylphenidate and antidepressants in recent years (The BBC News 2003; The Guardian 
2003; Boseley 2003). It is of concern because little research has been carried out to 
investigate prescribing patterns of stimulants to children and adolescents in the UK (Rey et al.
2003).
Several concerns regarding this growing trend of psychotropic drug use in children and 
adolescents need to be addressed. Firstly, many marketed psychotropic drugs have not been 
properly evaluated in terms of efficacy and safety in children and adolescents with 
psychiatric disorders, which is of even greater concern because the treatment of psychiatric
15
disorders is a chronic process and can also persist into adulthood (Simeon 1997; Vitiello 
1997b). As noted by Vitiello and Jensen (1997a), physicians prescribe psychotropic drugs to 
children based on the information for similar adult psychiatric disorders. However, as 
discussed above, drug absorption, distribution, metabolism and excretion differ between 
adults and children. Secondly, the development of the central nervous system and the 
neurotiansmitter system on which psychotropic drugs act is in a state of rapid change during 
childhood and adolescence. At present, there is limited knowledge about how these drugs 
affect the developing brain in the long term (Rey 2000; Coyle 2000). Thirdly, relatively few 
studies have been conducted to investigate adverse effects of psychotropic drugs in children. 
This is a particular concern for preschool age children because the long-term adverse effects 
on the CNS are unknown (Greenhill 1998; Minde 1998; Rey 2000). In addition, it has 
suggested that UK psychopharmacology in the paediatric population is under-developed and 
under-researched (Bramble 2003; Clark 2004).
In 1999, 1 in 10 children aged 5-15 in the UK had a diagnosis of a mental disorder 
(Department of Statistics). This figure implies more children and adolescents are being 
recognised as suffering with mental disorders. Consequently, it could possibly lead to a 
growing tiend of prescribing psychotropic drugs. Given the limited information from clinical 
trials and research in children and adolescents at this time, the characteristics of psychotropic 
drug use in this population remains unclear in the UK. Research to investigate the way these 
drugs are prescribed in UK practice is urgently needed. Therefore, the aim of this thesis was 
to investigate psychotropic drugs prescribing patterns and establish the safety profiles.
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1.5 Overview of thesis
The first two chapters contain background information relating to the study. Previous 
research that investigates psychotiopic drug prescribing in children and adolescents is 
reviewed in Chapter 2. The specific aims and objectives of this thesis are outlined in Chapter 
3.
Chapter 4 is concerned with the methods used to investigate psychotropic drug prescribing, 
including the database (the UK General Practice Research Database) database structure, data 
retrieval procedure, study population and age classification. The detailed methods i.e. 
prevalence calculation, and case-contiol study design are presented in each individual 
chapter.
The subsequent chapters contain three drug utilisation studies. The first study of prevalence 
of psychotropic drug prescribing presents in Chapter 5. Following this initial analysis, two 
drug utilisation studies are carried out in-depth. Chapter 6 describes methylphenidate 
prescribing in children and adolescents. Chapter 7 explores the anticonvulsant prescribing 
patterns.
After completing the drug utilisation studies, two risk assessment studies were carried out to 
investigate the risks relating anticonvulsant use in children and adolescents. Chapter 8 
describes a case series of sudden unexpected death in epilepsy (SUDEP) amongst 
anticonvulsant-treated children and adolescents. Chapter 9 presents a case-control study to 
investigate the association of anticonvulsant treatment and cutaneous reactions (e.g. Stevens- 
Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis).
17
Chapter 10 discusses the general findings, strength, limitations and clinical implications of 
studies present in this thesis. In addition, suggestions for further research in the context of 
established work are given in this chapter. Finally, the conclusions presente in chapter 11.
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Chapter 2 Literature review of psychotropic drugs prescribing in 
children and adolescents
2.1 Introduction
An article suggested that there is a dramatic increase in psychotropic prescribing to children 
and adolescents especially in the USA. This upward trend is primarily attributed to stimulant 
prescribing for the treatment of ADHD in children. Other conditions such as conduct 
disorder, depression, and psychiatric disorders as reasons for prescribing psychotropic drugs 
have also been reported (Conrad 2004). One of the leading authors, Zito, contributed 
considerably to our knowledge of psychotropic drugs prescription in young people. Her many 
studies were carried out in the USA. Two comprehensive studies by Zito et al. (2002; 2003) 
estimated overall prevalence of psychotropic drug prescribing using HMO and Medicaid 
databases in youths aged <20 years. Results demonstiated a significant increase in the use of 
antidepressants, lithium, antipsychotics, anticonvulsants, stimulants and a-agonists (clonidine 
and guanfacine) during the ten-year period. However, it should be noted that these two 
studies did not examine indications for prescribing. A study of Hunkeler et al. (2005), using 
data from Kaiser Permanente database in Northern California, estimated prevalence of 
antidepressant, lithium and anticonvulsant prescribing in youths aged 5-17 years over a 10 
year period (1994-2003). The level of antidepressants and anticonvulsant use increased 
significantly whereas lithium use remained stable during the study period. The authors 
investigated the indications for psychotiopic drug prescribing. It is striking that the 
percentage of anticonvulsant use for treating bipolar disorders was found to have increased 
from 4.8% in 1995 to 31% in 2003 whereas the treatment for epilepsy declined from 65% to 
39%. Analysis from a US psychiatric hospital (the Bradley Hospital, Rhode Island), showed 
an overall 3.9-fold increase in the psychotropic drugs use (from 490 drugs in 1991 to 1,915 in 
1998) in children and adolescents aged 4-18. The prescribing of antidepressants, mood
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stabilizer (carbamazepine, valproate, lithium), a-agonists (clonidine and guanfacine), 
stimulants (dextroamphetamine, methylphenidate and Adderall®) were all significantly 
increased over the 8 year period. The prescribing of antipsychotics did not show an 
increasing over time, but the use of atypical antipsychotics appeared higher than typical 
antipsychotics (Najjar et al. 2004).
Similarly, this increase trend of prescribing psychotropic drugs to children and adolescents 
has also been reported in Europe. In the Netherlands, using community phannacy data from 
the InterAction Database (lADB), reported that the overall prevalence of stimulants, 
antipsychotic, and hypnotic/anxiolytics dispensing has significantly increased, whereas the 
prescribing of clonidine and lithium remains fairly stable between 1995 and 1999 (Schirm et 
al. 2001). Another lADB-based study (1998-2000) also showed an increase of stimulant 
prescribing in youths aged <20 years (Faber et al. 2005). Hugtenburg et a l (2004) used 
PHARMO, a Dutch pharmacy database, reported that an overall increased of psychotropic 
drug prescribing between 1995-2001 and methylphenidate was attributed to this growing 
trend. A French study by Levy et al. (2006), examined the overall psychotropic drug 
prescribing in younger children (aged 0-5) in the Aquitaine region, data were drawn from the 
Extiaction Research Analysis for medico-economic follow-up (ERASME) database of the 
National Health Insurance System. In 2000, about 3.2% children (4,402/139,551) in the 
Aquitaine region had received at least one psychoti opic drug. Of these, the most commonly 
used psychotropic drugs were hydroxyzine (1.5%; 2,138/139,551), followed by diazepam 
(0.8%; 1,112/139,551). The most common indications for prescribing were sleep disorder 
(n=158) and behavioural disorders (n=87) in these younger children.
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This growing trend of psychotropic drug prescribing has also reported in the UK. Wong et ah 
(2004) used IMS DA database to compare psychotropic drug prescribing in nine countries: 
UK, France, Germany, Spain, Argentina, Brazil, Mexico, Canada and the USA between 2000 
and 2002. Overall prescribing of psychotropic drugs in children aged 0-17 rose in all nine 
countries and the UK had the highest percentage increase (68%). A national study (Clark et aL
2004) prospectively studied a cohort of children from 21 child and adolescent mental health 
services (CAMHS) in the North Western region of England. Following up 12 months (two 6- 
month period; September 1999 to February 2000 and September 2000 to February 2001), 845 
children (average age: 11.5 in boys and 13.6 in girls) were identified as being newly 
prescribed psychotropic drugs during the period covered. Hyperkinetic disorder (44%; 
372/845) was the most common indication and followed by depressive disorders (19%; 
157/845). Approximately 40% (n=334) of children were being issued stimulants and 24% 
(n=202) were prescribed selective serotonin reuptake inhibitors (SSRIs; anti depressants). 
Reasons for the discontinuation of psychotropic drugs were ineffectiveness (10%; 86/845), 
non-compliance (6.4%; 54/845), and intolerability (6.2%; 52/845). This study provides a 
clear understanding of psychotropic drug prescribing in youths in mental health care settings. 
It should be noted that this study cannot be generalized as young people can also received 
psychotropic drugs fi'om hospitals and general practices. An increase in psychotropic drug 
prescribing in UK practice has been demonstiated, however, these studies are not a fair 
representation of current practice, so the extent of prescribing in paediatric population 
remains unclear.
In order to have better understanding of how psychotropic drugs have been prescribed to 
young people. A literature review was initially conducted to evaluate prescribing trends of 
each individual psychotiopic drug class in children and adolescents. The outcome of interest
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of this literature review was prevalence of prescribing. We only included the leading 
psychotropic drug groups: stimulants, antidepressants, anticonvulsants and antipsychotics in 
the literature review. We considered the different methodology, sampling, and data source, 
and availability of psychotrpic drug products between countries so quantitative systematic 
review did not conduct. The descriptions of mechanism and licensed indications for each 
individual psychotropic drug class are initially discussed and followed by a literature review. 
In addition, the brief sections on the issue of concomitant psychotropic drug and factors 
which have reported to influence prescribing patterns are also discussed in turn.
2.2 Stimulants
Stimulants are drugs known to block the dopamine transporter and enhance dopamine release 
in the central nervous system (Segal & Kuczenski 1999). Currently, there are three stimulants 
in the UK clinic practice: atomoxetine, dexamefetamine and methylphenidate. The licensed 
indications for these drugs in children and adolescents are ADHD (attention deficit 
hyperactivity disorder) and hyperkinetic disorder (BNF Children 2005). Among stimulants, 
methylphenidate is extensively studied. This is possibly because dexamphetamine was 
licensed as an adjunct in refi'actory hyperkinetic children, so its usage can be expected not to 
be as prevalent as methylphenidate which was licensed mainly for ADHD treatment. In 
addition to this, estimates from UK community pharmacy dispensing revealed a steady 
increase in methylphenidate, in which 26,000 prescriptions were issued in 1992 and 254,000 
in 2001 (Figure 2.1). This increase was due to re-introduction of methylphenidate in 1995. It 
also illustrâtes that more children were being issued methylphenidate for treatment over a 
ten-year period. Although a growing tiend of methylphenidate use has been shown, little is 
known about to what extent this drug has been used in UK clinical practice especially in 
children and adolescents. This issue of limited information on stimulant prescribing in the
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UK has been noted (Rey & Sawyer 2003), with the authors suggesting that examining 
prescription trends is a way forward.
Figure 2.1 Total quantity of methylphenidate prescribed h orn community pharmacies in
England, 1992-2001.
300 -
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Year
Data source: Prescription Statistics Publications-Prescriptions Dispensed in the Community in England. 
(http://vvww.pubIicationSDoh.gov.uk/Drescrintionstatislics/index.htrn: accessed 18.11.2006)
Stimulants are licensed for the treatment of ADHD and hyperkinetic disorder. However, 
information on their usage in children under the age of 6 is lacking. Consequently, it is not 
recommended to prescribe these drugs to younger children. Pemoline, a stimulant, used to be 
licensed for ADHD treatment in children. However, following concern about the risk of 
serious liver toxicity, it was withdrawn from the UK market in 1997 (MHRA 1997). The 
National Institute for Health and Clinical Excellence (NICE) issued a guideline on the use of 
atomoxetine, dexamefetamine, and methylphenidate for treating ADHD in children and 
adolescents (2006). This guideline provides the effectiveness, prescribed dose, and cost of
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three stimulants use for ADHD. It provides a comprehensive understanding of stimulants use 
in young people with ADHD in clinical practice.
Literature review vrocess
A literature review was carried out to evaluate the prevalence of stimulant prescribing in 
children and adolescents. Original studies on drug utilisation studies, or cohort studies that 
include the reporting of prescribing trends of stimulants were sought in the MEDLINE from 
January 1966 to December 2005. The search criteria were designed to include drug 
utilisation, trend analysis and cohort study types that reported the use or prescribing of 
stimulants in young people aged 0-18 years. As we did not have capacity to translate other 
languages, the search criteria sought to only include papers published in English. A hand 
searching was also carried out to examine the reference lists of identified studies.
Selected studies were imported and managed in EndNote 9 (Thomson Reuters Corporation). 
Studies that clearly did not meet eligibility criteria were rejected on initial abstract review. 
Studies marked for inclusion were than obtained electronically or in paper copy. All studies 
of stimulants prescribing trend in children and adolescents were selected by MESH heading 
or text word combination: {methylphenidate or stimulants or attention deficit disorder with 
hyperactiviey) AND (child or paediatric or pediatrics or adolescents) AND {prescribing or 
drug utilisation) in the abstract or title.
Results:
The initial search identified 43 studies. Thirty-two articles were excluded. The reasons for 
excluding studies were: review articles (6), letters (7), no information on prescribing trend 
(11), and 6 studies reported over all psychotropic drug prescribing for ADHD treatment and 
did not report stimulants use separately, study subjects’ aged >20 years (1) and interview
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survey (1). Eleven studies were appraised in detail and assessed for inclusion. The studies 
are summarised in a tabular format (Table 2.1),
Most of studies were conducted in the USA. The data source to identify study subjects varied. 
This leads to the different prevalence of prescribing between countries. Prevalence was 
observed relatively high in Zito et al. (2003) study used 2 Medicaid database and 1 HMO 
database to estimate prescribing trends. Safer et aL (2000) identified students received 
methylphenidate through contacted schools and obtained information from school nurses. It is 
important to highlight that definition of stimulants was different between studies. There were 
5 studies only estimate methylphenidate prescribing (Rappley et al. 1995; Safer et al. 1996; 
Safer et al. 2000; Miller et al. 2001; Romano et al. 2002). Other studies included all 
stimulants (methylphenidate, amphetamines, dextroamphetamine, pemoline) as a drug group 
to estimate prescribing trend (Schirm et al. 2001; Rushton & Whitmire 2001; Shatin et a l 
2002; Cox et al. 2003; Zito et al. 2003; Faber et al. 2005). In addition, 2 studies by Safer et 
al. estimated prescribing trend in children with a diagnosis of ADHD (1996; 2000) whereas 
most studies did not specifically include children with ADHD but rather estimated prevalence 
in children received stimulants. Although stimulants are licensed for the treatment of ADHD, 
these drugs may also use for other psychiatiic disorder in clinical practice such as Tic 
disorder. Taking all these into account, it is not possibly easy to have direct comparison 
between studies. Nevertheless, an upward trend of stimulant prescribing in children and 
adolescents was observed in all these studies.
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2.3 Antidepressaiits
Anti depressants are the drugs that use to treat depression. A number of antidepressants have 
been established from controlled trials to treat other conditions such as panic disorder, 
enuresis, chronic pain, or obsessive-compulsive disorder (BNF Children 2005). According to 
the chemical structures, antidepressants are classified into three types: tricyclic 
antdepressants (TCAs), Selective Serotonin Reuptake Inhibitors (SSRIs), and Monoamine 
Oxidase (MAO) inhibitors (Bertram 2001). In BNF Children, it is stated that none of MAOI 
is recommended for use in children and adolescents. The absence of efficacy and safety of 
antidepressant use in the paediatric population is expressed. A warning appeared in the BNF 
Children, stating "^ the safety and efficacy o f drugs used in the treatment o f depression in 
children has not been established; long-term safety information is also lacking’.
In addition to limited information on efficacy and safety, little is known about how 
antidepressants have been prescribed to young people. A literature review was conducted to 
evaluate the prescribing trend of antidepressants in children and adolescents. The information 
on prescribing trend can provide us a better understanding of antidepressants use in this 
paediatric population.
Literature review vrocess
A literature review was conducted to evaluate the prevalence of antidepressant prescribing in 
children and adolescents. Studies on drug utilisation studies include the reporting of 
prescribing trends of antidepressant were sought in the MEDLINE from January 1966 to 
December 2005. The search criteria were designed to include drug utilisation, trend analysis 
and cohort study types that reported the use or prescribing of antidepressant in young people 
aged 0-18 years. Only English published studies were included, as we did not have capacity
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to translate other languages. A hand searching was also carried out to examine the reference 
lists of identified studies.
Selected studies were imported and managed in EndNote 9 (Thomson Reuters Corporation). 
Studies that clearly did not meet eligibility criteria were rejected on initial abstract review. 
Studies marked for inclusion were than obtained electronically or in paper copy. All studies 
of stimulants prescribing trend in children and adolescents were selected by MESH heading 
or text word combination: (antidepressant or selective serotonin reuptake inhibitors or 
tricyclic antidepressant) AND (child or paediatiic or pediatrics or adolescents) AND 
{prescribing or drug utilisation) in the abstract or title.
Results:
The initial search identified 134 studies. There were only 6 studies included in to this 
literature review. The reasons for excluding studies were: different outcome of interests 
(105), review article (8), study subjects’ aged >20 years (13), and clinical trial (2). The 
included studies were summarized in a tabular format (Table 2.2).
There was an overall increase in the prescribing of antidepressants in young people. Zito and 
Safer (2005) stated that this giowing trend of antidepressant use was due to ADHD and 
disruptive disorders in the USA. This is worrying, because FDA has not approved to use 
anti depressants for treating these conditions.
The prescribing trend varied between countries. In an analysis from North Carolina Medicaid 
database, Rushton and Whitmire (2001) reported the use of SSRIs steadily increased in 
children aged 1-19 during the years 1992 to 1998. In Italy, data from drug prescriptions 
showed that 1,200 of 1,600 patients aged <18 were issued SSRIs and 297 had a TCA in 2002. 
In addition, the prescriptions rate of SSRIs was found to have increased (from 0.47 per 1,000
28
to 2.11 per 1,000) between the years 2000 and 2002, yielding a 4.5-fold increased. A GPRD- 
based study by Murray et a l (2004) illustrated the use of SSRI was significantly increased 
whereas the use of TCAs declined in children and adolescents aged 0-18 between 1992 and 
2001. Fegert et a l (2006) using administrative claims data, showed TCA and St, John’s Wort 
were the most commonly prescribed antidepressants to children and adolescents in Germany.
There are two possible reasons to explain the difference prescribing trends between countries. 
In German study, authors included the herbal compounds (St. John’s Wort) into the analysis, 
whereas the UK and USA studies did not. Also, it should be noted that the study by Rushton 
and Whitmire (2001) only examined SSRI prescriptions which cannot generalise the overall 
antidepressant use. A recent study by Zito et a l (2006) has reaffirmed the variation of 
antidepressant prescribing between countries. They investigated one-year data (year 2000) 
from four countries: the Netherlands, Demark, Germany and the USA. Results suggested that 
antidepressant use was 3-fold higher in the USA by youths aged <20 than that in European 
counti'ies (1.63% vj:. 0.11-0.54%); the use of antidepressants was higher in male youths in the 
USA whereas female youths predominated the antidepressant use in European countries.
In conclusion, there is upward trend of antidepressants use in young people. This may due to 
antidepressants use for treating other psychiatric disorders in the USA. Reasons for increase 
use of antidepressants in this population remain unclear in other countries. A multinational 
comparison study clearly demonsti ated a variation of antidepressants use between counti'ies.
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2.4 Anticonvulsants
Anticonvulsants are a group of drug used to prevent or to control seizure in people with 
epilepsy. These drugs work in three ways (i) enhancement of GABAergic (inhibitory) 
transmission (ii) to reduce excitatory (usually glutamatergic) transmission or, (iii) 
modification of ionic conductance (Czapihski et al. 2005). After 1989, several newer 
anticonvulsants have been introduced into clinical practice and these drugs are classified as 
‘newer anticonvulsants’. These newer anticonvulsants were initially licensed as ‘add-on’ 
therapy, but monotherapy licences also being granted when effectiveness was evidenced from 
clinical trials. In general, the licensed indications for anticonvulsants are mainly for epilepsy 
treatment (seizure control), but other conditions have also been authorised. For example, 
sodium valproate was being approved for the treatment of acute mania associated with 
bipolar disorder (BNF Children 2005).
Although availability of anticonvulsants is expanding, many of these drugs still have not been 
fully investigated in the paediatric population (Trevathan 2000). The issue of limited 
information regarding anticonvulsants use in paediatric population, in particular new 
anticonvulsants, was addressed at National Institutes of Health workshop in USA. Several 
suggestions were made during the workshop such as conducting appropriate clinical trials and 
establishing post-marketing surveillance in safety (Sheridan & Jacobs 1996). An analysis of 
adverse drug reactions in children between 1964 and 2000 ftom the UK Committee on Safety 
of Medicines Yellow Card Scheme (YCS) showed that anticonvulsants as a drug group were 
most fiequently associated with death; newer anticonvulsants (e.g. vigabatrin, lamofrigine, 
topiramate and gabapentin) accounted for about 30% of these (Clarkson & Choonara 2002). 
This study did not examine the causality between anticonvulsants use and deaths, but it has 
raised concern whether death associated with anticonvulsant use in children.
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There are very few studies have been exclusively investigated anticonvulsant prescribing 
trends in young people. From our previous literature review, two studies have estimated the 
anticonvulsant prescribing trends in the USA (Zito et al. 2000; Zito et a l 2003). These two 
studies all demonstrated an increased prescribing of anticonvulsants. Zito and colleagues 
(2006) contended that no incidence or prevalence studies have examined the indications for 
anticonvulsant prescribing in children and adolescents. Hence, they carried out an utilisation 
study using the mid-Atlantic state Medicaid database. A total of 3,061 amongst 4,522 (68%) 
anticonvulsant-ti'eated youths (aged <18) reported that anticonvulsants were prescribed for 
treating psychiatric diagnosis rather than epilepsy. Of these, carbamazepine and valproate 
were the commonly prescribed anticonvulsant drugs. Authors stated that anticonvulsants are 
being prescribed as off-label to children and adolescents in the USA. Data from Tennessee 
Medicaid showed that amongst 647 new anticonvulsant users (aged 0-18 years), about 60% 
had a diagnosis of seizure associated with anticonvulsant prescriptions; the remaining 
prescriptions were issued for psychiatric disorders (Cooper et a l 1997). It is apparent that 
anticonvulsants are being prescribed off-label for psychiatric disorders in youths other than 
seizure control in the USA. As Zito et a l (2006) stated that a thoroughly investigation of 
anticonvulsant use in children and adolescents has not been well documented to date.
In the UK, it has reported that only 40% of patients have been referred to neurologists or 
paediatric neurologists (Hall et al. 1997). This indicates a large proportion of epilepsy 
children have not received adequate treatment. In addition, there is a shortage of neurologists 
in the UK clinic especially specialists with epilepsy expertise. To date, no study has been 
carried out in the UK practice, so there is no evidence to suggest how these drugs have been 
prescribed to children and adolescents. In addition, it is not appropriate to extrapolate US 
studies to UK practices as prescribing patterns may be different between countries.
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2.5 Antipsychotics
The terms ‘antipsychotics’ and ‘neuroleptics’ are used interchangeably to denote a group of 
drugs for the treatment of schizophrenia or psychoses. The mechanism of antipsychotics for 
heating these disorders is based on the dopamine hypothesis. It postulated these disorders are 
associated with an increasing dopaminergic function in the brain, and antipsychotics can 
improve the symptoms by blocking the receptors which are activated by dopamine (Horacek, 
et al., 2003). Antipsychotics are categorised into two groups: ‘typical agents’ (older 
antipsychotics) and ‘atypical agents’ (newer antipsychotics). This classification is not well 
defined but ‘atypical agents’ normally won’t cause extrapyramidal side effects (EPS), and 
elevation of serum prolactin which occurs in most typical antipsychotics such as haloperidol 
(NICE guidance 2002; Leonard 2003). It has been noted that the most commonly used 
antipsychotic in paediatric patients is risperidone (Quintana & Kesharan 1995), its use is not 
only in the treatment of schizophrenia but behaviour problems (e.g. ADHD), bipolar disorder 
or autism (Eapen et aL 2005; Findling et al. 2005).
An analysis of Tennessee Medicaid claims data through the years 1996 to 2001 revealed that 
new antipsychotics users (aged 2-18) for tieating ADHD, conduct disorders, and mood 
disorders increased 2.5-fold during the period covered (Cooper et al. 2004). The authors 
explained that prescribing antipsychotics for conditions other than schizophrenia results in 
this increasing trend. An analysis of Texas Medicaid prescriptions claim data during 1996 to 
2000, Patel et aL (2000) demonstrated that the use of typical antipsychotics amongst youth 
(aged 0-19) decreased by 1.1 per 1,000 enrollees, yielding 21% decreased rate whereas 
atypical antipsychotics with 13 per 1,000 enrollees increased rate (yielding 494% increased 
rate). Of which, risperidone was the most common prescribed drug, followed by olanzapine 
and quetiapine. The age-specific prevalence was shown to have increased at the age of 5-9
33
years (16 per 1,000 enrollees; 354%) and 10-14 years (30 per 1,000 enrollees; 173%); sex- 
specific prevalence was comparable in both sexes. Data from the National Ambulatory 
Medical Care Survey (NAMCS), a non-federally employed physicians office-based practice 
database, it revealed that the number of visits for antipsychotic prescriptions in youths (aged 
0-20) rose from 201,000 in 1993 to 1,224,000 in 2002 (Olfson et al. 2006). In addition, they 
also showed about 37.8% (70/173) of study subjects had diagnosis of disruptive behaviour 
disorder associated with an antipsychotic, 32% (48/173) had mood disorders. Similarly, a 
recent NAMCS-based study by Cooper et a l (2006) examined the antipsychotic prescriptions 
from 1995-2002 for those aged 2-18, it revealed the overall rate of prescribing increased fr om
8.6 per 1,000 US children in 1995-1996 to 39 per 1,000 US children in 2001-2002. Amongst 
these ADHD or conduct disorder was the most common diagnosis associated with an 
antipsychotic prescription. A GPRD-based study comprised of all age groups (aged 10-99) 
revealed an increase of prescription of antipsychotics fr om 10.5 per 1000 in 1991 to 12.2 per 
1000 in 2000, yielding an 16% increase rate (Kaye et al. 2003). Although this study did 
provide an overall view of antipsychotic prescribing in the UK practice, children under the 
age of 10 years were not included in the analysis so it cannot actually reflect the use in 
children and adolescents.
The growth of antipsychotics prescribing in children and adolescents is evident, with atypical 
antipsychotics use attributable for this trend. This growth has coincided with the introduction 
of atypical antipsychotics especially risperidone (Patel et a l 2002; Cooper et a l  2006). 
However, there is still no firm evidence to support the use of antipsychotics in children with 
behaviour problems (Cooper et a l 2006). Moreover, the information on the efficacy and 
safety information of the use of these drugs in the paediatric population is still lacking (BNF 
Children 2005).
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2.6 Hypnotics/anxiolytics
A guideline from CSM of benzodiazepine use in children and adolescents is outlined below 
(BNF Children 2005):
• Benzodiazepines are indicated for the short-term relief of anxiety that is severe, 
disabling or subjecting the individual to unacceptable distress, occurring alone or in 
association with insomnia or short-term psychosomatic, organic or psychotic illness.
• The use of benzodiazepines to treat short-term mild anxiety is inappropriate and 
unsuitable
• Benzodiazepines should be used to treat insomnia only when it is severe, disabling, or 
subjecting the individual to extreme distress.
Mancini et al, (2006) investigated anxiolytic, hypnotic and antidepressant use in adolescents 
aged 13-17 using data from French Health Insurance in 2002. A total of 3,286 adolescents 
were identified as having been issued with at least one prescription for anxiolytic, hypnotic, 
or antidepressant. Over 1 year period, there were 911 hypnotic prescriptions issued to 548 
adolescents in which the most commonly prescribed drugs were zolpidem (44%; 398/911), 
followed by zopiclone (20%; 184/911) and niaprazine (19%; 173/911). 3,752 anxiolytics 
prescriptions were issued to 2431 adolescents, and hydroxyzine was the most prescribed drug, 
accounting for 32% (1,192/3,752). Results of antidepressant prescribing showed that 
paroxetine was the most common antidepressant prescribed to adolescents, comparising 30% 
of antidepressant prescriptions (669/2,237). Apart from the overall examination of 
prescribing in anxiolytics, hypnotics and antidepressants, this study gave more details 
regarding individual drug use.
In comparison to other psychotropic drug groups such as stimulant or antidepressant, 
anxiolytics/hypnotics are far less studied. One explanation for this is that the indications for 
prescribing these drugs have not yet gained popularity. For example, to prescribe a stimulant
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for children with ADHD is more likely to draw public attention than sleep disorder in 
children. As the growing trend of psychotropic drugs becomes more evident, more in-depth 
research in this drug group is also needed. In addition, a clear understanding of the use of 
these drugs in anxiety disorders in children and adolescents is still unclear.
2.7 Concomitant psychotropic drugs use
The use of concomitant psychotropic drugs in youths is increasing especially in the US 
clinical practice. This is one of the reasons for the overall increase in psychotropic drugs use 
in children and adolescents (Safer et a l 2003). Data from four mental health centres in 
Maryland, suggest the average rate of concomitant psychotropic drug use in youths rose 
133% between 1990 and 1994 (Safer 1997). Of these, the most common concomitant uses 
were methylphenidate co-prescribed with clonidine and stimulants along with antidepressants. 
Prince et a l  (1996) reported that about 68% (n=62) of children and adolescents were being 
issued methylphenidate and clonidine for the treatment of ADHD. Rushton and Whitmire 
(2001), reported about 30% of 6,984 who were being given SSRI were also given a stimulant. 
However, this prescribing pattern is not prevalent in Europe. A study from the Netherlands 
indicated that the rate of concomitant use in children and adolescents ages 0 to 18 years was 
found to be low, suggesting that concomitant psychotropic drugs in this population was rare 
(Schirm et a l  2001). An Australian postal survey compiled by Efom and colleagues (2003), 
reported that use of concomitant psychotropic drugs in children and adolescents amongst 
specialists was prevalent, especially stimulant alone with clonidine. Martin et al (2003), 
using data from July 1998 to June 1999, reported the concomitant rate of 13.6% (1,286/9,447) 
to 18 year-old, antidepressants with antipsychotic was the most common combination (22%; 
282/1,286). Based on a review of many studies from Medline (1996-2002), Safer et a l  (2003) 
concluded that concomitant psychotropic drug in youths largely increased during the 1990s.
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This is the first comprehensive review article which was able to provide more knowledge 
about concomitant psychotropic drugs in youths at this time. It clearly demonstrated that this 
prescribing pattern is becoming accepted in clinics as a result the safety issues were noted, 
including drug-drug interaction and drug-induced behavioural toxicity after adding other 
psychotropic drugs. It is difficult to generalize the findings from these studies, as a broad 
range of definition on concomitant use i.e. a week, months or a year period was used. To date, 
a general consensus of psychotropic drug concomitant use has not yet been made.
2.8 Factors influenced prescribing patterns
Various factors have profound influence on psychotropic drug prescribing in youths, e.g., the 
study of Efron et al. (2003). It has been expressed that geography (rural vs. urban area), 
socioeconomic status, ethnicity, and data source can influence the drug use. Zito and 
colleagues (1998) examined the variation of psychotropic drug use in children in three 
databases in different regions: Medicaid administrative claims data ftom mid-Atlantic state. 
Health maintenance organization (HMO) in the northwest region of Kaiser Permanente, and 
National Ambulatory Medical Care Survey (NAMCS). It demonstrated the use of 
methylphenidate was higher in Medicaid than that in HMO, yielding 21.4 per 1000 enrollees 
and 10.3 per 1000 enrolees, respectively. Similarly, the use of antidepressant (desipramine) 
was 2.3 per 1,000 enrollees in Medicaid youths and 0.9 per 1,000 enrollees in HMO. 
Although this study did not analyse other factors, it illustrates different data sources could 
lead to the variation of prescribing. In 2003, a study of Zito et aL was able to examine the 
racial disparity in relation to the use of psychotropic drugs in children and adolescents. 
Results ft'om MAM (Medicaid data from mid-Atlantic state) and MWM (Medicaid data jftom 
a mid-western state), indicated the overall psychotiopic drug prevalence was higher in white 
Americans with 86.6 per 1,000 youths (95% Cl 84-89) in 1996 while 51.3 per 1,000 youths
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(95% CI 51-53) in African American. For the use of stimulants, white American and African 
American were 56 per 1,000 youths (95% Cl 54-58), and 31 per 1,000 youths (95% Cl 30- 
32), respectively. Similarly, the use of antidepressants was higher in white Americans than 
that in African Americans. Also, gender and age play an important role. For example, the 
overall psychotropic drug prevalence for 10- to 14- years-old group was higher than that in 
other age groups, yielding 129.4 per 1,000 youths (95% Cl 125-134). The use of stimulants 
was greater in boys than girls, with a prevalence of 60 per 1,000 per youths (95% Cl 56-62). 
These factors also reaffirmed by the studies of Zito and colleagues (2000; 2005).
Skurtveit et al. (2005) examined various factors amongst psychotropic drug users from Oslo 
National Health Screening Service, through the years 2000 to 2001, there were 7,307 
adolescents aged 15-16 participated. It demonstrated that health, physical and mental status 
had significant associations with psychotropic drug use whereas socio-economic and lifestyle 
factors were less likely to influence prescribing, gender was not found any different in 
relation to psychotropic drug use. Moreover, the variations amongst specialists’ attitude 
toward psychotiopic drug prescribing exist. The study of Efron et al. (2003), for example, 
noted paediatricians were more likely to prescribe stimulants (especially dexamphetamine) 
than child psychiatrists, whereas SSRIs was more likely to be prescribed by child 
psychiatrists than paediatricians. In addition, study by Mancini et al. (2006) noted the 
seasonal variation in relation to antidepressants and anxiolytics use especially in girls 
whereas this pattern did not occur in hypnotics users. During the summer holiday, the 
incidence of anxiolytics and antidepressants use decreased. They gave two possible reasons 
for such a unique pattern: the absence of prescribers themselves or the symptoms of an anxio- 
depressive improve during this period. Authors expressed that these assumptions needed 
further in depth research to explain this factor.
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2.9 Summai-y
To conclude, the prescribing patterns vary according to the population studied in terms of 
sampling, data source, geography, ethnicity, and socio-economic status (SES). This variation 
in psychotropic drug prescribing even appears between and within countries. It is, however, 
unclear to what extent these studies are applicable to UK clinical practice. This then leads to
the following questions concerning the use of psychotropic drug use:
• What are the characteristics of psychotropic drug prescribing in children and
adolescents in the UK clinical practice?
• Are the prescribing patterns similar to other countries?
• What kind of adverse reactions may occur in this population?
In order to answer these questions, a drug utilisation study can help to obtain a deeper 
understanding of prescribing patterns. As limited research has been carried out in UK, to 
examine the overall prescribing trend is the first step forward, which can give a
comprehensive knowledge of how psychoti opic drug have been prescribed to children and 
adolescents. Data source in this thesis were extracted from a large computerised primary care 
database in the UK. The specific aims and objectives of this thesis are outlined in the next 
chapters.
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Chapter 3 Aim and Objectives
From the literature review (see Chapter 2), a marked growth of psychotropic drug use in 
children and adolescents has become evident in recent years. Many of these studies were 
carried out in the USA using computerised databases such as Medicaid. In the UK, the 
research into this issue is far behind that of the USA. As a result, little is laiown about the 
characteristics of youths who received psychotropic drug treatment in UK clinics. As the 
treatment of psychiatric disorders is a chronic process and in some children and adolescents 
the conditions will persist into adulthood, further investigation is warranted. Pharmaceutical 
companies have been reluctant to seek licences in this population, so many drugs are being 
prescribed off-label or are unlicensed. It has been shown that the risk of adverse drug 
reactions is greater in off-label or unlicensed uses than recommended indications (Turner et 
al. 1999) To date, safety profiles in psychotropic drugs in the paediatric population have not 
been well established especially in long-term use. It implies that when clinicians prescribe 
they do not have clear knowledge on the risk of adverse reactions. This is also true for parents 
and children themselves.
The aim of this thesis is to investigate psychotropic drug prescribing and to ascertain 
the risk of these drugs in children and adolescents in general practice in the UK.
In the 1990s, several psychotropic drugs were introduced onto the market. These drugs not 
only provide more options for treatment of psychiatric disorders, this is reflected in-the 
prescribing patterns. The initial aim of this thesis was to describe prevalence of psychotropic 
drug prescribing during the past ten years. This analysis provides the overall picture of how 
these drugs were being prescribed to children and adolescents. This analysis will highlight 
areas worthy of more in-depth investigation.
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Objective 1
The first objective of this study was to estimate overall prevalence of psychotropic drug 
prescribing in children and adolescents aged 0-18 during the years 1992 to 2000, including 
sex-, age-specific prevalence, and the boy/girl prevalence ratio.
The results from this stage of the investigation are presented in Chapter 4, demonstrating that 
anticonvulsants and antidepressants were the most frequently prescribed psychotropic drug 
classes, and a dramatic increase in stimulant prescribing also appeared, in particular 
methylphenidate. Antidepressant use was not included for further analysis in this thesis. The 
reason for this was that a thorough investigation of antidepressant prescribing in youths had 
been completed using the same version of GPRD (see chapter 2). Therefore, the second 
objective of this study was to investigate the use of stimulants and anticonvulsants.
Objective 2
The purpose of an utilisation study is to provide the knowledge of prescribing patterns in a 
particular population i.e. indication for prescribing, concomitant medication, and co­
morbidity. This kind of study is also a very practical way to investigate the rationale of drug 
use i.e. to examine the association between recommended guidelines and actual practice in 
clinical settings. In addition, an utilisation study has important implications for further risk 
assessment studies. Following such broad perspective of drug use, some relevant issues 
regarding drug use may occur. Thus, in the subsequent analysis the focus was on stimulants 
and anticonvulsants. Two utilisation studies were carried out to characterise methylphenidate 
and anticonvulsant prescribing in children and adolescents ages 0 to 18 years. The specific 
objectives of these two utilisation studies and the results present in chapter 5 and 6.
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These results have an important implication for subsequent works. Firstly, a small proportion 
of anticonvulsant-treated children and adolescents died during the period covered. This led to 
the question of what was the cause of death: poor epilepsy management, underlying 
conditions, epilepsy itself, or adverse drug reactions. Secondly, the level of new 
anticonvulsant use increased to replace prescribing of drugs that had been on the market for 
longer in particular lamotrigine. Although the new anticonvulsants appear to offer 
considerable improvement in terms of tolerability, the warning of severe skin reactions in 
lamotiigine treated children has been clearly expressed in BNF for Children. In general, skin 
disorder is the most notorious adverse effect of anticonvulsant treatment. In some patients, 
unfortunately, this adverse effect can develop into life-threatening conditions such as 
Stevens-Johnson Syndrome. Therefore, a case series and case-control study were conducted 
to gain more in-depth understanding of anticonvulsant use and safety in this population.
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Objective 3
As sudden unexpected death has been often linked to people with epilepsy (sudden 
unexpected death in epilepsy; SUDEP), a case series study was carried out to examine 
SUDEP in the current study population and to identify any potential signals that a particular 
anticonvulsant drug may be implicated. This study is described in Chapter 8.
Objective 4
To investigate the risk of severe cutaneous adverse reactions (i.e. Stevens-Johnson syndrome, 
toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis) associated with 
anticonvulsant use in children and adolescents. This study presents in the Chapter 9.
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Chapter 4 General Methods
4.1 The UK General Practice Research Database (GPRD)
The source of data for this thesis was the UK General Practice Research Database (GPRD). 
The GPRD is the largest source of longlitudinal data from general practice in the UK. 
Anonymised data are available for about 40 million patient years and the population covered 
is demographically similar to the UK general population. Studies on mortality, hospital 
admissions, cancer registration and prescribing have yielded figures similar to those from 
other sources (Office for National Statistics; Prescription Pricing Authority, etc) (Hansell et 
ah 1999; Hollowell 1997). The GPRD was initially developed by Dr. Alan Dean in 1987. 
Since then the data collection started was from confributing practices and the amount and 
quality of the data have increased over the years. Most data are considered to have reached 
research standard (‘up-to-standard’). Data entered into the GPRD came from Value Added 
Medical Products Ltd (VAMP Ltd.) software, which was designed for general practitioners 
(GPs) to maintain patient records. Therefore, it was known as the VAMP Research Database 
(Mann et ah 1992). The participating GPs submit records at regular intervals, following the 
agreed guidelines for recording clinical and prescribing data. In 1993, Reuters Health 
Information acquired VAMP Ltd and donated the database to the Department of Health 
(DOH) for health research puiposes on a non-profit making basis, and renamed the database 
the GPRD. Since then, the database has been managed by the UK DOH. At present, it is 
being maintained by the Medicines and Healthcare products Regulatory Agency (MHRA).
The GPRD holds anonymous patient data, including demographic, diagnoses and symptoms, 
details of issued prescriptions, results of investigations, and hospital referrals and admissions. 
The population in the GPRD represent about 5-6% of the UK population. The age and sex
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distribution of the patient population in the database at any point in time is broadly 
representative of the population in England and Wales (see Figure 4.1). There is no accurate 
official figure for the population who are registered with a GP, however figures gathered by 
the Royal college of General Practitioners estimate that about 98% of the UK population is 
registered with a GP (htto://www.rcgp.org.ukl. As noted by Lawrenson and Farmer (1999), 
those who do not register with a GP often include the homeless or those who choose not to 
register, the majority of which are young male and ethnic minorities. Nevertheless, the 
majority of prescriptions are issued by GPs (Walley & Mantgani 1997). The database 
therefore is able to provide a denominator to estimate prevalence and incidence in a way that 
cannot be done by hospital-based studies.
Accuracy o f  GPRD data
Data from each practice is subject to quality control check for accuracy and validity. Each 
practice has been assigned an ‘up-to-standard date’: the date the practice started providing 
data deemed to be of research standard by the management of the GPRD (Walley & 
Mantgani 1997). For each practice, the data are left-censored by the ‘up-to-standard’ and 
right-censored by the date of last data available from that practice. A crucial concern for any 
computerised database is validity, which includes completeness and accuracy of recording. 
The quality and completeness of the data have been shown to be high (Hollowell 1997). Van 
Staa et a l (1994) investigated hypoglycaemia diagnosis on VAMP database by comparing 
the information fr om hospital discharge summaries alone with GP’s questionnaires. In 269 
practices, about 91% of hypoglycaemia diagnoses were recorded on the database at the time. 
With regard to the accuracy of diagnosis, this could be dependent on the conditions being 
recorded and supporting evidence such as relevant treatment, hospital admission, or hospital 
discharge letters. This supporting evidence can increase the likelihood of the diagnosis being
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valid. For example, to assess if a case has venous thromboembolism (VTE), evidence of 
anticoagulation treatment increases the reliability of a diagnosis. Within the recording of 
hospital admissions, a completeness of about 73% on a VTE study (Lawrenson et al. 2000) 
and 93% on inflammatory bowel disease (Lewis et al. 2002) was demonstrated. Another 
means of enhancing the accuracy is going back to the GP and asking for particular 
confirmation. Examples of studies on accuracy of diagnosis include the VTE study by 
Lawrenson et al. (2000) and Nazareth (1993) on psychosis.
Figure 4.1 The GPRD population compares with the England and 
Wales population in 1998. {data source: Office for National Statistics 1998.)
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Practical issues o f GPRD
In the GPRD, when a patient registers with a practice that is contributing to the database and 
generates data which satisfies quality check (up-to-standard), the clinical and prescribing 
information of this patient will be available on the GPRD. The date of up-to-standard is also 
referred to as ‘left censor date’. Similarly, the date which data cease to be contributed to the 
database- ‘right censor date’. This may be when the patient left the practice or died. However, 
information collected prior to the date of the patient’s registration with the general practice 
remains unknown. For example, diagnoses before the left-censor date might be missed and a 
relevant event may not be detected after right-censor date.
Figure 4.2 Schematic to illustrate GPRD censoring issues
Left censor date Right censor date
Study window
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The issues of censoring might have an impact on identification of cases, exposure status and 
confounding factors. For example, patients’ diagnoses made before the left-censor date may 
have been missed. Similarly, relevant diagnoses might occur after the right-censor date. This 
issue is particularly important on detecting incident cases. The method of ‘run-in period’- 
patients have a certain period of registration after the left censor date- can be used to establish 
whether conditions or exposure of interest are the first event. This is particular important in 
selecting incident cases. A study has conducted to investigate this issue in different 
conditions. It is suggested that in chronic conditions need to exclude at least one year follow- 
up time in order to pick up true incidence cases and 3-6 months in acute conditions (Lewis et 
al. 2005). Another issue of computerised databases is information bias (recording bias). This 
is due to the nformation GPs choose to record which might have influence on detection of 
potential cases. In addition, GPs aie more likely to record events associated with certain 
exposures. In order to identify potential cases of disease, some supporting evidence is 
required along with diagnosis (e.g. on-going treatment or hospital attendance).
Although the GPRD has its own limitations, the database has quality data and a large sample 
size, and has been extensively used for research in recent years. Numerous published studies 
include epidemiological studies of prevalence and incidence of diseases, studies on drug 
utilisation, case-control studies on risk assessment, and practice management. All research 
proposals that use data from the GPRD need to be approved by the GPRD’s Scientific and 
Ethical Advisory Group (SEAG), which was set up in 1995. A new committee, the 
Independent Scientific Advisoiy Committee for MHRA database research (ISAC) was set up 
in 2006. The intention of this committee is to review protocols of all GPRD research and 
ensure that study methodologies are well-defined and patients’ confidentiality is protected.
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Structure o f GPRD
The core structure of GPRD is made up of four tables; this includes PATIENT, MEDRECS, 
THERAPY, and PREVENTION. All patient records are stored on the database in relational 
tables linked by a unique patient identifier (EPATID). Detailed information included in the 
four tables is presented below:
Patient recordfile
Field Description
epatid Patient ID
patflag Flag indicating the integrity of the data for that patient
dob Date of birth
famnum Family number shared by patients living at same address
sex Sex of patient
orgreg Patients original registration date with the practice
regstat Registiation status
xferdate Transfer out date
regrea Extended registration information
dethdate Patients date o f death
Medical record file
Field Description
epatid Patient ID
evntdate Event date
medcode OXMIS or Read medical code
diagnosr Number of diagnoser
outcome Outcome (e.g. hospital letter, hospital admission)
mclinspe Clinical speciality
mlocate Location of consultation
textid Doctors' comments
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Therapy record file
Field Description
epatid Patient ID
prscdate Prescription date
drugcode Multilex drug code
doscode The prescribed dosage
prscqty Prescribed quantity
prscdays Duration of the prescription in days
prscber Number of the prescribe!'
dosgval The calculated dosage
Prevention recordfile
Field Description
epatid Patient ID
evntdate Even date
prevcode Prevention code (e.g. smoking, height, weight, blood pressure)
prevvall Prevention value
prevval2 Prevention value
medcode OXMIS or Read medical code
clinspec Clinical speciality
fiocate Location (e.g. in surgery, not in surgeiy, unknown)
The PATIENT table includes patient identification, year of birth, sex, registration status, 
transfer out date, and date of death if applicable. Information on ethnicity and socio­
economic status (SES) is not recorded. The registration information is also recorded in the 
PATIENT table, including the date registered in the general practice, registration status, and 
the date of leaving the practice. The MEDRECS table contains diagnoses and symptoms. 
Diagnoses, symptoms descriptions, and prevention are recorded using OXMIS (Oxford 
Medical Information System) (Perry 1978) or READ code (this coding system for diagnoses 
was introduced by the NHS in 1995) (Chisholm 1990).
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Prescriptions issued by the general practitioners are generated via the computer system and 
prescriptions are almost complete. The details of each prescription, including drug name, 
prescribing date, prescription quantity, duration, formulation, strength and dosing instruction, 
is stored in the THERAPY table. This information can be used to calculate the number of 
tablets or daily dosage in each individual patient. The drug is entered using the Prescription 
Pricing Authority (PPA) code. Each drug has a unique number code (MultilexEID) which can 
be mapped to the British National Formulary (BNF) chapter in which the drug appears. 
However, prescriptions issued to hospital in-patients, hospital out-patients, over-the counter 
(OTC) therapies, and some of the prescriptions prescribed during home visits, are not stored 
on the database. Immunization, treatment outcome, laboratory results, referral and admission 
to hospital, and lifestyle factors (body mass index, smoking habits, alcohol consumption, 
height, and weight) are recorded in the PREVENTION table. The completeness of data in this 
table varies by practice and no data are available for patients who do not consult the doctor.
Data retrieval
Two methods are used most frequently to retrieve data of interest from the GPRD, (i) using 
medical code list and (ii) a drug code list. A diagnostic dictionary containing Read and 
OXMIS codes can be used to create a medical code list. To create a medical code list, 
comprehensive research o f the condition is needed to ensure all codes are included. Another 
dictionary contains PPA codes, Multilex codes, BNF codes, and the strength and units of the 
drugs. This dictionary can be used to compile a drug list. There are two methods for creating 
drug lists for analysis. Firstly is to look up the BNF codes in the drug dictionary, and 
secondly is to use the generic drug name for searching. Using both methods for compiling a 
drug list can ensure that no codes are missed. The completed code lists for analysis are then 
checked in order to delete duplicates. The following steps were initially deal with in order to 
compile drug code list:
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Dru2 code compilins
a) Browsing Multilex code in the Microsoft Access table full drug dictionary
b) Word search in the Microsoft Access table full drug dictionary
c) Merging the word- and code search files
d) Removing duplicates and excluding unwanted codes
e) Making a record of the code compiling process
1) Processes o f code compiling
- The candidate and supervisor (Dr. de Vries) collaborate to define outcome of interest 
The candidate searched full drug dictionary through Multilex codes for relevant code 
stems
- The candidate developed a code list by conducting word and code searches in 
Microsoft Access
- Dr. de Vries checked compiled list for a) missing codes and b) irrelevant codes
- The candidate refined code list
2) Searching for outcomes of interest
Using complied drug code list to search these medical records for the outcomes of interest. 
Once the code list is completed, a suitable programme is written up using an SQL statement 
in order to retrieve data in Oracle from the SUN server where the GPRD is stored. All 
medical records of interest can be reviewed by automated coding in Access or by on-screen 
review for each individual record. Although the data quality have been shown to be high, 
additional data cleaning needs to be performed in order to avoid duplication. The on-screen 
software programme (GPRD browser) was developed by the University of Surrey 
Postgraduate Medical School. This browser presents all records in chronological order which 
can facilitate the assessment of medical records. A diagram below shows the procedure of 
data retrieval from GPRD to Microsoft Access or GPRD browser.
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Figure 4.3 Processes of data retrieval from the GPRD
SUN
Retrived data through SQL 
programming GPRD
(selected patients)
V y
Data export through 
ODBC
PC
published dataset
GPRD browser Microsoft Access for
data cleaning
SUN: the entire GPRD database was stored in SUN 
ODBC: Open Database Connectivity
GPRD browser: this software was developed by a senior researcher (Mrs. Annie Hutchison) at 
Postgraduate Medical School, University of Surrey.
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4.2 Study population
The source of data for this thesis was the GPRD version 2000. This version provided data 
recorded from 1987 up until Octobers 2001. Data collected in the year 2000 were not full 
year, so the study period in this thesis restricted to January 1992 to December 2000. Due to 
the consideration of data reliability, only practices that were contributing data to GPRD ftom 
1 January 1992 onward were included. Over five million children and adolescents between 0 
and 18 years had been registered on the GPRD at any time during 1992-2000.
Figure 4.4 illustrates the number of patient times for individuals aged 0-18 that were 
available for study on the GPRD. The GPRD population declined during the study period as a 
number of practices ceased to contribute data. The number of practices included in the GPRD 
version 2000 varied during the study period, failing from 602 in 1992 to 136 by 2000. One 
reason to explain this decline is probably due to the introduction of Vision software in 1996 
as the contributing GP computer system was converting fiom VAMP to Vision. Table 4.1 
shows the distribution of this population by age and sex. Table 4.2 illustrates the number of 
person-years for individuals aged 0-18 that was available on the GPRD version 2000.
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Figure 4.4 GPRD patient times and contributing practices in paediatric population
(GPRD version 2000)
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Table 4.1 Paediaftic population aged 0-18 years in GPRD, 1992-2000.
0-2 3-5 6-9 10-12 13-15 16-18 Total
1992
Boys
Girls
50,015
48,079
78,908
75,254
100,381
95,688
74,264
70,159
68,278
63,484
67,287
62,731
439,133
415,395
1993
Boys
Girls
48,643
46,319
78,310
75,020
100,351
95,791
72,934
68,875
71,041
66,534
64,424
59,759
435,703
412,298
1994
Boys
Girls
45,525
43,176
74,397
70,950
97,962
93,372
69,845
66,334
70,237
65,854
61,674
57,095
419,640
396,781
1995
Boys
Girls
43,399
41,051
72,120
68,710
95,920
91,342
68,955
65,745
68,228
64,503
62,173
57,842
410,795
389,193
1996
Boys
Girls
32,906
31,400
56,182
53,561
77,383
73,760
55,806
53,113
53,763
51,214
51,659
48,523
327,699
311,571
1997
Boys
Girls
25,275
24,081
43,951
41,710
61,017
59,000
45,234
42,836
42,952
41,144
42,086
39,636
260,515
248,407
1998
Boys
Girls
20,696
19,616
35,029
33,255
50,131
48,326
37,476
38,172
35,729
41,144
34,895
39,636
213,956
220,149
1999
Boys
Girls
15,534
14,704
25,643
24,352
37,089
35,523
28,034
26,796
27,056
25,777
25,755
24,477
159,111
151,629
2000
Boys
Girls
8,050
7,573
13,691
13,008
19,821
18,979
15,468
14,925
15,046
14,461
14,264
13,817
86,340
82,763
56
Table 4.2 Paediatiic population person-years aged 0-18,1992-2000.
0-2 3-5 6-9 10-12 13-15 16-18 Total
1992
Boys
Girls
48,970.86
46,987.82
76,630.64
73,155.60
97,365.41
92,911.69
72,010.10
68,102.04
66,132.86
61,546,18
65,029.64
60,598.20
42,6139.51
40,3301.53
1993
Boys
Girls
47,871.61
45,622.98
77,415.72
74,112.60
99,283.71
94,741.17
72,075.46
68,040.06
70,088.31
65,685.81
63,352.57
58,727.84
43,0087.38
40,6930.26
1994
Boys
Girls
45,348.46
43,034.50
74,180.54
70,699.11
97,601.21
93,086.01
69,547.55
66,052.83
69,882.48
65,579.97
61,245.04
56,678.21
41,7805.28
39,5130.63
1995
Boys
Girls
42,063.03
39,792.71
70,373.79
67,117.13
93,633.74
89,162.52
67,314.37
64,159.44
66,495.25
62,864.75
60,390.83
56,110.82
40,0271.01
37,9207.37
1996
Boys
Girls
32,371.41
30,888.95
55,775.28
53,159.61
76,888.65
73,266.93
55,408.22
52,683.42
53,428.36
50,866.25
51,183.80
48,023.24
32,5055.72
30,8888.40
1997
Boys
Girls
24,958.73
23,759.25
43,697.27
41,471.30
60,671.33
58,579.08
44,910.44
42,471.50
42,700.67
40,846.16
41,731.04
39,213.31
25,8669.48
24,6340.60
1998
Boys
Girls
20,453.62
19,418.52
34,776.83
33,040.37
49,888.84
48,011.97
37,315.80
35,314.25
35,652.12
34,297.85
34,667.06
32,403.63
212,754.27
202,486.59
1999
Boys
Girls
14,418.87
13,716.61
24,766.16
23,477.69
35,815.01
34,375.87
27,196.86
25,934.85
26,228.24
24,996.04
24,973.07
23,736.78
15,3398.21
14,6237.84
2000
Boys
Girls
7,757.55
7,287.97
13,341.00
12,652.11
19,323.01
18,455.34
15,067.38
14,513.88
14,712.01
14,077.49
13,870.68
13,400.89
8,4071.63
8,0387.68
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The study period of this thesis was between January 1, 1992 and December 31, 2000. Study 
subjects comprised all children and adolescents aged 0-18 at any time during the study period. 
All of the subjects included needed to have at least one-year ‘up-to-standard data’, this was to 
ensure better validity of data and meaningful analysis.
4.3 Age classification
Age categories were stratified using 3-4 year age bands: 0-2, 3-5, 6-9, 10-12, 13-15, and 16- 
18 years. The age category in this thesis differs fiom the International Conference of 
Harmonisation (ICH) guidelines: preterm newborn infants, term newborn infants (0-27 days), 
infants and toddlers (28 days to 23 months), children (2 to 11 years), adolescents (12 to 16-18 
years) (Anonymous 2000). The ICH age classification is particularly useful to investigate 
efficacy- This is because this classification is based on physiology and developmental 
considerations. However, the aim of this research was not investigating efficacy of 
psychotropic drugs use, so this classification was not adopted. A study has shown that brain 
development in children and adolescents continues up to aged 20 (Giedd et al. 1999). In 
addition, the onset of psychiatric disorders needs to be considered. For example, 
schizophrenia is normally diagnosed in late adolescence but some individuals will be 
diagnosed with early-onset schizophrenia i.e. before aged 12 years. (Pappadopulos et al 
2004). Taking these into account, we decided to define our study subjects aged 0-18 years. 
The reason did not include those individuals up to aged 20 was because many paediatric 
studies used ICH age classification, and in order to have direct comparision with other 
studies, we did not include those aged up to 18 years. We also adopted the 3-4 year age band 
because it can provide detailed reflection of the difference within narrow age groups than that 
of the ICH age classification.
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4.4 Classification of psychotropic drugs
In this analysis, the classification of psychotropic drugs was defined using the British 
National Formulary (BNP) 48 Section 4.1-4.4 and 4.8:
• 4.1: Hypnotics and anxiolytics: hypnotics, anxiolytics, and barbiturates
• 4.2: Drugs used in psychoses and related disorders: antipsychotic drugs, antipsychotic 
depot injections, antimanic drugs (lithium).
• 4.3: Antidepressant drugs: tricyclic and related antidepressant drugs, monoamine- 
oxidase inhibitors, selective serotonin re-uptake inhibitors, and other antidepressant 
drugs.
• 4.4: CNS stimulants and other drugs used for attention deficit hyperactivity disorder.
• 4.8: Anticonvulsants: control of epilepsy, drugs used in status epileptics, and febrile 
convulsions.
Lithium was separated fi*om other antipsychotics for analysis as it was licensed specifically 
for the treatment of manic and bipolar disorder. Clonidine, an a-adrenergic agent, was 
licensed for the treatment of hypertension in adults and Tourettes syndrome. As discussed in 
Chapter 2, the level of clonidine use has increased dramatically in the USA although it has 
not been licensed for the treatment of ADHD in children. Thus, its usage was also included in 
this analysis. The term ‘anticonvulsant’ is used throughout this thesis. Although 
‘antiepileptic’ is also a term to describe drug use for the treatment of epilepsy, 
‘anticonvulsant’ is defined as MeSH (Medical Subheadings) term on the Medline. Other drug 
groups presented in BNF Chapter 4, such as drugs used in obesity, analgesics, drugs used in 
parkinsonism or dementia were not included in this thesis. The reason for this is these drugs 
are not often used in children and adolescents with psychiatric disorders. The complete list of 
psychotropic drugs for this analysis is presented in Appendix II.
4.5 Summaiy
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This chapter mainly focused on the GPRD structure, the process of data extraction, 
description of study population, classification of psychotropic drugs, and age classification. 
Other study designs and methodology such as prevalence and incidence prescribing, case 
series study, and case-control study is presented in more detail in each chapter.
60
Part I
Drug Utilisation Studies
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Chapter 5 Trends in prevalence of psychotropic drug prescribing 
over 9 years
5.1 Introduction
As discussed in Chapter 2, limited research has been carried out to examine the psychotropic 
drug prescribing patterns in children and adolescents in the UK, so the first step was to 
investigate the extent of drug use in this population over the past ten-year period. This 
chapter investigates the prevalence of psychotropic drug prescribing in this population, with 
the aim of obtaining an understanding how these drugs have been prescribed in the UK 
clinical practice.
5.2 Methods
Study population
The study population was drawn from the GPRD and included all children and adolescents 
aged 0-18 years registered with a GP who contributed data to the GPRD any time between 1 
January 1992 and 31 December 2000. Study subjects were identified as those who had 
received at least one prescription for psychotropic drug. Psychotropic drugs were grouped 
according to the British National Formulary (BNF) as follows: hypnotics/anxiolytics, 
antipsychotics, antidepressants, stimulants and anticonvulsants. Lithium was separated from 
other antipsychotics as it is used mainly for manic and bipolar disorders as opposed to other 
antipsychotics, which are licensed for the treatment of psychosis. As studies from the USA 
have suggested an increased of clonidine in children with hyperactivity problems (Zito et a l  
2000; Zito et al. 2003); the prevalence of clonidine use was also examined. The data were 
stratified by 3-4 years age bands (0-2, 3-5, 6-9, 10-12, 13-15, and 16-18 years).
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Prevalence o f psychotropic drug prescribing
Prevalence was defined as the number of subjects receiving a prescription of psychotropic 
drug divided by the population at risk in the paediatric population in a particular year. The 
numerator for prevalence was the number of subjects aged 0-18 prescribed at least one 
psychotropic drug. The denominator was the number of mid-year population aged 0-18 years 
observed in each year of the GPRD. The age-specific and gender-specific annual prevalence 
of prescribing was calculated. In order to investigate gender differences in prescribing 
patterns over time, boy/girl prevalence ratios were estimated by dividing the prevalence of 
prescriptions in boys by that of girls.
Prevalence = subjects prescribed psychotropic drug in a particular year
Total mid-year population in GPRD aged 0-18 year in a particular year
Variation prescribing by practice
To investigate whether prescribing of psychotropic drug varied by practice, all practices 
contributed data in 2000 issued psychotropic drug to children and adolescents aged 0-18 
years were identified. For each practice, the proportion of young people received at least one 
psychotropic drug was calculated.
Statistical Analysis
A test (Cochran-Armitage test for trend) was used to examine the yearly trend in 
psychotropic drug prescribing. The exact method was used to calculate the 95% confidence 
intervals: CI=p-(1.96xs.e.) to p+(1.96xs.e.) (Tobi et al. 2005). Boy/girl prevalence ratios for 
psychotropic drug prescribing were calculated the Taylor series method for calculating 95%
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confidence intervals (Armitage & Berry 1994). Analyses were carried out using Stata/SE, I
version 8.0 (Stata Corp, College Station, Texas).
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5.3 Results
A total of 39,511 children and adolescents received a total of 276,897 prescriptions, 40.7% 
(16,099) of whom were boys. The average number of prescriptions per user was 4.2 
(SD=8.6). On average, study subjects were prescribed 1.2 different psychotropic drugs 
(SD=0.67; range 1-18). 70.8% (27,975) of study subjects received only one psychotropic 
drug class. Table 5.1 contains the number of prescriptions and the characteristics of the 
subjects by drug group.
Table 5.1 Characteristics of study subjects by psychotropic drug class
Clonidine Stimulants^ ATD Anticonvulsants Hypnotics/
anxiolytics
Antipsychotics Litiiium
Prescription (%) 7,373 (2.66) 12,470 (4.50) 69,553(25.1) 161,957 (58.5) 7,752 (2.79) 16,897 (6.10) 895 (0.32)
Most commonly Clonidine MPH^ Imipramine Sod. valproate Temazepam Thioridazine Litiiium
prescribed dnig
Prescription (%) 7,373(100) 12,454 (99.8) 18190(26.2) 93333 (57.6) 2231 (28.7) 4987 (29.5) 895(100)
Subjects 681 1,287 19,716 7,972 7,098 3,381 78
Boys/girls 297/384 1145/142 7658/12058 4160/3812 3175/3923 1716/1665 29/49
Mean age at 1st 14.1 (3.3) 9.7 (3.0) 13.8(4.4) 9.4 (5.6) 11.7(6.8) 16.3 (4.0) 15.2(4.4)
prescription (SD), y
ATD: antidepressant.
 ^MPH: methylphenidate.
^Stimulants included methylphenidate and dexaphetamine.
 ^Subjects were counted more than once if prescribed psychotropic drug from more than one drag class.
The overall prevalence of psychotropic drug prescribing between 1992 and 2000 is shown in 
Figure 5.1. A test for trend showed a statistically significant increase in stimulants and 
antidepressant prescriptions over time. Stimulant prescriptions to boys increased dramatically 
with a 96-fold increase between 1992 and 2000; methylphenidate accounted for 92.1% 
(13,241/14,370) of these prescriptions. Antidepressant prescribing showed a 1.6-fold increase 
over time (p<0.001) mainly due to an increase in prescribing amongst girls; the prevalence of 
antipsychotic, hypnotic/anxiolytics, and anticonvulsant prescriptions was also increased 
(p<0.001). The level of clonidine prescribing remained constant (p=0.63), and lithium 
prescribing also remained relatively stable throughout the study period (p=0.59). 
Antidepressants and anticonvulsants were the most commonly prescribed psychotropic drugs.
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Two tables of age-, sex-specific prevalence of psychotropic drug prescribing with 95% 
confidence intervals are presented in Table 5.2 and Table 5.3. Number of patients for 
prevalence calculation is presented in Appendix IV.
Figure 5.1 Overall prevalence of psychotropic drug prescribing in study subjects, 1992-2000.
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Figure 5.2-5.3 shows the sex-specific prevalence. There was a 98-fold increase in stimulant 
prescribing in boys from 0.04 per 1,000 (95% Cl 0.03-0.07) in 1992 to 3.92 per 1,000 (95% 
Cl 3.52-4.37) in 2001, whereas prescribing in girls increased from 0.01 per 1,000 (95% Cl 
0.01-0.03) to 0.41 per 1,000 (95% Cl 0.28-0.57). The boy/girl prevalence ratio for stimulant 
prescriptions increased from 3.00 (95% Cl 1.20-7.50) in 1992 to 9.52 (95% Cl 6.69-13.6) in 
2000. This clearly indicates that boys were more likely to receive stimulant tieatment than 
girls. The use of antidepressants was predominant in girls, prescribing amongst boys 
remained relatively stable whereas amongst girls it increased 1.9-fold. Consequently, the ratio 
reduced from 0.87 per 1,000 (95% Cl 0.81-0.93) in 1992 to 0.50 per 1,000 (95% Cl 0.43-
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0.57) in 2000, Prevalence of anticonvulsant prescribing was comparable in both sexes. Girls 
were more likely to be prescribed hypnotics/anxiolytics, with a prevalence ratio of 0.89 (95% 
Cl 0.82-0.98) in 1992 and 0.86 (95% Cl 0.69-1.07) in 2000. Prevalence of antipsychotic 
prescribing was similar in both sexes. Although there was no overall increase in the 
prevalence of clonidine prescribing, the prevalence ratio revealed that proportionally 
clonidine prescribing increased amongst boys. The complete data of boy/girl prevalence ratio 
with 95% confidence intervals is presented in Table 5.2. The number of patients by age, sex, 
calendar year and psychotropic drug class is given in Appendix IV.
Figure 5.2 Sex-specific prevalence of psychotropic drug prescribing in children and 
adolescents aged 0-18 years, 1992-2000.
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Figure 5.2 (continued)
Prevalence of psychotropic drug prescribing in girls
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Figure 5.3 depicts the age-specific prevalence of psychotiopic drug prescriptions by drug 
group. Detailed information on age-specific prevalence and 95% confidence intervals of 
prescribing is given in Table 5.1. Except for those aged 0 to 2 years, the prescribing of 
stimulants increased significantly over time in all age groups and it was highest amongst 
children aged 10-12 years. The prevalence of clonidine prescribing increased significantly 
amongst those aged 6-9 years (p<0.001). Antidepressant and anticonvulsant prescribing 
increased with age. The prescribing of antidepressants was highest amongst those aged 
between 16 and 18 years old. The prescribing of antipsychotics declined in children aged <10 
years, while an increase was observed amongst those 10-18 years of age. A significant 
increase of hypnotics/ anxiolytics prescribing appeared amongst the 13 to 18 year group.
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Figure 5.3 Age-specific prevalence of psychotropic drug prescribing by drug class 
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Figure 5.3 (continued)
Prevalence of clonidine prescribing
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Figure 5.3 (continued)
Prevalence of antidepressants prescribing
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Figure 5.3 (continued)
Prevalence of hypnotics/anxiolytics prescribing
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Figure 5.3 (continued)
Prevalence of anticonvulsant prescribing
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Figure 5.3 (continued)
Prevalence of antipsychotics prescribing
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Figure 5.3 (continued)
Prevalence of lithium prescribing
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There was 136 practices were identified, of which a total of 2,218 study subjects received at 
least one psychotropic drug aged between 0 and 18 years in 2000. Prescribing varied by 
practice as can be seen in Figure 5.4.
Figure 5.4 Percentage of children and adolescents aged 0-18 years in 2000, prescribed
psychotropic drug, by practice
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5.4 Discussion
This study indicates that the prescribing of antidepressants (aged 13-15 years), 
hypnotics/anxiolytics (aged 13-18 years), antipsychotics (aged 10-18 years), anticonvulsants 
(aged 6-18), and in particular, stimulants amongst some children and adolescents (aged 3-18) 
has statistically increased in the UK between 1992 and 2000. The level of clonidine and 
lithium prescribing in this children and adolescents remained relatively stable. The majority 
of study subjects received only one psychotropic drug class.
StJ'engths mid limitations
To our knowledge, this is the first analysis that provides a comprehensive overview of 
psychotropic drug prescribing in children and adolescents in the UK. However, several 
limitations need to be highlighted. Firstly, the indications for prescribing, dosage, switching, 
and duration of use did not analysis in this study. Such data are crucial to evaluate the 
rationality of use hom a clinical perspective. The aim of this analysis, however, was to 
examine the overall trend of psychotropic drug prescribing in a primary care setting. 
Secondly, in the UK, the prescribing of stimulants should be initiated by specialists. Although 
referral data are recorded in the GPRD, the type and number of specialists involved in 
assessing cases and prescribing stimulants is unrecorded. Therefore, it is not feasible to 
evaluate specialists’ attitudes toward prescribing. Thirdly, the GPRD does not contain 
information on socio-economic status and ethnicity. As a result, we were unable to examine 
how these factors might be associated with the prevalence of psychotropic drug prescribing.
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Comparison with other studies
Based on data firom a Health Maintenance Organization (HMO) database and two state 
Medicaid databases, Zito et ah (2000;2003) observed a steady increase in the use of a- 
agnoist, antidepressants, anticonvulsants, lithium, antipsychotics, and stimulants in youths 
aged <20 years. In the Netherlands, the prevalence of stimulant, antipsychotic, and 
hypnotic/anxiolytic use was shown to have increased significantly from 1995 to 1999, while 
clonidine and lithium use remained stable (Schirm et a l 2001). The level of antidepressant 
prescribing in the present study is similar to that reported by Murray et al using an older 
version of the GPRD (Murray et a l 2004). In contrast to Zito et al. studies, girls were more 
likely to be prescribed antidepressants than boys. Antipsychotic use in this analysis shows 
that adolescents aged 16-18 years were more likely to be prescribed antipsychotics than 
children, which is consistent with the nature of schizophrenia as an adolescent-onset 
condition (Pappadopulos et a l 2004).
Few studies have characterised the use of anticonvulsants in children and adolescents. Those 
studies were mainly based in the USA. In these studies, however, the definition of 
anticonvulsant products was different. For example, the study in Zito et a l (2003) only 
included carbamazepine, lamotrigine, and sodium valproate which cannot directly be 
compared with our analysis. The evidence of anticonvulsant prescribing in this population 
has not yet been characterised in the UK.
The number of clonidine and lithium prescriptions remained relatively stable in the study, 
which is inconsistent with previous USA studies. In term of concomitant use of psychotropic 
drugs it was found to be rare amongst our study subjects. Approximately 80% of our subjects 
received only one class of psychotropic drug, this prescribing pattern is similar to that in the
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Netherlands (Schirm et a l 2001). However, this prescribing pattern is different horn the USA 
practice. Safer et a l (2003) reviewed published data from MEDLINE search between 1996 to 
2002, the authors stated that concomitant prescribing of psychotropic drug has increased, 
particularly in the USA. It should be noted that several factors such as sampling, geography, 
ethnicity and socio-economic status have been reported to be associated with psychotropic 
drug prescribing (Zito et a l 1998; Zito et a l 2000; Zito et a l 2003; Cox et a l 2003). 
Consequently, the estimation of prevalence can be expected to be different between countries 
or even different data sets.
The growth of stimulant prescribing is striking. This increasing trend in the present study is in 
line with that seen in other countries; however, the overall prevalence of stimulant 
prescriptions is comparatively lower in my analysis. According to the National Institute for 
Clinical Excellence (NICE) guidelines on the use of methylphenidate for ADHD, about 1% 
of children aged 6-16 years (69,000 in England and 4,200 in Wales) meet the diagnostic 
criteria for hyperkinetic disorder (a sub-group of ADHD). Of this group, approximately
48,000 (65.5%) were not receiving treatment with methylphenidate (Technology Appraisal 
Guidance No. 13, 2001). It has been suggested that underdiagnosis of ADHD in the UK is of 
greater concern than over-diagnosis (Thapar & Thapar 2003). In a GPRD-based study, which 
estimated the prevalence of stimulant-treated Attention Deficit Disorder (ADD) in boys aged 
5-14 years, the authors noted a lower incidence rate of stimulant treatment for ADD in UK 
compared with that of other countries (Jick et a l 2004). However, it should be noted that 
lick’s study was resti icted only to children with a recorded diagnosis of ADD,
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The increase in stimulants prescribing observed in our study may in part be attributed to a 
change in its licensing status in the UK. As a controlled drug, methylphenidate was 
previously available only on a named patient basis from the license holder. In 1995, the drug 
was re-licensed for general use and became available via wholesalers, which may provide a 
plausible explanation for the growth in prescriptions (Bramble 2003; Taylor & Hemsley, 
1995), In addition, ADHD is becoming a more recognised disorder, due to the broader 
definition of ‘hyperkinetic disorder’ in ICD-10 than that in ICD-9. Because of these factors, 
an increase in stimulant prescribing, associated with ADHD being more readily diagnosed, is 
expected (Thapar & Thapar 2003; Taylor & Hemsley 1995; Steinhausen & Erdin 1991).
5.5 Conclusion
In the past decade, there has been a significant increase in the prescribing of most 
psychotropic drugs in children and adolescents in the UK practice. Many of these drugs are 
not licensed to use in paediatric population. Given the limited information available to date, 
findings from this study provide an evidence of how these drugs have being prescribed. The 
most commonly prescribed psychotropic drugs groups were stimulants, antidepressants, and 
anticonvulsants. Of these groups, stimulants have received a lot of attention although under­
prescribing is considered in the UK. As ADHD is getting more public attention, a steady 
increase of stimulants prescribing is expected in the following few years. This is worrying 
because the rationale of stimulant use in children and adolescents has not yet been reviewed 
in the UK, as well as the prescribing patterns. In addition, the long-term side effects of 
stimulant are still unclear at this time. Hence, its usage needs more in-depth research. The 
level of antidepressant use appeared to be high, but a GPRD-based study on antidepressants 
in children and adolescents had already been carried out (Murray et al. 2004), so the use of 
this drug group was not included in this thesis. Limited research has been carried out with
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respect to anticonvulsant prescribing in young people. After 1989, several newer 
anticonvulsants were introduced into UK clinics. Although the newer anticonvulsants appear 
to have a more acceptable safety profile, the absence of long-term data should lead to a 
guarded opinion. It is worthwhile gaining more knowledge of how anticonvulsants have been 
prescribed. Hence, two drug utilisation studies on methylphenidate and anticonvulsants in 
children and adolescents aged 0-18 years were carried out.
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Chapter 6 Methylphenidate prescribing patterns in children and 
adolescents
6.1 Introduction
In the previous chapter, a dramatic increase in stimulant prescribing amongst children and 
adolescents was evident. It was also noted that there were only 10 caffeine prescriptions 
issued during the period covered. Pemoline used to be licensed for the treatment of attention 
deficit hyperactivity disorder (ADHD), however, following a suspected increase in risk of 
‘life threatening hepatic failure’, the Committee on Safety of Medicines (GSM) decided to 
withdraw Pemoline from the UK market in 1997. The level of dexamfetamine prescribing 
was much less than methylphenidate. Therefore, methylphenidate prescribing accounted for 
the increasing trend and to my knowledge this increase has not been investigated in detail. 
Thus, this chapter investigates methylphenidate prescribing in children and adolescents in the 
UK using the GPRD.
Methylphenidate
Methylphenidate (MPH) is a piperidine-derived CNS stimulant, and classified as a Schedule 
2 controlled drug (Figure 6.2). It is licensed for the treatment of attention- 
deflcit/liyperactivity disorder (ADHD) in children and adults, and it only licensed for use in 
children older than the age of 6. The precise mechanism of action of methylphenidate is not 
clear at this time. Early animal studies have shown that methylphenidate acts on the 
dopamine transporters in the presynaptic cell membrane, blocking reuptake of dopamine, and 
resulting in an increase of extracellular dopamine levels (Butcher et a l 1991). As it has been 
hypothesised that the development of ADHD may due to insufficiency of dopamine in the 
prefrontal cortex, so this mechanism can explain the effective of MPH in ADHD treatment.
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Figure 6.1 The chemical structure of methylphenidate.
(reference source: Challman & Lipsfy 2000)
Methylphenidate is currently available in immediate-release tablet and modified release 
formulations in 5-, 10-, and 20-mg in the UK. It has been suggested that treatment with 
methylphenidate is efficacious for about 70-90% of children with ADHD (Elia 1993). Its 
efficacy has been extensively studied (Greenhill 1992; Shaywitz et a l 1997). In 1999, a study 
caiTied out by The National Institute of Mental Health (NIMH), the Multimodal Treatment 
Study of Children with ADHD (MTA study), included elementary school children aged 7-9 
(14-month follow-up). Children were randomly assigned to one of four treatments: (i) 
medication alone (methylphenidate) (ii) behavioural treatment alone (iii) a combination of 
both, or (iv) routine community care. Findings fi'om MTA study showed a significant 
improvement of ADHD symptoms with medication tieatment alone over that of the other 
approaches (MTA 1999).
In 2000, a NICE guidance on the use of methylphenidate in children with ADHD stated that a 
large number of randomised controlled trials of methylphenidate have been carried out. 
However, the US evidence does not necessarily generalise to a UK context. In addition, it has 
highlighted in the guidance that result from MTA study is of mixed quality due to some study 
designs that could have favoured methylphenidate over other treatments.
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In addition to methylphenidate, two others drugs are also licensed for the treatment of ADHD 
in children and adolescents in the UK: atomoxetine and dexamfetamine. In 2006, the NICE 
guidance on using these three drugs (methylphenidate, atomoxetine, dexamfetamine) in 
children with ADHD was released. This guidance provides an overview of effectiveness of 
the three drugs individually and the comparison between their use. The review committee 
stated in the guidance that these three drugs for the treatment of ADHD are effective compare 
to no treatment. It should be noted that there were no studies comparing atomoxetine and 
dexamfetamine directly. It is not easily to draw any firm conclusion on the effectiveness of 
these drugs on ADHD treatment. It is recommended that these methylphenidate, atomoxetine, 
dexamfetamine should be offered when drug treatment is considered appropriate. To date, 
methylphenidate is still the most commonly prescribed drug for ADHD treatment in children 
and adolescents. This is possibly because its efficacy for ADHD treatment has been studied 
in more depth than other drugs. In addition, it has been on the market for long, consequently 
it may have gained more popularity.
The prescribing patterns of methylphenidate have been extensively studied USA, however, its 
usage has not been systematically evaluated in UK practice. In addition, the evidence horn 
the USA cannot be generalised to the UK practice. Hence, a drug utilisation study was 
designed to gain a better understanding of its prescribing patterns in children and adolescents 
in UK practice. This study was comprised of two parts: the first was to calculate the 
prevalence and incidence of methylphenidate prescribing during the years 1992 to 2000 and 
the second was to characterise the indications for prescribing, dosage, co-morbidity and 
concomitant use with other psychotropic drugs.
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6.2 Methods
Study population
The study population consisted of all children and adolescents aged 0-18 years in the GPRD 
who received at least one methylphenidate prescription between 1 January 1992 and 31 
December 2000. In order to achieve meaningful analysis, at least one-year’s medical data had 
to be available for each study subject included. The data for boys and girls were analysed 
separately and stratified by the following bands: 0-2, 3-5, 6-9, 10-12, 13-15, and 16-18 years.
Incidence o f  methylphenidate prescribing
Study subjects who did not receive methylphenidate in the previous year but did thereafter 
were classified as new users (incident cases). Incidence was defined as the number of 
subjects classified as incident cases divided by the person-years at risk in the GPRD 
paediatric population aged 0-18 years. The number of patient-years of observation was 
calculated by summing the number of days in each year that each child contributed data to the 
GPRD and dividing this by 365. Annual sex-specific incidence rates of methylphenidate 
prescribing were calculated. The incidence rate of prescribing was expressed as the number 
of users per 1,000 patient-years.
Incidence = subjects classified as new methylphenidate users in a particular year
Total person-time in GPRD population aged 0-18 year in a particular year
Prevalence o f  methylphenidate prescribing
The annual age- and sex-specific prevalence of methylphenidate prescribing for 1992 through 
2000 was calculated. The numerator for prevalence was the number of study subjects who 
received methylphenidate in that year. The denominator for the prevalence was the number of
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the children and adolescents aged <19 present in each mid-year population in the GPRD. 
Prevalence of prescribing was expressed as the number of users per 1,000. The boy/girl 
prevalence ratios were also calculated during the period covered.
Prevalence = subjects prescribed methylphenidate in a particular year_______
Total mid-year population in GPRD aged 0-18 year in a particular year
Annual, sex and age-specific prevalence and incidence of prescribing with 95% confidence 
intervals were calculated. The exact method was used to calculate the 95% confidence 
intervals: CI==p-(1.96xs.e.) to p+(1.96xs.e.) (Tobi et a l 2005). The prevalence ratio between 
boys and girls was also calculated. A test (Cochran-Armitage trend test) was performed to 
examine the usage trend over time. Analyses were carried out using Stata/SE, version 8 (Stata 
Corp, College Station, Texas).
Dosage and duration o f methylphenidate use
Methylphenidate is available in 5, 10 and 20mg tablets. The number of tablets prescribed 
divided by the duration for each prescription was used to estimate how many tablets were 
taken on a daily basis. The maximum daily dosages were then calculated by using the number 
of tablets prescribed multiplied by their strength. In some study subjects where prescribed 
daily dosage of methylphenidate was not given, this was then estimated as the most 
commonly prescribed daily dosage of methylphenidate in the rest of the database for study 
subjects of the same age. For each prescription, the date of methylphenidate prescribing was 
taken as the assumed date on which methylphenidate use started. Using all of the 
methylphenidate prescriptions, the theoretical end date was calculated using the amount of 
methylphenidate prescribed and the prescribed daily dosage.
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Indication and co-morbidity patterns
All methylphenidate prescriptions were scrutinized through the GPRD browser to evaluate 
the indications which were associated with the licensed indication at any time in medical 
records. Co-morbidity was defined as the co-occurrence of more than one condition in the 
same subject at any time during the study period. The patterns of co-morbidity were 
quantified by sex.
Patterns o f concomitant psychotropic drug use
Concomitant use of other psychotropic drugs was quantified. Psychotropic drug classes were 
grouped as: antidepressants, a-agnoist (clonidine), antipsychotics, hypnotics/anxiolytics and 
anticonvulsants. Study subjects were described as concomitant users if they received 
methylphenidate and at least one drug fi oin one of these drug classes in the same month.
Variation prescribing by practice
To investigate whether prescribing of methylphenidate varied by practice, all practices 
contributed data in year 2000 issued methylphenidate to children and adolescents aged 0-18 
years were identified. For each practice, the proportion of young people received at least one 
methylphenidate prescription was calculated.
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6.3 Results
A total of 12,054 methylphenidate prescriptions were identified which had been prescribed to 
1,280 subjects. On average, there were 10 prescriptions per user. The age distribution at first 
methylphenidate prescription by gender presents in Figure 6.2. The mean age at first 
methylphenidate prescription was 9.4 years (SD=2.9). In total, 146 prescriptions had been 
issued to 50 children under the age of 6 years. Most first time users were aged between 5 and 
13. 84.2% (1,078) subjects received more than one methylphenidate prescription in the study 
population.
Figure 6.2 Age-sex distribution of study age at first recorded 
methylphenidate prescription, 1992-2000.
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Incidence rate o f methylphenidate prescribing
The incidence rate of methylphenidate prescribing increased significantly from 0.006 per
1,000 (95% Cl 0.002-0.01) in 1992 to 0.62 per 1,000 (95 % Cl 0.51-0.75) in 2001 (p <0.001). 
Annual incidence rate of methylphenidate prescribing is shown in Table 6.1. Incidence rate 
of methylphenidate prescribing increased dramatically after 1995. The incidence of 
prescribing significantly increased in both sexes (p<0.001) and boys were more likely to 
receive methylphenidate than girls (Table 6.2).
Table 6.1 Incidence of methylphenidate prescribing in study subjects'
Year No. of new users person-years incidence^ 95% CIS
1992 5 829,441 0.006 0.002-0.01
1993 9 837,018 0.01 0.005-0.02
1994 21 812,936 0.03 0.02-0.04
1995 101 779,478 0.13 0.10-0.15
1996 309 633,944 0.48 0.43-0.54
1997 303 505,010 0.60 0.53-0.67
1998 237 415,241 0.57 0.49-0.64
1999 185 299,636 0.60 0.51-0.69
2000 105 164,459 0.62 0.51-0.75
’There was a significant increase o f  methylphenidate prescribing (p< 0.001). 
^Incidence o f  prescribing was expressed as per 1000 person-years.
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Table 6.2 Sex-specific incidence of methylphenidate prescribing"
Year No. of 
subjects
person-
yeai-s
Incidence^ 95% CIS
1992
Boys 4 426,140 0.01 0.003-0.02
Girls 1 403,302 0.001 0.00001-0.01
1993
Boys 9 430,087 0.02 0.01-0.04
Girls 0 406,930 0 NA
1994
Boys 17 417,805 0.04 0.02-0.06
Girls 4 395,131 0.01 0.003-0.03
1995
Boys 87 400,271 0.22 0.17-0.27
Girls 14 379,207 0.04 0.02-0.06
1996
Boys 273 325,056 0.84 0.74-0.95
Girls 36 308,888 0.12 0.08-0.16
1997
Boys 272 258,669 1.05 0.93-1.18
Girls 31 246,341 0.13 0.09-0.17
1998
Boys 245 212,754 1.15 1.01-1.31
Girls 27 202,487 0.13 0.09-0.19
1999
Boys 170 153,398 1.11 0.95-1.29
Girls 15 146,238 0.10 0.06-0.17
2000
Boys 94 84,072 1.11 0.90-1.37
Girls 11 80,388 0.14 0.07-0.24
Abbreviation: NA, not available.
’There was a significant increase o f  methylphenidate prescribing (p< 0.001). 
^Incidence rate o f  prescribing was expressed as per 1000 person-years.
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Prevalence o f methylphenidate prescribing
The overall prevalence of methylphenidate prescribing increased steadily throughout the 
study period. In 1995, a rapid increase in prescribing was observed. Table 6.3 shows the 
estimated prevalence of methylphenidate prescribing by calendar year. The annual prevalence 
increased fi'om 0.01 per 1,000 (95 % Cl 0.004-0.02) in 1992 to 2.13 per 1,000 (95 % Cl 1.92- 
2.36) in2001(p<0.001).
Table 6.3 Prevalence of methylphenidate prescribing*
Year Prevalent users Population Prevalence (95% CI)^ 95%CIs
1992 8 854,528 0.01 0.004-0.02
1993 15 848,001 0.02 0.01-0.03
1994 30 816,421 0.04 0.02-0.05
1995 124 799,988 0.16 0.12-0.18
1996 401 639,270 0.63 0.56-0.69
1997 574 508,922 1,13 1.04-1.22
1998 610 417,604 1.46 1.34-1.58
1999 555 310,740 1.79 1.64-1.94
2000 360 169,112 2.13 1.92-2.36
'There was a significant increased o f  metliylphenidate prescribing (p< 0.001).
‘Prevalence was expressed as per 1000 population.
The sex-specific prevalence of methylphenidate prescribing presents in Table 6.4. 
Methylphenidate was prescribed mainly to boys reaching 3.82 per 1,000 (95% Cl 3.42- 4.26) in 
2000. The ratio of boys to girls was 7:1 in 1992 and 11:1 in 2001, respectively. Except for the 
0 to 2 years, there was a significant increase in methylphenidate prescribing in all age groups 
(p<0.001). Figure 6.3 presents the age-specific prevalence of methylphenidate prescribing.
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Table 6.4 Sex-specific prevalence of methylphenidate prescribing"
Year No. subjects Population Prevalence^ 95% CIS
1992
Boys 7 439,133 0.02 0.06-0.03
Girls 1 415,395 0.002 0.006-0.01
1993
Boys 14 435,703 0.03 0.02-0.05
Girls 1 412,298 0.002 0.006-0.01
1994
Boys 25 419,640 0.06 0.03-0.08
Girls 5 396,781 0.01 0.004-0.03
1995
Boys 105 410,795 0.26 0.21-0.31
Girls 18 389,193 0.05 0.03-0.07
1996
Boys 351 327,699 1.07 0.96-1.18
Girls 50 311,571 0.16 0.11-0.21
1997
Boys 513 260,515 1.97 1.86-2.15
Girls 60 248,407 0.24 0.18-0.31
1998
Boys 547 213,956 2.56 2.35-2.79
Girls 62 203,648 0.30 0.23-0.39
1999
Boys 497 159,111 3.15 2.88- 3.43
Girls 54 151,629 0.36 0.27-0.46
2000
Boys 329 86,349 3.82 3.42-4.26
Girls 31 82,763 0.37 0.25-0.53
‘Tliere was a significant increased o f  prescribing (p< 0.001). 
'Prevalence was expressed as per 1000 population.
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Figure 6.3 Age-specific prevalence of methylphenidate prescribing in study subjects.
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Dosage and duration o f methylphenidate use
Figure 6.4 shows the average daily dosage by age. The average daily dosage for each user 
was 28.4nig (SD= 13.9) and it increased with age. 1.7% (199/12,054) of prescriptions 
exceeded the licensed maximum daily dosage of 60 mg. The average duration for each 
prescription was 36 days (SD= 24.2). (Figure 6.5)
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Figure 6.4 Distribution of the average daily dosage of methylphenidate 
prescription by age.
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Figure 6.5 Distribution of the average duration of methylphenidate 
prescriptions by age.
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Indication o f prescribing and co-morbidity
Behaviour disorder (57.7%) was the diagnosis most commonly associated with 
methylphenidate; 37% had a diagnosis of ADHD or HKD followed by learning problems, 
concentration problems and psychological disorders (Table 6.5). A large proportion of 
children and adolescents had a record of asthma. The frequency of hearing problems was also 
high. In addition, 9.8% of study subjects had a diagnosis of epilepsy (Table 6.6).
Table 6.5 Indications associated with methylphenidate prescriptions (n=l,280)
Diagnosis No. subjects* %
Behaviour problems
Boys 798 62.3
Girls 82 6.4
ADHD/HKD/hyperactivity
Boys 451 35.2
Girls 52 4.1
Learning problems
Boys 86 6.7
Girls 20 1.6
Concentration problems
Boys 41 3.2
Girls 10 0.8
Psychological disorders
Boys 30 2.3
Girls 8 0.6
No diagnosis associated with MPH use
recorded
Boys 108 8.4
Girls 20 1.6
'Study subjects may bave more titan one diagnosis..
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Table 6.6 Co-morbidity patterns in methylphenidate-treated subjects (n=l,280)
Diagnoses No.subjects* %
Asthma
Boys 324 25.3
Girls 41 3.2
Hearing Problem
Boys 230 17.9
Girls 34 2.65
Epilepsy
Boys 108 8.4
Girls 22 1.7
Sleep disorder
Boys 14 1.1
Girls 5 0.4
Autism
Boys 14 1.1
Girls 3 0.2
Tic
Boys 12 0.9
Girls 1 0.08
'Study subjects may have more than one co-morbidities.
Concomitant prescribing patterns
Table 6.7 summaries the concomitant use patterns by drug classes and calendar years. 
Detailed descriptions of the products used within each drug class are presented in tables 6.8- 
6.11. Clonidine was the most commonly prescribed drug together with methylphenidate, and 
its use increased slightly in 1997. None of the clonidine users had a diagnosis of 
hypertension. This implies that clonidine prescription was issued for the treatment of 
behaviour disorders along with methylphenidate. In addition, it can be assumed hypertension 
is not a common condition in paediatric population. Other psychotropic drug groups such as 
antidepressants and anticonvulsants were also prescribed concomitantly with 
methylphenidate.
Approximately 58.0% of antidepressant users with MPH received antidepressants without 
evidence of licensed indications being recorded. This implies that antidepressant was being 
prescribed with MPH for the treatment of behaviour problem. Resperidone, an antipsychotic,
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was frequently prescribed concomitant with methylphenidate. Dexamfetamine was rarely 
prescribed with methylphenidate simultaneously.
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A total of 100 practices were identified, of which 361 study subjects aged 0-18 received at 
least one methylphenidate prescription in 2000. Figure 6.6 presents the prescribing variation 
by practice.
Figure 6.6 Percentage of children and adolescents aged 0-18 years in 2000, 
prescribed methylphenidate, by practice
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I6.4 Discussion '
From the analysis of prevalence and incidence of methylphenidate prescribing, a dramatic 
increase in prescribing was evident over the past decade. Boys were more likely to receive 
methylphenidate than girls. The use of methylphenidate was especially high amongst those 
aged 10-12. Nearly 60% of children and adolescents who were treated with methylphenidate 
had a diagnosis of behaviour problems and about a third had a diagnosis of ADHD or HKD- 
the licensed indication for methylphenidate. Clonidine and antidepressants were the most 
commonly prescribed psychotropic drug groups together with methylphenidate. The 
diagnoses of asthma and hearing problems appeared commonly in this methylphenidate 
treated population. Study by Rappley et a l (1999) also noted that asthma was one of common 
chronic conditions amongst ADHD children.
Strengths and limitations
Little is known about methylphenidate prescribing in children and adolescents in the UK. To 
our Icnowledge, this study is the first to provide insight into prescription trends over the ten- 
year period (1992-2001). However, several limitations need to be highlighted. Firstly, the 
diagnosis of ADHD/HKD and subsequent prescription of methylphenidate should be initiated 
by specialists in UK practice (BNF Children 2005). Although the referral data was recorded 
in the database, the type and number of specialists involved in assessing cases and 
prescribing methylphenidate were unrecorded. Moreover, types of non-pharmacological 
interventions (e.g. psychosocial intervention) used along with methylphenidate were not 
investigated. Secondly, previous studies showed that significant factors such as socio­
economic status (SES) and ethnicity could affect the prevalence of methylphenidate 
prescribing (Zito et a l 2000; Zito et a l 2003). However, the GPRD does not contain 
information on socio-economic status (SES) and ethnicity and therefore it was unable to
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evaluate any association between these factors and methylphenidate prescribing. Thirdly, 
although this study was able to estimate incidence of methylphenidate prescribing, this 
analysis cannot reflect the actual incidence of ADHD/HDK. This is because some individuals 
might only receive non-pharmacological interventions which can not be identified hom the 
GPRD. Fourthly, many study subjects only had a diagnosis of behaviour problem alone with 
methylphenidate prescription. This raises the concern of inaccurate and imcompleteness of 
ADHD/HKD diagnoses in the database. Due to the shortage of funding, we were unable to 
obtain additional data through GPRD verification service via OP questionanres. This 
information can verify the diagnosis of ADHD/HKD. Thus, we did not estimate incidence of 
ADHD/HKD in our study. Fifthly, in the analysis of co-morbidity, there was no comparion 
group such as non-users of methylphenidate to justify whether these co-morbidities in 
methylphenidated-treated subjects were higher than in general population. This limits us to 
interpret our findings accurately.
Comparison with other studies
The level of methylphenidate prescribing dramatically increased after 1995. Several reasons 
have been suggested for this growing trend. Firstly, licensing status changed (Taylor 1995; 
Bramble 2000). Methylphenidate was previously available only on a named-patient basis 
from the licence holder. In 1995, it was re-licensed and available to the wholesalers, which 
can provide a plausible explanation for the growth in prescription. Secondly, ADHD is 
becoming more recognised, the ‘hyperkinetic disorder’ is more defined in ICD-10 than in 
ICD-9. This could result in children being more likely to receive methylphenidate (Taylor & 
Hemsley, 1995; Swanson et a l 1998; Bramble 2003). All these reasons have resulted in 
increased MPH prescribing during the past decade. It should be noted although
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methylphenidate prescribing dramatically increased in UK, overall prescribing rates are 
comparatively lower than other countries.
As discussed in Chapter 2 (see Table 2.1), several studies have estimated the prevalence of 
stimulants prescribing. Studies conducted in the USA by Rappley et al. (1995) showed the 2- 
month point prevalence of methylphenidate was 11 per 1,000; Safer et a l (1996) estimated 
that 28 per 1,000 children aged between 5 and 18 years used methylphenidate, whereas a 
figure of 11 per 1,000 was reported by Miller et al. (2001). However, these figures should be 
interpreted with caution, because several factors such as data source, sampling, geographic 
variation and economic status have been documented as influencing methylphenidate 
prescribing (Zito et a l 1997; Elia et a l 1999; Miller et a l 2001; Cox et a l 2003).
A GPRD-based study conducted by Jick et al. (2004) using a different version of the GPRD 
estimated the prevalence of ADD (Attention Deficit Disorder) with stimulants 
(methylphenidate, dexamethylphenidate) treated boys aged 5-14 years to be about 5.3 per
1,000 in 1999; the incidence rate was constant: 1.2 per 1,000 in 1996 and 1.3 per 1,000 in 
2001. Results from this study indicated a lower rate of ADD treatment in the GPRD 
compared with that of other countries.
However, it should be noted that this study was restricted to boys with a recorded diagnosis 
of ADD. In 2000, the National Institute for Clinical Excellence (NICE) guidelines on the use 
of methylphenidate for ADHD suggested about 1% of children aged 6-16 years (69,000 in 
England and 4,200 in Wales) meet the diagnostic criteria for hyperkinetic disorder. Of this 
number, approximately 48,000 (65%) are not receiving methylphenidate for treatment 
(NICE). The under-diagnosis of ADHD in the UK is of greater concern than over-diagnosis
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(Thapar 2003). With regard to the lower methylphenidate prescribing rate in the UK, it could 
possibly indicate under-treatment, under-diagnosis of ADHD or that nonpharmacologic (e.g. 
behavioural therapy, cognitive therapy) interventions are preferred in UK practice. Moreover, 
Taylor et al. (1999) stated little evidence exists regarding the superiority of methylphenidate 
treatment over behavioural therapy in the long term, and doctors are reluctant to use 
methylphenidate for the treatment of ADHD/HKD. This could be one of the explanations for 
this lower rate of prescribing compared with other countries. However, due to the evidence 
available on record in the database, it is not feasible to investigate which behavioural 
interventions had been used for ADHD/HKD treatment. In addition, it is difficult to verify 
whether under-treatment of ADHD/HKD occurs since many patients may only present 
symptoms, and as a result, a definite diagnosis of ADHD or HKD possibly was not recorded 
by GPs. Also, many study subjects received methylphenidate only had a diagnosis of 
behaviour problem, this has caused the concerns of inaccurate and incompleteness recording.
Previous studies showed that some ADHD/HKD children receiving dmg treatment did not 
meet the diagnostic criteria (Jensen 1999; Sawyer 2002; Angold 2000). This could possibly 
be due to the difficulty of ADHD/HKD assessment. In our analysis, a substantial number of 
study subjects were found only to have behaviour problems without definitive ADHD/HKD 
diagnoses. There are several explanations for this. Firstly, a computerised database is subject 
to recording bias by GPs, i.e. information is recorded based on what GPs choose to record 
(see Chapter 4). Secondly, methylphenidate may possibly have been issued to subjects who 
did not meet ADHD/HKD criteria (over-treatment). However, this explanation is less likely 
as the prevalence of methylphenidate prescribing is lower than that of other counties. Thirdly, 
the issue of whether clinicians are fiilly equipped to meet the needs for assessing 
ADHD/HKD or have knowledge in using stimulants in the paediatric population. Results 
fi'om a national survey revealed that only 21% out of 67 paediatricians felt competent to
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prescribe psychotropic drugs, in which methylphenidate was the most commonly used drug 
in their clinical practice (McNicholas 2001).
A small number of prescriptions were found to have a dosage use over the recommended 
maximum level. Dosage use of methylphenidate is tailored by patients’ clinical performance, 
so we cannot infer that exceeding dose was due to ineffective or inappropriate use. In general, 
dosage use in children is weight-based. According to BNF Children, the recommended dose 
use of methylphenidate is initially 5mg twice a day and increased gradually by weekly 
interval, if necessary. Our analysis of dosage increased with increasing age which is in line 
with study in the Netherlands (Faber et a l 2005).
“Drug holiday” in ADHD children is recommended; that is stopping the use of drugs (e.g. 
stimulants) on weekends and during school holiday (Holowenko 1999). Manos (2005) has 
expressed that a drug holiday in ADHD treatment can be used to: (i) demonstrate the clinical 
need for the drug (ii) temporarily remove the side effects of the drug and, (iii) satisfy the 
notions of parents that a drug should not be used if it can be avoided. A study by Martins et al. 
(2004) included 40 ADHD boys to assess the efficacy and tolerability to methylphenidate 
during the drug holiday (weekend). The satisfaction of tolerability was reported by parents 
and teachers. Results demonstrated that a weekend holiday from methylphenidate treatment 
can reduce the insomnia and appetite without an increase of ADHD symptoms. Due to this 
pattern of methylphenidate use, it is problematic to calculate its exposure status. In the 
database, reasons for methylphenidate discontinuation did not record. Also, we did not obtain 
additional information fi*om GP questionnaires to confirm compliant use. Hence, we were 
unable to caiTy out further safety study in methylphenidate.
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Methylphenidate is not licensed for use in children under the age of 6. Rapple et. aL (1999) 
noted that methylphenidate use in children aged 3 or younger with ADHD was found high 
(57.0%; 127/223). In our study, a small proportion of young children aged <6 years were 
being issued methylphenidate. This raises concern about the safety of methylphenidate use in 
younger children. In 2006, a study conducted by the National Institutes of Health's National 
Institute of Mental Health (NIMH) showed that a low dose (3.75 mg daily of 
methylphenidate) is safe for younger children (aged 3-5) with ADHD. A total of 303 children 
were included, and about 89% of children tolerated methylphenidate. There was 11% subjects 
had to come off treatment due to adverse effects (e.g. weight loss, insomnia, loss of appetite). 
Although this study demonstrated the safety and effectiveness of methylphenidate use in 
young children, a suggestion of closely monitoring adverse effects in this age group was 
expressed (Greenhill et a l 2006).
In co-morbidity analysis, we observed that asthma was the most common co-morbidities. 
There are three suggestions to explain this finding. Firstly, the prevalence of asthma appears 
high in children and adolescents. Data from the Office for National Statistics (1998) showed 
that the prescribing rate of asthma treatment was highest in aged 5-15 and the prevalence of 
asthma treatment was increased continually fi'om 128.0 per 1,000 in 1994 (n=9,593) to 132.0 
per 1,000 in 1998 (n=l 1,979). This indicates that asthma has become increasingly common in 
this paediatric population. Secondly, methylphenidate-treated patients who are under the care 
of paediatric service are possibly more likely to be identified. Thirdly, a question of whether 
asthma or its treatment triggers ADHD has been expressed. A study by Biedennan et a l 
(1994) investigated the association between asthma and ADHD boys. A total of 140 subjects 
aged 6-17 years were identified and compared with a group of boys without ADHD (n=120). 
No evidence has shown an association between asthma and ADHD. However, a study by
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Leibson et a l (2001) contradicted Biedennan et a l study. Leibson and colleagues conducted 
a population-based cohort study to compare the medical care and costs in children and 
adolescents with and without ADHD. A total of 350 ADHD subjects were identified from 
4,880 cohort population. Their results showed that subjects with ADHD were more likely to 
have multiple diagnoses, including asthma, injury, and psychosocial than those without 
ADHD. Obviously, the issue of ADHD and asthma needs a proper study design to reassure 
the causality. As mentioned, we did not have comparison group to justify whether these co­
morbidities were higher in methylphenidate-treated subjects, it is not possibly easy to have 
firm conclusion regarding co-morbidity.
We also observed a high proportion of study subjects had a diagnosis of hearing problem. To 
date, there is no actual figure to demonstrate the frequency of hearing problems amongst 
ADHD children. However, to have hearing tested is suggested for ADHD/HKD case 
assessment. We cannot speculate whether these subjects actually suffer with hearing 
problems. The possibility of an incomprehensive assessment on ADHD/HKD should not be 
dismissed.
The intention of co-morbidity analysis was to stir up the relevant issues surrounding 
methylphenidate treatment. However, our approach was not a successful design. It is 
recommended to carry out a study to investigate the prevalence of these co-morbidites in 
methylphniedate treated population and general population (non-users). This study design 
would take a considerable amount of time, however the reulsts are informative.
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6.5 Conclusion
Methylphenidate has gained popularity in many years. It should be emphasized that research 
on methylphenidate treatment in children and adolescents is in its early stage in the UK. 
Despite a huge increase in prescribing over the last decade, suggesting that there is still under 
treatment. Although the issue of whether to use stimulants for the treatment of ADHD or 
HKD is still under debate, appropriate diagnosis should be confirmed before methylphenidate 
is prescribed. A national guideline has been released to assist clinicians in using stimulants in 
this study population, but the information with regard to safety profile is insufficient. A 
number of potential adverse drug reactions have been suggested with methylphenidate such 
as weight loss, appetite changes, anxiety, insomnia etc. (BNF Children 2005). In the GPRD, 
however, the issues with exposure assessment and outcome measurement make it difficult to 
carry out risk assessment in methylphenidate treatment. For example, growth retardation is 
one of the most concerning effects of its treatment so that height and weight monitoring is 
suggested. The database contains weight and height records, but infonnation is not adequate 
to investigate this adverse effect. Moreover, some individuals received methylphenidate on 
an irregular basis such as drug holiday which makes it difficult to evaluate the causality and 
also the exposure assessment is imprecise, thus, the subsequent chapters focus on 
anticonvulsants treatment.
I l l
Chapter 7 Anticonvulsant prescribing patterns in children and 
adolescents
7.1 Introduction
In previous analysis (see Chapter 5), results showed that anticonvulsants were amongst the 
most common used psychotropic drugs, with about 4 per 1,000 prevalence of use amongst 
girls and slightly over 4 per 1,000 of boys being prescribed an anticonvulsant. A number of 
epidemiological studies have investigated anticonvulsant use in the community. However, 
these studies have been based on a mix of an adult and paediatric population. Very few 
studies have focused their investigations on children and adolescents in particular. Treating a 
child with epilepsy depends upon each individual i.e. frequency of seizures or epilepsy 
syndrome, and also the wishes of the parents (Appleton & Gibbs, 1997). Differences of 
seizure types in a paediatric population make the choice of anticonvulsants different to that of 
adults. The International League Against Epilepsy (ILAE) has expressed several important 
aspects in relation to children with epilepsy:
• Greater multiplicity of epileptic conditions.
• Heterogeneity with respect to syndrome types, causes and progress.
• Usual refractory seizure type is generalised rather than partial.
• Condition may change with age, one syndrome may evolve into another.
• Greater potential impact on the social, educational and behavioural spheres of life.
The concern of anticonvulsant treatment may even differ between children and adolescents 
such as teenage girls in childbearing age. For example, some enzyme-inducing 
anticonvulsants (e.g. carbamazepine, phenytoin, phénobarbital and topiramate) reduce the 
effectiveness of oral contraceptives (Appleton and Gibbs, 1997). The issue of anticonvulsant 
treatment in girls with epilepsy of childbearing age has been a major concern in clinical 
practice. However, discussion of this issue is beyond the scope of this thesis.
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To date, there is still a lack of comprehensive knowledge and understanding about how 
anticonvulsants are prescribed in the paediatric population, as well as concerns about the long 
and short-term side effects of anticonvulsant use. Although the newer anticonvulsants appear 
to have a more tolerable safety profile, this should remain somewhat guarded in view of the 
absence of long-term data (BNF Children 2005). The prescribing of anticonvulsants was 
comparatively high throughout the study period in the previous analysis (Chapter 5). 
Prescribing pattern of anticonvulsants in youths has not yet been characterised in the UK. 
This is particularly important as epilepsy is a chronic condition and patients need to receive 
treatment for seizure control. Similarly, the issue of limited research on the use of 
anticonvulsants in youths has been noted in the USA (Berg 1999). Thus, there is a need to 
understand to what extent anticonvulsants have been prescribed to children and adolescents in 
current UK practice. The aim of this chapter was firstly to explore epilepsy in children and 
adolescents, anticonvulsant treatment, adverse effects, and then lead to an utilisation study. 
Anticonvulsant prescribing patterns were characterised, including trend in incidence over 
nine years of prescribing, any records which corresponded with anticonvulsant licensed 
indications, concomitant use with other psychotropic drugs and co-morbidities.
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Epilepsy m children and adolescents
Epilepsy is defined as ‘recurrent seizures that are unprovoked by any immediate underlying 
cause’ (Hall et al, 1997). A clear distinction between epilepsy and seizure should be made, 
because people can also have seizures under some conditions without having epilepsy. 
Epilepsy is a common neurological condition in children. Epilepsy Action suggests about 
66,500 children and adolescents suffer with epilepsy in the UK fhttm/Avww.enilensv.ors.ukl. 
However, this figure may possibly be an underestimate. Appleton and Gibbs (1997) estimated 
that school children with epilepsy at any point in time would be approximately 85,000 in 
England, Wales, Scotland, and Northern Ireland; if it included pre-school children, then the 
number can add up to about 90,000 or 95,000. The reason for not having precise data on 
epilepsy in children is in part as a result of the difficulty of diagnosis. This issue will be 
discussed later.
According to the classification of the International League Against Epilepsy (ILAE), there 
are two major divisions of seizures: partial seizure and generalised seizure (Commission on 
Classification and Terminology of the International League Against Epilepsy 1981). The 
generalised seizure normally affects the whole brain whereas partial seizure only involves 
part thereof (Appleton & Gibbs 1997). Focal or localized seizures are also referred to as 
partial seizures. A summary of the ILAE classification of seizure presents in Table 7.1.
In a paediati'ic population, many epilepsy syndromes and causes of epilepsy are broadly 
different from those in adults. These syndromes are often age dependent, some are common 
and some appear rarely. Because of the variety of clinical presentations, it is not easy to 
propose an exact definition of epilepsy especially in paediatric patients. An article by 
Appleton published on the National Society for Epilepsy (http://www.epilepsvnse.org.ulO.
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argued that the differential diagnosis of epilepsy is particularly difficult in infancy (aged < 12 
months). This is because clinicians need to establish whether the seizures are epileptic or 
non-epileptic in origin before a diagnosis can be made. Consequently, Appleton and Gibbs 
(1997) suggested that in about 30-40% of the paediatric population, epileptic syndromes will 
not be identified, especially the initial onset.
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Table 7.1 International League Against Epilepsy (ILAE) classification of seizure*
-Partial seizure beginning locally 
Simple (consciousness not impaired)
• With motor symptoms
• With somatosensory or special sensory symptoms
• With autonomic symptoms
• With psychic symptoms 
Complex (with impairment of consciousness)
• Beginning as simple partial seizure (progressing to complex seizure)
• Impairment of consciousness at onset
• Impairment of consciousness only
• With automatism
Partial seizures becoming secondaiily generalised 
-Generalised seizures 
Absence seizures
• Typical
• Atypical 
Myoclonic seizures 
Clonic seizures 
Tonic seizures 
Tonic-clonic seizures
Atonic seizures______________________________________________________
*tlie reference source: Commission on Classification and Tenninology o f  the International League 
Against Epilepsy 1981).
The accurate diagnosis of difference epileptic syndromes is crucial in terms of aetiology, 
progress, and treatment selection (Appleton & Gibbs, 1997). The classification of epilepsy 
and epileptic syndromes is based on the origin of the seizures, i.e. localization-related (partial 
seizure). The ILAE classification (1989) of epilepsies and syndromes is presented in Table 
7.2. It is anticipated that this classification will be regulary revised.
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Table 7.2 Classification of epilepsies and epileptic syndromes 
_____________ of the International League Against Epilepsy (ILAE)* _______ __
Localization-! elated (focal, local, partial) epilepsies and syndrom es 
Idiopatliic (with age-related onset)
-benign childhood epilepsy with centio-temporal spikes 
-childhood epilepsy with occipital paroxysms 
-primary reading epilepsy 
Symptomatic
-clironic progressive epilepsia partialis continua o f  childhood (Kojewnikow's syndrome)
-syndromes characterized by seizures with specific m odes o f  presentation 
Cryptogenic (presumed symptomatic but aetiology unknown)
G eneralized epilepsies and syndrom es
Idiopathic (witli age-related onset, listed in order or age)
-benign neonatal familial convulsions 
-benign neonatal convulsions 
-benign myoclonic epilepsy in infancy 
-childhood absence epilepsy 
-juvenile absence epilepsy
-epilepsy with grand mal (generalized tonic-clonic seizures) on awakening 
-other generalized idiopathic epilepsies not defined above
-epilepsies with seizures precipitated by specific modes o f  activation (reflex and reading epilepsies)
Cryptogenic or symptomatic (in order o f  age)
-West's syndrome 
-Lennox-Gastaut syndrome 
-epilepsy with myoclonic-astatic seizures 
-epilepsy with m yoclonic absences 
Symptomatic 
Non-specific aetiology 
-early myoclonic encephalopatliy
-early infantile epileptic encephalopatliy with suppression buist 
-otlier symptomatic generalized epilepsies not defined above 
Specific syndromes/aetiologies 
-cerebral malformations
-inborn eiTors o f  metabolism, including pyridoxine dependency and disorders frequently presenting as myoclonic 
epilepsy
Epilepsies and syndrom es undeterm ined, w hether focal or generalized  
With botli generalized and focal seizuies 
-neonatal seiziu es
-severe m yoclonic epilepsy in infancey
-epilepsy witli continuous spike-waves during slow-wave sleep 
-acquired epileptic aphasia (Landau-Kleffher syndrome)
-other undetennined epilepsies not defined above 
Without unequivocal generalized or focal featuies 
Special syndrom es (Situation-related seizures)
-febrile convulsions
-isolated seizures or isolated status epilepticus
-seizures occurring only when tliere is an acute metabolic due to factors such as alcohol, drugs, non-ketotic 
hyperglycinaemia
rreflex epilepsy____________________________________________________________________________________________________
the reference source: Commission on Classification and Tenninology o ftlie  International League Against Epilepsy 1981.
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Epidemiology
It is problematic to estimate the precise extent of epilepsy due to the nature heterogeneous 
conditions and difficulty of diagnosis particularly in a paediatric population. As a result, there 
are no precise data on the prevalence and incidence of epilepsy in children and adolescents in 
the UK (Appleton & Gibbs 1997). Several epidemiological studies have made attempts to 
establish the prevalence and incidence rate in this population.
Table 7.3 presents the published studies on epilepsy point prevalence in children and 
adolescents. The point prevalence was from 3.9 per 1000 population to 5.1 per 1000 
population from aged 0-15 years. On the basis of various diagnostic criteria, the point 
prevalence of epilepsy is about4 per 1000 population in paediatric population. In 1993, a 
standard definition of epilepsy was given by The International League Against Epilepsy 
(ILAE) which suggested that despite drug treatment, cases should be considered to have 
active epilepsy when at least one epileptic seizure occurred within the previous 5 years. 
Although the definition of epilepsy case ascertainment has been made, different definitions 
have been applied in studies. A national study by Tidman et a l (2003), reported that 69 out of 
15,970 school children (aged 4-10) suffered with epilepsy, yielding the overall prevalence 4.3 
per 1,000 population. It should be noted that estimation in this study cannot actually be 
deemed as a model for the UK, as the sample was drawn only fr om the West Cheshire region.
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Table 7.3 Point prevalence of epilepsy in children and adolescents
Study Country Point prevalence Age No. of cases
Endziniene et al (1997) Lithuania 4.3 0-15 378
Eriksson et a l (1997) Finland 3.9 0-15 329
Waaler et al (2000) Norway 5.1 6-12 198
Tidman et a l (2003) UK 4.3 4-10 69
*point prevalence was expressed as 1000 per population.
A summary of the incidence of epilepsy in children and adolescents is shown in Table 7.4. 
Based on various definitions and methodology, a considerably higher incidence rate appeared 
in the first few years of life (Camfield et a l 1996; Beilmann et a l 1999; Freitage et a l 2001). 
It should be note that the method of case ascertainment was different in these studies i.e. by 
specialist vs any epilepsy diagnostic codes in the database. A study by using UK GPRD 
database, reporting a higher rate of incidence of epilepsy (Wallace et a l 1998). The authors 
stated that as the completelness of case asceitamine in their study result in the higher rate 
than other previous studies. As a consequence of the lack of consensus on diagnostic criteria, 
case ascertainment, and age range, it is difficult to compare these figures directly.
Table 7.4 Incidence rate of epilepsy in children and adolescents
Study Wallace et at^ Camfield et ah Beilmann et al. Freitage et al
(1998) (1996) (1999) (2001)
Country UK Novia Scotia Estonia Germany
Setting GPRD Tertiaiy pediatinc 
center
Hospital Hospital
Study period 1995 1977-1985 1995-1997 1999-2000
No. subjects 275 693 216 36
Diagnosis of epilepsy Diagnosis code & Unprovoked Single seizure Newly diagnosis of
anticonvulsant treatment seizure epilepsy
Age band (year)
<0 NA 118 (<13 mo) NA 145
1-4 NA 48 (aged 1-5) 76 62
5-9 63 43 (aged 6-10) 54 49
10-14 54 21 (aged 11-16) 44 55
15-19 101 NA 11 NA
Abbreviation: NA, not available; GPRD, tlie General Practice Research Database.
^incidence rate was expressed as million per person-years.
Ltudy subjects were identified by first diagnosis o f  epilepsy and first anticonvulsant prescription in 1995.
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Diagnosis
As discussed previously, it is not easy to establish a diagnosis of epilepsy in the paediatric 
population. Chinthapiii (2003) stated that about 30% of children with epilepsy are 
misdiagnosed. This is because many conditions such as night terror or migraine could 
sometimes be misread as epilepsy in children (Appleton & Gibbs 1997). A guideline of 
management of adults and children with epilepsy was released by NICE (2004a). The 
guideline suggested that patients should be seen by a specialist within 2 weeks of the onset of 
seizure, to ensure an accurate diagnosis is made and initiate appropriate treatment. The 
recommendations from the NICE guideline to assess epilepsy diagnosis include: detailed 
history of the attack, prospective recording (video and written), supporting investigations (e.g. 
EEG, neuroimaging), or giving children and their family an opportunity to discuss the 
diagnosis with a healthcare professional. In addition, a detailed care algorithm with epilepsy 
referral procedure was also drawn up in the guideline (Figure 7.1). A clear guideline of 
epilepsy management was made, but misdiagnosis of epilepsy in children is a significant 
concern in UK practice (Appleton 1999; Chadwick & Smith 2002).
The issue of wrongly diagnosed epilepsy in children has drawn the attention of the media in 
recent years. Dr. Holton, a paediafric consultant, was suspended by the Leicestershire NHS 
(National Health Service) T rust due to wrongly given epilepsy diagnoses and anticonvulsant 
treatments to about 500 children during the years of 1990 and 2001. A £10 million settlement 
scheme was approved by the High Court as compensation for the families (Wliite 2001; Dyer 
2005). The misdiagnosis wsa attributed to a lack of specialist paediatric neurologists and 
paediatricians who have expertise in epilepsy. Morton (2002) noted only 62 paediatric 
neurologists in the UK. The major concern of misdiagnosis in the paediatric population is the 
choice of anticonvulsants. The selection of an appropriate anticonvulsant should depend upon
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the seizure type. If the diagnosis was wrongly made, it may lead to inappropriate drug 
treatment being given to children and adolescents. This inappropriate anticonvulsant 
treatment could lead to unwarranted effects i.e. poor seizure control which would influence 
the prognosis of epilepsy and the quality of life. To make an accurate diagnosis is therefore a 
crucial step for epilepsy management in particular with regard to the choice of 
anticonvulsants.
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Figure 7.1 Outline of the UK epilepsy care algorithm (reference: NICE guideline 2004a)
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Anticonvulsants treatment
Once the epilepsy diagnosis has been made, the choice of anticonvulsant can be established. 
One study has shown that about 80% of children were treated with anticonvulsants for 
epilepsy (Berg et al. 1999). There are a number of considerations which must be taken into 
account regarding the selection of anticonvulsants such as seizure type, age, adverse effects 
(Steinhoff et al. 2003). Several clinical principles of anticonvulsant selection in the paediatric 
population have been addressed by Appleton and Gibbs (1997), including (i) when to start a 
drug; (ii) which drug and in what dose; (iii) when to change the drug; (iv) when and how to 
add a second drug and which one; (v) when to seek a specialist opinion (paediatric 
neurologist) and, (vi) when to stop the drug.
After the 1990s, many anticonvulsants were launched on the market and these drugs have 
been defined as ‘newer anticonvulsants’. To date, 18 anticonvulsants are available in the UK. 
The summary of these licensed drugs is given in Table 7.5. In general, monotherapy is the 
best option when an anticonvulsant is initiated (Sander 2004). Several newer anticonvulsants 
are licensed for use in the UK as ‘add-ons’ or as monotherapies in a range of seizure types: 
vigabatrin (VGB), lamotrigine (LTG), gabapentin (GBP), topiramate (TPM), tiagabine, 
levetiracetam (LVT), oxcarbazepine (OXC), pregabalin, and zonisamide. Some of these 
newer anticonvulsant would appear to have a broad spectrum of action, being effective for 
managing many generalised and partial seizure types.
Although a better tolerability of newer anticonvulsant has been claimed, this has not yet been 
well-established. LaRoche et al. (2004) used data from Cochrane Central Register of 
Controlled Trials to evaluate efficacy and tolerability of newer anticonvulsant, and found that 
there was limited evidence to support these newer anticonvulsant being more efficacious but
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less drug interaction and better tolerability were shown. The newer anticonvulsants provide a 
wide availability of selection for the treatment of epilepsy. Research evidence on efficacy and 
long-term adverse effects is far less compared with that available for the conventional 
anticonvulsants. This is partly because newer anticonvulsants have had a short period of time 
on the market and less experience in clinical use. For example, the deficit of bilateral visual 
field causes by vigabatrin treatment was identified 10 years after its introduction (Appleton & 
Gibbs 1997). In addition, many newer anticonvulsants have not been fully tested in paediatric 
population (Trevathan 2000). The evidence for the effect of treatment with tiagabine in 
childhood epilepsy for instance remains unclear (Wallace 2001).
With the introduction of the newer anticonvulsant, the pattern of anticonvulsant use has 
changed over the past few years. A GPRD-based study showed that the use of newer 
anticonvulsant gradually increased and the prescribing rate was age dependent; it appeared 
the rate was high amongst those aged 5-15 years in both sexes in 1998 (Purcell 2002). A 
guideline on the use of newer anticonvulsant in children with epilepsy was released by NICE 
in 2004. There were six newer anticonvulsant included in this guideline: gabapentin (GBP), 
lamotrigine (LTG), oxcarbazepine (OXC), tiagabine, topiramate (TPM) and vigabatrin 
(GVB). Apart fr om the recommendations regarding indication and dosage, the information on 
cost was also provided to achieve cost-effective epilepsy management. According to the 
guideline, if a seizure cannot be well controlled by conventional anticonvulsants or children 
cannot tolerate the adverse effects, then a new anticonvulsant can be considered (NICE 
2004b). Although the tolerability of newer anticonvulsant is superior to conventional 
anticonvulsants, data from the USA reported that a new anticonvulsant was rarely the first 
line choice for the treatment of newly diagnosed children (Berg et a l 1999).
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The choice of an appropriate anticonvulsant treatment aims to achieve seizure control, but 
also to minimize adverse effects. Anticonvulsants may cause significant physical and 
intellectual disabilities such as learning difficulties in children even if seizure control is 
improved (Appleton & Gibbs 1997). Although children can have their seizures controlled 
with anticonvulsants, adverse effects in some children are inevitable. A study carried out by 
Herranz et a l (1988) identified 392 children who were given monotherapy with 
phénobarbital, primidone, phenytoin, carbamazepine or valproate; adverse effects occurred in 
about 50% of study subjects. Other factors such as over-treatment and compliance should 
also be taken into account. Over-treatment was also noted, i.e. anticonvulsant prescribing 
when not required and the unnecessary and inappropriate use of polytherapy (Perucca 2002). 
Non-compliance regarding anticonvulsant treatment may result in poor seizure control.
Unlike most psychotropic drug groups (e.g. stimulants, antidepressants), no attempt has been 
made to evaluate anticonvulsant prescribing patterns in children and adolescents in the UK. 
However, the optimisation of prescribing for epilepsy treatment in children is urgently 
required since it would lead to better outcome for the child, family and carers. The initial step 
is to monitor the prescribing trend in which in-depth understanding of how these drugs are 
used can be obtained, and this is able to priority the issues deserving further safety studies.
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7.2 Methods
The study population included all children and adolescents aged 0-18 at any time during the 
study period and permanently registered in practices contributing data to the GPRD at any 
time between 1 January 1992 and 31 December 2000 (Study period). Every individual subject 
who had had received at least one prescription for an anticonvulsant at the aged between 0 
and 18 years was identified.
Anticonvulsants
All anticonvulsant prescriptions were identified. Anticonvulsants were grouped as 
conventional and newer. The conventional anticonvulsants included acetazolamide, 
carbamazepine, clobazam, diazepam, ethosuximide, gabapentin, lamotrigine, levetiracetam, 
lorazepam, methsuximide, methylphenobarbital, oxcarbazepine, paraldehyde, phénobarbital, 
phenytoin, piracetam, sodium valproate, tiagabine, topiramate, and vigabatrin. Prescriptions 
for non-orally administered lorazepam and diazepam (i.e. injections, suppositories) were also 
identified, as these products were licensed for the treatment of status epilepticus. Newer 
anticonvulsants included vigabarin (VGB), lamotiigine (LTG), topiramiate (TPM), 
Gabapentin (GBP), Oxcarbazepine (OXC), and Levetiracetam (LVT).
Incidence o f  anticonvulsant prescribing
Study subjects who had not received any anticonvulsant prescription in the previous year 
were defined as new users (incident users). To achieve meaningful analysis, at least one- 
year’s medical data had to be available prior to first anticonvulsant prescription for each new 
user. Incidence was defined as the number of subjects classified as incident cases divided by 
the person-years at risk in the GPRD paediatric population aged 0-18 years. The numerators 
were the number of new anticonvulsant users. The denominator was the sum of the person-
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years calculated using the number of patients aged 0-18 years who contributed censoring data 
to GPRD, divided by 365. The incidence rate of prescribing was expressed as the number of 
users per 1,000 patient-years.
Incidence = subjects classified as new anticonvulsant users in a particular year
Total person-time in GPRD population aged 0-18 year in a particular year
Prescribing patterns
All prescriptions for anticonvulsants within the study period were identified. The recorded 
indications for treatment and co-morbidity patterns were evaluated by age and sex. 
Concomitant use of other psychotropic drugs was quantified in which a concomitant was 
defined as one where the prescriptions were issued in the same month (within 30 days) as 
anticonvulsants. Psychotropic drugs were grouped as follows: stimulants, antidepressants, 
antipsychotics, hypnotics/anxiolytics, and clonidine. Lithium was not included in this study, 
because the level of lithium use was found to be relatively low in previous analysis (see 
Chapter 5).
Epilepsy diagnosis
There were 146 epilepsy codes were identified from GPRD (version 2000) which related to 
epilepsy diagnoses and symptoms. Based on the recorded diagnoses and symptoms of 
epilepsy, the seizure type was then grouped as generalised seizure, partial seizure and 
unclassifiable, in accordance with the classification which was proposed by the International 
League Against Epilepsy (ILAE) (Commission 1981). A summary of epilepsy codes is 
shown in Appendix II.
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Variation prescribing by practice
To establish whether prescribing of anticonvulsants varied by practice, all practices 
contributed data in 2000 issued anticonvulsant prescription to children and adolescents aged 
<19 were identified. For each practice, the proportion of study subjects received at least one 
anticonvulsant was calculated.
Statistical analysis
A test for trend (Cochran-Armitage trend test) was used to examine whether there was a 
yearly trend in anticonvulsant prescribing. The exact method was used to calculate the 95% 
confidence intervals: CI=p-(1.96xs.e.) to p+(1.96xs.e.) (Tobi et a l 2005). Analyses were 
conducted using Stata/SE, version 8 (Stata Corp, College Station, Texas).
73 Results
A total of 7,972 study subjects were prescribed 161,957 anticonvulsant prescriptions, 52.2% 
(n=4,160) of whom were boys. Of these, 63.6% (n=5,165). On average, study subjects were 
prescribed 1.5 different anticonvulsants (SD 1.06; range 1-9). Table 7.6 shows the number of 
prescriptions and the characteristics of study subjects by conventional and newer 
anticonvulsant group. There were 150 study subjects had a death record during the study 
period.
Table 7.6 Study subjects characteristics by anticonvulsant group
Conventional anticonvulsants Newer anticonvulsants Total
Prescription (%) 125,133 (77.3) 36,824 (22.7) 161,957(100.0)
Most commonly prescribed drug Sodium valproate Lamotrigine
Prescription (%) 93,522 (57.7) 19,782 (12.2)
Subject’ 7,470 (93.7) 1,644 (20.6) 7,972(100.0)
Boys/girls 3,942/3528 812/832 4,160/3,812
Mean age at f  * prescription (SD), y 9.7 (5.6) 10.2 (5.4)
‘subjects were counted more than once if  prescribed anticonvulsants from both conventional and newer anticonvulsants.
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Incidence rates of anticonvulsant prescribing are presented in Table 7.7. Incidence rate of 
anticonvulsant prescribing remained relatively stable from 1.40 per 1000 (95%CI 1.41-1.57) 
in 1992 to 1.05 per 1000 (95% Cl 0.90-1.22) in 2000.
Table 7.7 Incidence rates of anticonvulsant prescribing in study subjects'
Year New cases Person-years lincidence 
(95% Cl)
Boys 
(95% Cl)
Girls 
(95% Cl)
1992 1,234 829,441 1.40(1.41-1.57) 1.54(1.42-1.66) 1.44(1.32-1.56)
1993 1,142 837,018 1.36 (1.29-1.45) 1.40(1.29-1.52) 1.32(1.21-1.44)
1994 1,033 812,936 1.27 (1.19-1.35) 1.29(1.18-1.40) 1.25 (1.14-1.37)
1995 958 779,478 1.23 (1.15-1.31) 1.24(1.14-1.36) 1.21 (1.10-1.33)
1996 762 633,944 1.20(1.12-1.29) 1.16(1.05-1.28) 1.25 (1.13-1.38)
1997 622 505,010 1.23 (1.14-1.33) 1.22(1.09-1.36) 1.24(1.11-1.39)
1998 438 415,241 1.05 (0.96-1.16) 1.08 (0.95-1.23) 1.03 (0.89-1.18)
1999 301 299,636 1.00 (0.89-1.12) 1.07 (0.91-1.25) 0.94 (0.79-1.11)
2000 173 164,459 1.05 (0.90-1.22) 1.18 (0.96-1.43) 0.92 (0.72-1.16)
Incidence rate was expressed as per 1,000 person-years.
Figure 7.2 shows the age-specific incidence of anticonvulsant prescribing. The incidence 
rates of prescribing was highest in young children aged 0-2 years from 3.16 per 1000 (95%CI 
2.81-3.53) in 1992 to 1.99 (95%CI 1.35-2.85) in 2000. Incidence rates of prescribing were 
relatively stable between aged 3 to 18 years over study period.
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Figure 7.2 Age-specific incidence rates of anticonvulsant prescribing in study subjects
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Figure 7.3 shows the changes in the patterns of use of anticonvulsants over time. The 
prescribing of sodium volproate was higher than that of other drugs throughout the period 
covered. Carbamazepine prescribing declined fractionally whereas phenytoin decreased from 
337 subjects (337/7,972; 4.1%) in 1992 to 27 subjects (27/7,972; 0.34%) in 2000. The use of 
newer anticonvulsant increased constantly, especially lamotrigine. This was due to the 
introduction of gabapentin in 1993 and topiramate in 1995.
Figure 7.3 Proportional use of anticonvulsant by calendar year
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7,059 (88.5%; 7,059/7,972) had at least one record indicating epilepsy diagnosis in which 
‘epilepsy convulsion’ was the most commonly recorded diagnosis associated with 
anticonvulsant prescriptions (Table 7.8). There were 74 subjects out of 913 had only one 
diagnosis of febrile convulsion in their medical records. Amongst 74 study subjects, sodium 
valproate (n=59) was the most commonly prescribed anticonvulsant, followed by non-orally 
administered diazepam (n=15) and phénobarbital (n=l 1).
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A total of 913 subjects who had no epilepsy diagnosis but received anticonvulsant for 
treatment, of these 377 practices were identified. This prescribing pattern did not concentrate 
in specific practices. Amongst these patients, 71 had a diagnosis of headache, 70 had 
behavioural problems, 70 had a record of head injury, 53 had a record of pain, 38 had a 
diagnosis of migraine, and 31 had a diagnosis of depression associated with their 
anticonvulsant prescriptions. Of 45 subjects with a diagnosis of pain, sodium valproate was 
the most commonly prescribed drug (n=17), followed by carbamazepine (n=15) and 
phenytoin (n=13).
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Table 7.8 Diagnoses of epilepsy in 7,972 study subjects prescribed an anticonvulsant"
Read/OXMIS term Patient number %
Epilepsy convulsions 5078 63.36
Fit 2920 36.6
Convulsion 1744 21.87
Fit epileptic 1281 16.06
Seizure 1361 17.07
Epilepsy 910 11.41
Febrile convulsion 875 10.97
Petit mal 743 9.32
Grand mal epilepsy 584 7.32
Status epilepticus 221 2.77
Absence attack 165 2.06
Temporal lobe epilepsy 181 2.27
Funny turns 167 2.09
Epileptiform attacks 162 2.03
Convulsion febrile 178 2.23
Epilepsy monitoring 105 1.32
Epileptic absence 102 1.28
Infantile spasm 101 1.27
Seizure Jacksonian 97 1.22
Post ictal state 73 0.92
Seizure febrile 72 0.90
Nocturnal epilepsy 65 0.82
FIT (in known epileptic) 63 0.79
Petit mal (minor) Epilepsy 59 0.74
Drop attack 59 0.74
Epileptic absences 54 0.67
Grand mal seizure 47 0.59
Jerks Myoclonic 44 0.55
Post-traumatic epilepsy 23 0.28
Neonatal convulsion 21 0.26
Epilepsy resolved 18 0.22
Seizure Akinetic/Myoclonic 15 0.19
Focal epilepsy 14 0.18
A seizure 14 0.18
Seizure dystonie 10 0.12
Tonic-Clonic epilepsy 9 0.11
Juvenile absence epilepsy 9 0.11
Epileptic seizures - Tonic 9 0.11
Epilepsy Nonconvulsive generalised 8 0.10
Follow-Up epilepsy assessment 7 0.09
Status epilepticus, unspecified 7 0.09
Post-ictal state 7 0.09
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Table 7.8 (Continued)
Read/OXMIS term Patient number %
Epileptic seizures - Myoclonic 6 0.07
Complex Partial status epilepticus 6 0.07
Epileptic seizures- Clonic 6 0.07
Traumatic epilepsy 6 0.07
Myoclonic seizure 5 0.06
Grand mal fit 5 0.06
Seizure hysterical 5 0.06
Epilepsy Temporal benign childhood 5 0.06
Lennox-Gastaut Syndrome 4 0.05
Eye witness to epileptic seizure 4 0.05
Migraine epilepsy 4 0.05
Idopathic epiliepsy 4 0.05
Seizures in newborn 3 0.04
Epileptic seizures-Atonic 3 0.04
Psychosis epileptic 3 0.04
Epilation eyelash 3 0.04
Initial epilepsy assessment 3 0.04
Generalised convulsive epilepsy 3 0.04
SPELLS (meaning seizure) 3 0.04
Partial epilepsy with impainnent of 
consciousness 3 0.04
Petit mal fit 3 0.04
Acquired aphasia with epilepsy [Landau - 
Kleffner] 2 0.02
Epilepsy associated problems 2 0.02
Generalised nonconvulsive epilepsy 2 0.02
Petit mal status 2 0.02
Partial epilepsy without impairment of 
conscious 2 0.02
Hysterical seizures 2 0.02
Epilepsy peripheral 1 0.01
Myoclonus 1 0.01
Epilepsy treatment changed 1 0.01
Benign Rolandic Epilepsy 1 0.01
Absence seizure 1 0.01
Grand mal status 1 0.01
Focal fit I 0.01
Other forms of epilepsy 1 0.01
'diagnoses were not mutually exclusive; study subjects were counted for more tlian once if  they had more tlian one epilepsy 
codes in their medical records.
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According to ILAE epilepsy classification, there were 1,814 subjects with primarily 
generalised seizure, 275 had a diagnosis related to partial seizure, and 785 subjects with 
unclassified seizure. A total number of 4,386 had a record with only ‘epilepsy’ or 
‘convulsion’, and the seizure type could not be firmly established. A total of 221 subjects had 
a record of status epilepticus at any time in their medical records.
Approximately 5.14% (410/7972) received hypnotics/anxiolytics along with anticonvulsants, 
a total of 232 of study subjects had been given antipsychotics simultaneously. A summary of 
concomitant use of psychotropic drugs in anticonvulsant-treated study subjects is presented in 
Table 7.8. Individual psychotropic drug product of hypnotics/anxiolytics, antidepressants, 
and antipsychotic are presented in Table 7.9-7.12.
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Approximately 20% of study subjects had a concurrent diagnosis of asthma, 1,122 (14.1%) 
had a diagnosis of mental disorders, and 861 (10.8%) had one or more behavioural problems 
were recorded in their medical records (Table 7.13).
Table 7.13 Co-morbidity patterns amongst anticonvulsant-treated subjects (n=7,972)
Diagnoses Patient number (%) Percentage (%)
Asthma 1,582
Boys 883 11.1
Girls 699 8.7
Mental disorders 1,122
Boys 626 7.8
Girls 496 6.2
Behaviour problems 861
Boys 559 7.0
Girls 302 3.8
Sleep problem 612
Boys 323 4.1
Girls 289 3.6
Speech problem 593
Boys 371 4.6
Girls 222 2.8
Cerebral palsy 505
Boys 301 3.8
Girls 204 2.6
Migraine 424
Boys 186 2.3
Girls 238 2.9
Depression 247
Boys 76 0.9
Girls 171 2.1
Anxiety 161
Boys 64 0.8
Girls 97 1.2
ADHD 86
Boys 64 0.8
Girls 22 0.3
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There was a variation of anticonvulsant prescribing by practice (Figure 7.14). A total of 136 
practices identified in year 2000, of which 641 study subjects received at least one 
anticonvulsant prescription aged between 0 and 18 years.
Figure 7.14 Percentage of children and adolescents received anticonvulsant aged 0-18 years
in 2000, by practice.
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7.4 Discussion
The incidence rate of anticonvulsant prescribing has remained relatively stable over time; the 
incidence rate of prescribing was highest in children aged 0-2 years. Our observation is 
consistent with previous studies (Camfield et al. 1996; Beilmann et al. 1999; Freitage et al. 
2001). The most commonly prescribed anticonvulsant was sodium valproate in children and 
adolescents. The level of new anticonvulsants use increased continually in particular 
lamotrigine whereas the use of carbamazepine and phenytoin declined over time. Hypnotics 
and anxiolytics were the most commonly concomitant use psychotropic drug group, 8.2% in 
1992 and 8.6% in 2000 respectively. The majority of anticonvulsant prescriptions appeared to 
have been prescribed for epilepsy treatment, however, seizure type was not specifically 
recorded.
Limitations and Strengths
To our knowledge, this is the first study to provide a comprehensive description of 
anticonvulsant prescriptions patterns amongst children and adolescents in UK general 
practice. The GPRD provides a rich source of diagnostic and prescribing data, however, 
several limitations of the data need to be considered. Firstly, it has been demonstrated that 
socio-economic deprivation is associated with epilepsy. Morgan et a l (2000) have reported a 
strong association between social deprivation and epilepsy prevalence. This study was carried 
out in the district of South Glamorgan and the association between social deprivation and 
epilepsy was estimated in two cohorts: all patients with epilepsy and patients with epilepsy 
without any psychiatric disorders. The results have shown a strong correlation between social 
deprivation and epilepsy in both cohort groups (p<0.001). Also, a prospective community- 
based study in southeast England reported that incidence rate of epilepsy increased with 
socio-economic deprivation (Heaney et al. 2002). The reasons of people with low
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socioeconomic status are more likely to have epilepsy remain unclear at this time. Heaney 
and colleagues stated a plausible reason is that several risk factors such as birth defects, poor 
nutrition, and trauma are common in a deprived population, and these risks may lead to the 
development of seizures. The GPRD version (2000) does not contain information on socio­
economic status (SES) so we were unable to investigate this association in our study. 
Secondly, although prescribing data were recorded, the compliance of anticonvulsant 
treatment cannot be firmly established in computerised database. Thirdly, epilepsy diagnoses 
did not validate in our study. We did not send off GP questionnaires to confirm the diagnosis 
on an individual basis. Consequently, we were unable to further investigate the rational of 
anticonvulsant as the seizure type cannot be clarified. Fourthly, this version of GPRD does 
not contain the information of NHS administrative regions and country for Wales, Northern 
Ireland, and Scotland. Hence, the variation of region cannot be further investigated. Fourthly, 
the results of co-morbidity were not informative. This is because we did not have a 
comparison group to compare whether this co-morbidity pattern is different from the general 
population.
The incidence rate of anticonvulsant prescribing was apparently highest amongst children 
aged 0-2 years and declined thereafter. It has been reported that the incidence rate of epilepsy 
is high during the first years of life (Camfield et al. 1996; Beilmann et al. 1999; Freitage et 
al. 2001), a higher anticonvulsant prescribing in this age group can be expected. This 
suggests that anticonvulsant prescription data can be used as proxy to estimate the incidence 
of epilepsy itself.
Few studies have been characterized anticonvulsant prescribing in paediatric population. 
Using Medicaid data in Tennessee, Cooper et a l (1997) identified 647 new users of
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anticonvulsant aged 0-18 years. Of these 378 had at least one epilepsy diagnosis in the 
medical record, yielding an increased rate of 1.84 per 1000, the highest prevalence rate (2.44 
per 1000) appeared in children under aged 5 years; sex-specific prevalence was observed 
higher in male than female users. The most commonly anticonvulsants were barbiturates, 
hydantoin and carbamazepine. For those study subjects who did not have a diagnosis of 
epilepsy, headache and psychiatric diagnoses were associated with anticonvulsant 
prescriptions. Similarly, a population-based study by Zito et al. (2006) demonstrated that 
many children and adolescents were received anticonvulsants for other psychiatric condition 
other than seizure control. This prescribing pattern in the US practice, however, is not 
consistent with our study. The majority of anticonvulsant prescriptions appeared to have been 
issused for epilepsy treatment in our study subjects.
The majority of our study subjects had a diagnosis of epilepsy, however, which seizure type 
was not specifically recorded in the database. For example, some patients had only a 
diagnosis of ‘funny turn’ or ‘fit’ recorded in medical records. These terms are commonly 
used in clinical practice (Appleton & Gibbs 1997), however, it cannot be distinguished which 
type of seizure was implicated from these unspecific diagnoses. To make an accurate epilepsy 
diagnosis is difficult especially in children.
Anticonvulsants can also be prescribed for the treatment of trigeminal neuralgia, pain and 
bipolar disorder. (McQuay et al. 1995; Leo & Narendran 1999). With regard to the pain 
management, only three anticonvulsants (e.g. carbamazepine, phenytoin, gabapentin) are 
licensed for the treatment of trigeminal neuralgia in the UK. However, sodium valproate was 
found to be the most commonly prescribed anticonvulsant in those subjects who did not have 
epilepsy diagnosis and only had a diagnosis of pain. It should be noted that for those subjects
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who did not have a diagnosis of epilepsy, it remains unclear whether the GPs did not record 
the diagnosis or anticonvulsants had been prescribed for other conditions.
Proportionally, the level of newer anticonvulsant prescribed increased steadily over time. A 
study carried out in Northern England and Yorkshire between 1992 and 1995 demonstrated 
that the use of phenytoin and barbiturates decreased whereas carbamazepine and sodium 
valproate prescribing increased (Roberts et a., 1998). In 1998, using a questionnaire-based 
study from 80 primary care settings in the UK, Moran and colleagues reported that 68% out 
of 1,652 study subjects were being issued anticonvulsants for epilepsy treatment of which 
carbamazepine and sodium valporate were the most commonly prescribed whereas the use of 
phenytoin and phénobarbital declined. In our analysis, the level of newer anticonvulsant (e.g. 
gabapentin, topiramate) had steadily increased in particular lamotrigine. This change was due 
to the introduction of newer anticonvulsant in 1990s.
7.5 Conclusion
During the past decade, the use of anticonvulsants has changed considerably after the 
introduction of these newer anticonvulsants. This present analysis can be used as a starting 
point for providing information on anticonvulsant use in young people. Despite the increased 
use of anticonvulsants in this population, information regarding adverse effects of 
anticonvulsants is not fully established. As discussed in Chapter 2, various factors regarding 
the safety profile of anticonvulsants use in paediatric population possibly may differ from in 
adults. To date, few studies have been carried out to investigate anticonvulsant adverse 
reactions exclusively in children and adolescents. As many anticonvulsants have limited 
indications in paediatric seizure types, this may be difficult to quantify adverse reactions in 
paediatric population. A study carried out by Herranz et a l (1988) identified 392 children
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who were given monotherapy with phénobarbital, primidone, phenytoin, carbamazepine or 
valproate, about 50% of study subjects had adverse reactions. A comparative review article 
on the adverse effects of anticonvulsants in children, indicated that there were a variety of 
such adverse reactions which may occur in children who received an anticonvulsant for 
treatment, and skin disorders being the most common adverse reactions (Wallace 1996). A 
prospective study identified 21 children undergoing treatment with vigabatrin, of this 16 
children were shown to have evidence of visual abnormality. Although there was no strong 
evidence to demonstrate the causality, authors stated that children who receive vigabatrin for 
treatment need to have eye examinations regularly (Koul et a l 2001).
It was noted that a small proportion of our study subjects had records of death during study 
period. It has suggested that sudden unexpected death has been often linked to people with 
epilepsy (sudden unexpected death in epilepsy; SUDEP) (Nashef et a l  1995). It is worth to 
investigate the causes of death in this subgroup. In addition, a steadily increasing use of 
lamotrigine has been shown in our analyses. It has a clear warning of cutaneous adverse 
reactions of new anticonvulsants in the BNF Children (2005). In order to establish the 
association of these cutaneous adverse reactions with anticonvulsants in young people, a 
further investigation is deemed worthwhile. In the subsequent chapters, two safety studies on 
anticonvulsant use- Sudden unexpected death in epilepsy (SUDEP) and severe cutaneous 
reactions- were conducted to obtain more in-depth understanding of these issues.
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Part II
Safety Assessment studies
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Chapter 8 Sudden unexpected death in epilepsy (SUDEP) in 
children and adolescents
8.1 Introduction
This chapter characterises the cause of death amongst anticonvulsant tieated study subjects 
(see Chapter 7). It has suggested that patients with epilepsy have an increase risk of mortality 
when compare to the general population (Cockerell et ah 1994). This leads to the question of 
whether these deaths study subjects were attributable to anticonvulsants, epilepsy itself or 
other causes. Several causes are associated with patients with epilepsy, including drowning, 
status epilepticus, accident or other underlying disease. There is a group of epilepsy patients 
under healthy condition may die suddenly and unexpectedly. This phenomenon is referred to 
as sudden unexpected death in epilepsy (SUDEP) (Nashef et al. 1995). It is estimated that 
every year there are about 1,000 young people who die and half of these caused by SUDEP in 
the UK (Donaldson 2001).
Attention has been drawn to the issue of SUDEP in recent years. In 2002, the National 
Sentinel Audit of Epilepsy Death was released under the title ‘Epilepsy- death in the 
shadows’ by the National Institute for Clinical Excellence (NICE). This clinical audit was 
conducted by Epilepsy Bereaved to investigate epilepsy-related deaths. They examined 2,412 
deaths based upon their death certificates during September 1999 and August 2000. A 
commentary was published the key findings from this audit (Pedley & Hauser 2002). There 
are nine key messages addressed:
1. Medical records were generally poor. In primary-care settings, information related to 
epilepsy was incomplete or absent, and the situation was only slightly better in 
speciality settings.
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2. Therapeutic management was inadequate in one-fifth of the adults and in almost half 
the children.
3. Referral to a specialist could take longer than 6 months, and in only 48% of patients 
was the initial referral to a neurologist. For patients with multiple handicaps, referral 
to other specialists was rare.
4. A few of the patients who died were seizure-free at the time of their last visit to a 
physician, and 7% were not taking anticonvulsant drugs at the time of death.
5. Follow-up was inconsistent: 37% of the adults who continued to have seizures had not 
seen a physician in the year before they died.
6. Information provided to patients and their families was not documented and probably 
poor.
7. Post-mortem examination was frequently not performed when the circumstances of 
death should have mandated one before a certificate was issued.
8. Most (87%) of autopsy investigations were inadequate given the suspected diagnosis.
9. Only few families were contacted by physician after a patient’s death.
This audit revealed that many of these deaths were possibly due to poor epilepsy management 
and these were potentially avoidable (Donaldson 2001). It also highlighted the absence of 
guidelines in relation to the investigation of SUDEP and epilepsy management. Additionally, 
inadequate post-mortem examination and inaccuracies in recording cause of death were also 
addressed in this clinical audit. Without accurate death certification may lead to 
misclassification of the cause of death.
In 2004, the National Institute for Health and Clinical Excellence (NICE) states: “Children 
with epilepsy face an increase risk o f premature death, but the excess risk is concerned in 
children with symptomatic epilepsy and in children with learning or physical disabilities ” 
The SUDEP is particularly distressing for parents and carers of a child with epilepsy. It is 
therefore important to investigate this issue further. This chapter builds on the results from 
Chapter 7, by focusing on this particular study subjects who died during study period. In
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order to characterise this effect more closely a literature review was performed to determine 
mortality rate of children and adolescents with epilepsy and causes of death. In addition, the 
incidence rates of SUDEP were also examined.
Systematic literature review o f mortality) rate
This literature review was to investigate the mortality rate and cause of death in children and 
adolescents with epilepsy. Original studies reporting mortality rate associated with epilepsy 
in children and adolescents were sought in the MEDLINE from 1966 to December 2005. The 
reference lists of selected studies were also reviewed. Selected studies were imported and 
managed in EndNote 9 (Thomson Reuters Coiporation). The search criteria sought to include 
papers in English. As we did not have capacity to translate other languages, the search 
criteria sought to only include papers in English. Papers that clearly did not meet eligibility 
criteria were rejected on initial abstract review. Papers marked for inclusion were than 
obtained electronically or in paper copy. All papers of mortality in young people with 
epilepsy were selected by MESH heading or text word combination: {epilepsy or antiepileptic 
drug or anticonvulsant) AND {child or paediatric or pediatrics or adolescent) AND {death or 
mortality or sudden death or cause o f death) in the abstract or title.
The initial search identified 1,070 studies. O f these, 85 studies were included after reviewing 
the abstracts as containing information on mortality or cause of death. Eight studies were 
appraised in detail and assessed for inclusion. The reasons for excluding studies were: study 
subjects’ age>20 years (25), review article (26), case report or case series report (8), no 
information on mortality (18). Table 8.1 summaries the characteristics of 10 studies.
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It is apparent that there is limited evidence on the mortality rates and causes of death in 
children and adolescents with epilepsy. These paediatric studies have suggested the SMR 
ranged from 3.21 (1.48-4.95) to 8.8 (4.16-13.43) for all children with epilepsy which is 
higher than that of general population. Only one study stratified SMR by gender, of which 
girls was had a higher SMR [7.4 (95%CI 2.0-19.0)] than boys [6.6 (95%CI 2.2-15.5)] 
(Callenbach et al. 2001). Nashef et a l (1995) reported that SMR was highest in aged 10-14 
years [39.3 (95% Cl 17-77.5)] and SMR decreased in the 15-19 year age group [13.0 (95% 
Cl 5.2-26.8)]. Two studies were stated that death rates were higher in those children with 
severe epilepsy or severe underling conditions (Camfield et al. 2002; Berg et al. 2004).
A national report obtained data from the Office for National Statistics (ONS) mortality 
database, examining the overall mortality rate in patients with epilepsy between 1993 and 
2000 (Bruce et a l 2004). In 2000, it reported that the mortality rate was highest in female 
patients aged over 65 years (1.71 per million per population) and male aged 35-64 years (3.0 
per million per population) whiles considering epilepsy was cause of death. The mortality 
rates in both boys and girls however were relatively low. In 2000, the mortality rate was 0.33 
per 100,000 per population in girls and 0.36 per 100,000 per population. Similarly, these 
figures were considering epilepsy as the cause of death. It is not easily to compare national 
figures with these published studies as the age band from ONS report in children was from 
aged 0-14 year-old. Nevertheless, the mortality rates in young people with epilepsy are 
equally low in both sexes.
The causes of death in these published articles were mainly due to non-epilepsy related 
conditions such as respiratory insufficiency, pneumonia or suicide. In ONS report, about 40% 
of study subjects (n=l 5,990) the diagnosis of epilepsy itself was considered as the underlying
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cause of death, following by cerebrovascular diseases (14%), pneumonia (9%) and ischaemic 
heart disease (8%) (Bruce et a l 2004). The underlying cause of death in epilepsy patients in 
ONS report is presented in Table 8.2.
No study was reported the possibility of death was due to anticonvulsant treatment. However, 
a study using UK Safety of Medicines Yellow Card Scheme (YCS) data reported that 
anticonvulsants as a drug group were most frequently associated with mortality (Clarkson & 
Choonara 2002). This leads to the concern of whether anticonvulsant would be a risk factor 
for sudden death in young people with epilepsy.
It is difficult to have direct comparison between studies because of patients were identified 
from different settings either in community or secondary care. Additionally, it is questionable 
whether these reported SMR are a fair representation of mortality rate in young people with 
epilepsy as the sample sizes were relatively small in these studies.
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Incidence of sudden unexpected death in epilepsy (SUDEP)
A number of studies have estimated the incidence rate of SUDEP (Table 8.3). There were 
only 2 studies carried out in paediatric population (Nashef et a l 1995; Donner et a l 2001). A 
Canadian study examining the records from the coroner’s office during the period 1988-1998, 
identified 27 SUDEP cases under the age of 18 years, yielding a rate of SUDEP of 2 per 
10,000 person-years (Donner et a l 2001). The authors in both studies stated that SUDEP is 
rare in children with epilepsy. However, it needs to be addressed that these studies were case 
series and it is therefore not a fair representation in general paediatric population.
The SUDEP incidence rates from these published studies vary from 0.2 per 1,000 person- 
years to 5 per 1,000 patient-years. There are several seasons to explain this variation. Firstly, 
the study population was drawn fiom different sources. Two studies were using the GPRD as 
data source to estimate SUDEP incidence rate (Jick et al 1992; Derby et a l 1996). Both 
studies were obtained clinical records from GPs to confirm the diagnosis of SUDEP. The 
overall incidence rate of SUDEP was reported from 1.3 per 1000 person-years (Jick et a l 
1992) to 2.2 per 1000 person-years (Derby et a l 1996). It needs to note that study subjects 
were different in these two studies. Jick et a l (1992) study included subjects aged 15-49 
years whereas subjects in Derby et a l (1996) were all patients under aged 50 year-old. 
Secondly, the differing definition of SUDEP was applied between studies. For example, the 
studies by Jick et a l (1992) and Nashef et a l (1995) did not clearly define SUDEP cases. 
These two studies have reported higher incidence rate of SUDEP than that of other studies. 
As the definition of SUDEP was not clearly defined and age range was different between 
studies, it is difficult to make direct comparison. In addition, three studies were used 
anticonvulsant as a surrogate for the diagnosis of epilepsy (Jick et a l 1992; Tennis et a l 
1995; Derby et a l 1996). This approach may miss some patients who did not received
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anticonvulsant for epilepsy treatment, and also anticonvulsant can be used for conditions (e.g. 
bipolar disorder) other than epilepsy.
To date, no consensus has been reached on the definition of the SUDEP and there is no 
consistent clinical approach. A UK researcher Nashef (1997) proposed the definition of 
SUDEP as follows: ‘A sudden unexpected, nontraumatic and nondrowning death in an 
individual with epilepsy with or without evidence fo r a seizure and excluding documented 
status epilepticus where post-mortem examination does not reveal a toxicologic or anatomic 
cause fo r death ’. The USA Food and Drug Administration (FDA) along with Burroughs- 
Wellcome attempted to standardize this condition, so the criteria were initially developed to 
define SUDEP cases in lamotrigine clinical trial programme (Racoosin et al 2001). To date, 
this is the most frequently adopted criteria for SUDEP case assessment. SUDEP is 
ascertained as the cause of death if: The victim had epilepsy, defined as recurrent unprovoked 
seizures and,
• The victim died unexpectedly while in a reasonable state of health.
• If observed, the death occurred within minutes.
• The death occurred during normal activities and benign circumstances, thus 
excluding accidental deaths such as drowning, motor vehicle accidents (where the 
patient was the driver), and falls with immediate death due to trauma.
• An obvious medical cause of death was not found. An autopsy was necessary to 
establish a definite SUDEP; if  an autopsy was not performed and an obvious 
medical cause of death was also not established, the case was considered a 
probable SUDEP.
• The death did not occur in the setting of status epilepticus.
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The potential SUDEP cases then fall into four categories: (i) definite: other causes excluded 
by sufficient description of circumstances of death and autopsy with toxicologic screening; 
(ii) probable: no obvious cause of death but no autopsy; (iii) possible: possible but 
information regarding circumstances of death insufficient; (iv) not SUDEP: other causes of 
death established. It has been suggested that because of the lower rate of autopsy in the USA, 
normally the definition of SUDEP includes definite and probable cases (Walczak 2003).
The mechanism of SUDEP remains unclear to date. Three mechanisms of SUDEP have been 
proposed: respiratory insufficiency, cardiac arrhythmias and apnoea (Nashef 2001; Walczak 
2003; Camfield & Camfield 2005), however evidence for these mechanisms has not been 
fully confirmed at this time. A number of risk factors associated with SUDEP have been 
reported: young males (aged 20-40) (Langan et a l 2000), generalized tonic-clonic seizure, 
multiple anticonvulsants treatment, poor seizure control, increasing seizures attacks, switched 
anticonvulsants fiequently, poor compliance, sub-therapeutic anticonvulsant level (Nilsson et 
a l 1999; Kloster 1999; Opeskin et a l 2000; Walczak et a l 2001; Nashef 2001), and 
concomitant with psychotropic drugs (Tennis et a l 1995). It is apparent that these factors are 
not consistent between studies. This is possibly because of the lack of better understanding of 
SUDEP, leading to the analysis of risk factors being tentative.
Despite the evidence of SUDEP is rare in children, we proposed to assess the causes of death 
of children with epilepsy whom received anticonvulsant for treatment. A case series study 
was performed to identify the causes of death in study subjects prescribed anticonvulsants. 
The design of case series is to describe a group of patients with a similar outcome of interest. 
This kind of design cannot be used to investigate causality but can examine possible causal 
factors (Hennekens & Buring 1987). There are two reasons for choosing case series designs 
for this study. Firstly, the death cases presented a small proportion in anticonvulsant-treated
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subjects, so there might not be enough definite SUDEP cases to carry out a case-control study. 
Secondly, the evidence of risk factors of SUDEP in the paediatric population has not yet been 
firmly documented, to use a descriptive study design could assist to identify possible causal 
factors. The disadvantage of a case series study is lack of a comparison (control) group and 
therefore a false result may occur. However, it can be a good source for generating 
hypotheses. In addition, this study design can be valuable early evidence for further case- 
conti'ol study or prospective study.
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8.2 Methods
The study subjects were those aged 0-18 and permanently registered in practices contributing 
data to the GPRD at any time between 1 January 1992 and 31 December 2000. The study 
subjects were defined as those who had been prescribed at least one prescription for 
anticonvulsant. Anticonvulsants were defined according to the British National Formulary 
(BNF). Non-orally administered lorazepam and diazepam (i.e. injections, suppositories) 
prescriptions were also included. In this population, death cases were identified in three 
ways: (i) diagnostic codes (ii) register status, or (iii) death record described in the medical 
file, whichever was available in the database. In order to determine the cause of death, all 
records were reviewed manually. The detailed information included age of death, duration of 
anticonvulsant treatment, anticonvulsant regimen, and neurological co-morbidities.
The criteria of SUDEP established by Food Drug Administration (FDA) and Burroughs- 
Wellcome, was adopted to ascertain SUDEP cases. The criteria of SUDEP were: (i) patients 
died unexpectedly while in a reasonable state of health (ii) the death occurred during normal 
and benign circumstances (iii) the death may have occurred fiom complications of cardiac 
arrest. Each potential case was categorized into one of four categories: (i) definite SUDEP: 
cases meet all criteria with sufficient descriptions and post-mortem report (ii) probable 
SUDEP: cases fulfil all criteria without post-mortem record (iii) possible SUDEP: cases 
cannot be ruled out but evidence was insufficient (iv) not SUDEP: other causes of death were 
ascertained clearly. An algorithm of SUDEP cases is presented in Figure 8.1.
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Figure 8.1 Algorithm of SUDEP cases evaluation
Not SUDEPPossible SUDEPProbable SUDEPDefinite SUDEP
Retrieve Data from GPRD
Death cases identified^:
• Diagnostic Codes
• Register Status
• Death Date
Burroughs-Wellcome Criteria:
• The patient has epilepsy, which is defined as recurrent unprovoked seizures
• The patient died unexpectedly while in a reasonable state of health
• The death occuiTed during normal and benign circumstances
• An obvious medical cause of death could not be determined at autopsy
'^subjects were those who prescribed anticonvulsant at aged 0-18 between January 1992 and 
December 2000.
^cases were identified through Read/OXMIS codes indicating a death category; subject had a record 
o f  ti'ansfer out reason specified as "death"; date o f  death M>as also screening if  available.
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8.3 Results
A total of 7,972 subjects were identified received anticonvulsants, of which 150 deaths were 
identified. These 150 subjects form the basis of this analysis. Of these 150 deaths, 86 (57.3%) 
were boys. The average age at death was 8.9 years (SD= 5.6) (Figure 8.1). Sixty-four subjects 
(42.6%) were received only one anticonvulsant. On average, anticonvulsant treatment period 
was 20.8 months (SD=22.5). This study cohort (n=7,972) was contributing 42,607 person- 
years, the estimated overall death rate was 3.5 per 1000 person-years (95%CI 2,98-4.12). It 
was slightly higher in boys at 3.74 per 1000 person-year (95 % Cl 2.98-4.63) than in girls, 
where the death rate was 3.08 per 1000 person-year (95 % Cl 2.37-3.95). It should be noted 
that the causes of death were not validated at this stage. There was no death case was reported 
after 1996.
Figure 8.1 Age distribution at time of death in 150 anticonvulsant-treated subjects
25
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Table 8.4 Number of death subjects and percentage prescribed anticonvulsant with a
comparison of percentage of subjects in cohort study
Anticonvulsants No. of 
subjects^
Percentage
(n=150)
Comparison-No. of 
subjects  ^in study cohort 
(n=7,822)
Comparison-percentage 
of subjects in stud  ^
cohort (n= 7,822)
Sodium Valproate 83 55.3 6,129 78.3
Carbamazepine 54 36.0 614 7.8
Vigabatrin 31 20.6 728 9.3
Phenytoin 30 20.0 842 10.8
Lamotrigine 29 19.3 1,109 14.2
Phénobarbital 29 19.3 842 10.8
Clonazepam 26 17.3 390 4.9
Clobazam 10 6.6 89 1.1
Ethosuximide 3 2.0 408 6.1
Topiramate 3 2.0 110 1.4
Primidone 3 2.0 36 0.5
Paraldehyde 2 1.3 39 0.5
Gabapentin 3 2.0 187 2.4
*subjects ill the cohort study were those who received anticonvulsant for treatment and still alive during study period (n=7,822).
^subjects could have been received more than one anticonvulsant.
Table 8.4 shows the individual anticonvulsants prescribed in death subjects with a 
comparison of subjects who still alive during study period. Sodium valproate was the most 
common prescribed anticonvulsant in both groups, 55.3% in death subjects and 78,3% in 
comparison group. However, there is variation in other anticonvulsants use between groups.
Lamotrigine, phenytoin, and phénobarbital were commonly prescribed in comparison group 
whereas carbamazepine and vigabatrin were commonly prescribed amongst death subjects. 
Fifty-nine study subjects (39%; 59/150) were receiving another psychotropic drug at any time 
during the study period. Orally administered diazepam (n=29) was the most commonly 
prescribed psychotropic drug together with anticonvulsant, followed by chloral hydrate 
(n=15) and nitrazepam (n=12).
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Table 8.5 Number of death subjects and percentage of neurological co-morbidity with
a comparison of percentage of subjects in cohort study
Diagnosis No. of 
patients^
Percentage
(n-150)
Comparison-No, of 
subjects  ^in study 
cohort (n=7,822)*
Comparison-percentage 
o f subjects in study 
cohort (n= 7,822)*
Palsy cerebral 38 25.3 463 5.9
Brain tumour 19 12.6 11 0.1
Sleep problem 17 11.3 597 7.6
Mental Retardation 16 10.6 31 0.4
Quadriplegia 8 5,3 41 0.5
Learning difficulties 8 5.3 337 4.3
Agitation 6 4.0 69 0.9
Behavioural 6 4.0 584 7.5
problems 
Cerebral atrophy 6 4.0 44 0.6
Cerebral anoxia 3 2.0 9 0.1
Anxiety 3 2.0 158 2.0
Neuroblastoma 3 2.0 4 0.05
♦subjects in the cohort study were those who received anticonvulsant for treatment and still alive during study period (n=7,822),
^study subjects were counted more than once if  they have more than one neurological co-morbidities.
As expected, h equency of most of studied neurological co-morbidities was higher in those 
deceased subjects than that in comparison group. However, sleep problem (7.6%) and 
behavioural problem was higher in comparison group (7.5%) than that in deceased subject 
group (4.0%).
Table 8.6 shows the classification of SUDEP amongst 150 subjects. It needs to be addressed 
that we did not obtain additional data from GPs to confirm the diagnosis and cause of death. 
So we were only able to present these findings descriptively. The majority of subjects were 
not considered to be SUDEP cases. The epilepsy diagnoses were found inadequately 
recorded. There were only 3 deaths with a record of ‘referred to coroner’ and another 8 had a 
record of post-mortem report. The cause of death amongst 150 subjects is shown in Table 8.7. 
There were 39 subjects without a clear description related to their death causes, 31 had a 
record of pneumonia leading up to their date of death, and 19 had a record of organ failure. 
Most children and adolescents who died were suffering from multiple severe disorders in the
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months leading up to their death. This implies that their cause of death was not directly 
attributable to SUDEP but other underlying conditions. It needs to be address that we only 
used available data in the GPRD to verily SUDEP cases, no other additional information was 
obtained (e.g. GP questionnaires, hospital summary, post-mortem reports) to reassure these 
cases.
Table 8.6 Classification of SUDEP in 150 deceased subjects, 1992-2000.
Classification of SUDEP No. subjects Percentage (%)
definite cases 4 2.6
probable cases 4 2.6
possible 12 8
not SUDEP cases 130 86.6
Diagnoses of epilepsy or seizure symptoms were 
recorded 27
18.0
Post-mortem report/ referred to coroner 11 7.3
The table 8.7 presents the causes of death in deceased subjects. The most common causes of 
death described in their medical records were death unknown causes (subject 39), pneumonia 
(31 subjects), and followed by organ failure (19 subjects). Four subjects’ cause of death was 
sudden death, 3 subjects who died from epilepsy. There were 20 cases considered where their 
deaths occurred in healthy conditions. As the record of post-mortem was relatively low, only 
8 cases of the 20 deaths were considered as probable SUDEP cases.
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Table 8.7 Causes of death for subjects (n=150) received anticonvulsant, 1992-200*
Descriptions No. of subjects Percentage (%)
Death unknown causes 39 26.0
Pneumonia 31 20.1
Organ failure 
Cancer
19 12.6
Brain 9 6.0
Other 9 6.0
Cardiac arrest 5 3.3
Sudden death 4 2.7
Cerebral palsy 4 2.7
Epilepsy 3 2.0
Status epilepticus 2 1.3
Chest infection 2 1.3
Metabolic disorder 2 1.3
Encephalitis 2 1.3
Congenital hydrocephalus 2 1.3
Other causes 17 11.3
'the causes o f  deatli w ere based upon the records in tlieir m edical records.
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Swmnaiy histoiy o f 8 probable SUDEP cases from medical record review 
Patient 1. 14-year old boy, died August 16 1996. This boy had received anticonvulsant 
treatment (sodium valproate, diazepam) for 3 years since 1993, and had no neurological co­
morbidity. However, the indication of anticonvulsant prescriptions did not clearly record him 
having epilepsy. Although anticonvulsant prescriptions were issued, no specific epilepsy 
diagnosis was found in his medical history. A diagnosis of pneumonia was recorded 6 months 
prior to his death. The descriptions o f ‘referred to coroner’ and ‘sudden death’ were recorded.
Patient 2. 8-year old girl, died January 25 1994. This girl started using carbamazepine for 
epilepsy treatment in October 1993, sodium valproate was added six months later. Her last 
anticonvulsant prescription was issued 5 days before her death. No specific cause of death 
was recorded.
Patient 3. 8-year old boy, died January 7 1994. This boy had asthma, behaviour problem, and 
phobia along with epilepsy. He started receiving sodium valproate for the treatment of 
epilepsy in October 1992, and 6 months prior to his death carbamazepine was added along 
with sodium valproate for epilepsy treatment. The description of death was recorded as 
‘unknown cause death’.
Patient 4. 14-year old boy, died August 5 1995. This boy had epilepsy and behaviour 
problem. Anticonvulsant for epilepsy treatment was carbamazepine and this was started in 
January 1993. He had a history of self-mutilation. The prescription of thioridazine was started 
6 months prior to his death. The death was described as ‘unknown cause’, no other specific 
cause was recorded.
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Patient 5. 18-year old boy, died April 12 1994. This boy had Grand mal epilepsy and started 
treatment since 1991. Anticonvulsant included carbamazepine and vigabatrin. He also had a 
history of hay fever. From his medical records it appeared that he was in a healthy status prior 
to his death. No specific death cause was recorded.
Patient 6. 17-year old boy, died August 3 1996. In 1994, this boy started using 
anticonvulsants for the treatment of epilepsy. Anticonvulsants included sodium valproate and 
phenytoin. The prescription of diazepam for epilepsy treatment was recorded one month 
before his death. This possibly indicates that he had a status epilepticus attack. The actual 
cause of death was not specifically recorded.
Patient 7. 2-year old boy, died November 30 1993. This boy received sodium valproate for 
epilepsy treatment in March 1992 and added carbamazepine in October 1992. The last 
prescriptions for anticonvulsant was seen a day before his death. No specific cause of death 
was recorded.
Patient 8. 7-year old girl, died October 20 1994. This girl had a history of sleep inability 
along with epilepsy. She received chloral hydrate, diazepam (orally administration), and 
triclofos for sleeping problem. Anticonvulsant prescribing for epilepsy began in December 
1991. She had a 3year history of epilepsy treatment, the regimen included sodium valproate, 
carbamazepine, vigabatrin and lamotrigine; these anticonvulsants were switched very 
ftequently, this might indicate that inadequate seizure control in this child. No specific death 
cause was recorded.
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8.4 Discussion
In this case series, we assess the causes of death in subjects received anticonvulsants. It 
should be noted that we were not confident to confirm definite SUDEP cases by using the 
available data recorded in the GPRD. Hence, we cannot draw any firm conclusion regarding 
the rate of SUDEP in our analysis. Sodium valproate was the most common prescribed 
anticonvulsant in both deceased subject group and comparison group (comparison group: 
those who were alive during study period). However, other individual anticonvulsants use 
was different in both groups. Apart fiom sleep problem and behaviour problems was higher 
in comparison group than in deceased subjects, most neurological co-morbidities was higher 
in deceased subjects than comparison group. The rate of post-mortem reporting was 
considerably low. In addition, the cause death was not adequately recorded in their medical 
files.
Limitations
Several limitations need to be addressed. Firstly, several factors such as poor seizure control, 
treatment compliance, or sub-therapeutic level have been reported as risk factors of SUDEP. 
However, it is not possible to investigate these risk factors through a computerised database. 
Although the GPRD contains information of prescription, we cannot determine whether the 
prescriptions for anticonvulsants were dispensed or whether the subjects were compliant with 
anticonvulsants. Secondly, the anticonvulsant therapeutic level did not record in the database 
so we were unable to investigate whether cause of death was attributable to poor seizure 
control. Secondly, type of seizure was not specifically recorded, so we cannot verify the 
rationale of anticonvulsant prescribing. Thirdly, although the FDA SUDEP criteria have been 
exclusively adopted in many published works, it is not feasible to adopt in a study where 
medical records were retrospectively evaluated. The reason for this is that limited death
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information was recorded in the database. In addition, the FDA criteria were originally 
developed to assess SUDEP cases in a clinical trial. Their criteria of definite SUDEP case 
were based upon patient epilepsy history and post-mortem report. As we cannot confirm the 
actual of death through available data in the database, it is not easy to confirm the definite 
SUDEP cases. Fourthly, we did not obtain data from GP questionnaires, hospital summary, 
post-mortem reports or death certificates via the GPRD verification service. Through this 
service will allow us to have additional information to confirm the SUDEP cases. For 
example, post-mortem report can be used to confirm the actual cause of death in each 
individual subject.
Previous studies have reported that SUDEP was rare in paediatric population. Two studies 
indicated that SUDEP was rare in children (Harvey et al. 1993; Donner et al. 2001). 
Similarly, a prospective population-based study has investigated the mortality rate with 
epilepsy and showed the causes of death due to SUDEP were rare (Cockerell et al. 1994). A 
national study by the National General Practice study of Epilepsy identified 1091 newly 
diagnosed patients (all age groups) during years 1984 to 1987 with an average follow-up of 
6.9 years. There were 161 deaths during the period covered. Of all these deaths, only 2 
patients appeared to be epilepsy-related deaths with no cases of SUDEP (Cockerell et al.
1994). A Dutch study identified 472 children with epilepsy at ages between 1 month and 16 
years in 1988-1992, all patients were followed for 5 years. 9 cases died during the study 
period, but there were no SUDEP cases (Callenbach et al. 2001). A study by Camfield et al. 
(2002) identified children who were first diagnosed with epilepsy aged from 28 days to 16 
years from 1977 to 1985, and with an average of 8 years follow up. There were 22 cases who 
died unexpectedly, in which most of the cases (n=14) dying due to pneumonia and no cases 
of SUDEP. A GPRD-based study by Derby et al. (1996) identified sudden unexplained death
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patients aged under 50 years who had received two or more anticonvulsants from the GPRD. 
15 cases were identified, of which 10 cases were considerate as probable cases.
We made an attempt to calculate the overall death rate in our study subjects. Most published 
studies were reported incidence rate of SUDEP, as we were not confident to confirm the 
definite SUDEP cases, so it is not possibly to have direct comparison with published studies 
(Jick et a l 1992; Nashef et a l 1995; Tennis et a l 1995; Derby et a l 1996; Walczalc et al 
2001; Donner et a l 2001).
The majority of subjects died which the cause of death did not specially recorded (26%) in 
the database, followed by pneumonia (20%) and organ failure (12.6). It is not possibly easy to 
compare our findings with what was reported in the literature as actual causes of death were 
unknown in most of our study subjects. However, it is considered that many subjects died 
from a cause that was not epilepsy related condition. A Study hom Australia showed that 
pneumonia was more likely to cause death in children with epilepsy (Haiwey et a l 1993). A 
Dutch study reported that infection and respiratory insufficiency were the major causes of 
death (Callenbach et a l 2001). Similarly, Camfield et al. reported that pneumonia, infection 
and circulatory problems were the main causes of death (2002). This observation is not 
similar to UK national report. Bruce et al. used ONS mortality database documented that 40% 
of cause of death in patients with epilepsy related, followed by Cerebrovascular disease 
(14%), pneumonia (9.27%) (2004). The only possible explanation of this difference is that 
these published studied only investigate the cause of death in children whereas the ONS 
report was in general population.
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Sodium valproate was the most common prescribed anticonvulsant in both deceased and 
comparison groups. However, other individual anticonvulsant prescribed was different. In 
comparison group, about 14% of subjects received lamotiigine, followed by phenytoin (10.8) 
and phénobarbital (10.8). Carbamazepine and vigabatrin were commonly prescribed 
anticonvulsants in deceased subjects. In this present study, we were unable to investigate the 
association between death and anticonvulsant use. Study by Clarkson and Choonara (2000) 
used UK Yellow Card Scheme (YCS) data to investigate the fatal outcomes in children aged 
< 16 years, reporting that amongst 65 deaths (n=331) anticonvulsant was the most frequently 
mentioned. This study did not look at association between death and anticonvulsant. To date, 
no paediatric studies have assessed the association between anticonvulsant and death. Hence, 
it is not appropriate to draw any conclusion whether anticonvulsant would cause the death in 
epilepsy patients. Nevertheless, we were able to demonstrate the difference of anticonvulsant 
use between deceased group and comparison group.
Approximately 25% of deceased subjects had a diagnosis of cerebral palsy in our study. It is 
suggested that cerebral palsy is often associated with epilepsy in children (Guerrini 2006). 
Frequency of neurological co-morbidities was relatively higher in deceased subjects than 
comparison group (subjects received anticonvulsant for treatment but still alive during study 
period). However, sleep problem and behaviour problem was observed higher in comparison 
group. Night terror is often associated in children with epilepsy (Guerrini 2006), so we would 
expect that sleep problem will be high in patients with epilepsy (comparison group).
In our study, there were only 8 cases considered as possible SUDEP over between 1992 and 
2000. As the majority of study subjects did not have a record of post-mortem report and 
insufficient details on the causes of death, it is not easy to confirm definite SUDEP cases. It
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has been reported about 90% of SUDEP will undergo a post-mortem examination or be 
referred to a coroner in the UK (Langan et a l 2002). If so, then the question arises why the 
rate of post-mortem and coroner referral was found extremely low in our study subjects? This 
could be that GPs did not record it. A study by Coyle et a l (1994) investigated 40 SUDEP 
cases through post-mortem reports, witness statements and relevant information. There were 
70% of cases without epilepsy diagnosis in their medical records. The inconsistencies were 
observed in post-mortem examination procedures, the observations at time of death and 
statement in certification. The recording of attributed causes of death varied considerably. 
This is in line with the findings from the National Sentinel Audit of epilepsy deaths showed 
that the majority of post-mortem reports were inadequate. In addition, detailed information 
about diagnosis of epilepsy, medical history and prescriptions were rarely recorded in post­
mortem report. This may be because pathologists did not have information or did not record it 
in the reports. Devis and Rooney (1999) had expressed that UK physicians are not skilled in 
completing death certificates and lack knowledge of their legal obligations within this regard. 
It is not surprising that the inadequate death records in the GPRD.
Interestingly, there was no death case was reported after 1996. The reason may probably due 
to the introduction of new software in 1996. This incomplete data entry may result in 
“immortal period”. The immortal period is defined as “a period o f follow-up time during 
which death cannot occur" (Suissa 2007). There is a possibility that when software was 
converted to Vision, only those records of patients alive being kept in the GPRD.
8.5 Conclusion
This case series was not an appropriate design to investigate the causes of death in children 
with epilepsy or who received anticonvulsant. It is mainly due to lack of information ft om GP
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questionnaire, post-mortem report, death certificate or hospital summary to reassure definite 
SUDEP cases. This additional information can be obtained through GPRD verification 
service. The causes of death in our study subjects were based on the infonnation available in 
the database. Using Burroughs-Wellcome criteria, we identified 4 definite SUDEP cases. It 
should be noted that we did not obtain additional information to confirm these SUDEP cases. 
Cerebral palsy was the common neurological co-morbidity in subjects who died, followed by 
brain tumour and sleep problem. There is variation of anticonvulsant use between deceased 
and comparison groups.
SUDEP has been given an increasing amount of attention in recent years, clinicians and 
patients have become more aware of this issue. Prior to the UK National Sentinel Clinical 
Audit in 2002, there have been five government reports (in 1953, 1956, 1969, 1986, and 
1999) that expressed a similar concern with regard to the need to improve the epilepsy 
service. However, there has been no improvement to date. Although the risk of SUDEP is 
very low, with better epilepsy management it may be avoidable.
It is suggested that prospective study would be a better study design to investigate SUDEP in 
children with epilepsy. This approach can obtain all clinical records include the severity of 
epilepsy, type of seizure and possible risk factors. In addition, death certificate or post­
mortem reports need to obtain to confirm the actual cause of death. This can help us to better 
understand the SUDEP in young people with epilepsy.
176
Chapter 9 Severe cutaneous reactions with anticonvulsant 
treatment in children and adolescents
9.1 Introduction
Findings from previous work (see Chapter 7) showed a steady increase in the use of 
newer anticonvulsants, in particular lamotrigine. It has suggested that lamotrigine has 
significant fr'equency (>10%) of cutaneous drug reactions which included TEN (TEN) 
(Svensson ei a l 2000). In 1997, the Committee on Safety of Medicines (GSM) 
addressed a warning of lamotrigine use and serious skin reactions in children. In the 
UK, a study by Wong et a l (2001) evaluated newer anticonvulsant-treated 
(lamotrigine, gabapentin, and vigabatrin) patients from five epilepsy referral centres 
over 3 years period (1993-1996), a total of 1,375 patients were included. Of these, 
1,050 received lamotrigine, 361 received gabapentin and 713 received vigabatrin 
treatment. Skin rash was the most common adverse reaction amongst lamotrigine- 
treated patients. In a MEDLINE survey (January 1985 to April 1998) along with 
WHO spontaneously reported cases, Raymond and colleagues (1998) identified 43 
SJS cases and 14 TEN cases that have been associated with lamotrigine use. It has 
suggested that the risk of developing Stevens - Johnson syndrome (SJS) and TEN 
amongst lamotrigine users is higher in children, yielding a frequency of 1:300 to 
1:100, and normally occur within 8 weeks of starting treatment. Other anticonvulsants 
such as phenytoin, phénobarbital and carbamazepine are also reported to cause severe 
cutaneous reactions such as hypersensitivity syndrome maculopapular, urticarial, 
erythematous, exfoliative, TEN (Friedmann et al. 1994; Svensson et a l 2000).
The definition of cutaneous drug reaction is ’'an adverse cutaneous reaction caused by 
a drug is any undesirable change in the structure or function o f the skin, its
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appendages, or mucous membranes’ (Drake et al. 1996). About 2-3% of all adverse 
drug reactions are cutaneous, and it was been estimated that about 1 in 1000 
hospitalized patients has a life-threatening cutaneous drug reaction (Roujeau & Stern 
1994; Wolkenstein & Revuz 1995; Svensson et al. 2000). Severe cutaneous drug 
reactions include Stevens-Johnson syndrome, TEN, hypersensitivity syndrome (HSS), 
angioedema, erythema multiforme or small-vessel etc. (Roujeau & Stern 1994; Wolf 
et al. 2005). Most cutaneous reactions are not serious and only 2% are severe. 
However, in some patients these conditions may cause severe morbidity (e.g. 
blindness) and mortality (Wolf et al. 2005). It has been suggested that TEN has the 
highest mortality rate, reaching 30-50%. Although cutaneous drug reactions are rare, 
all patients who use medication for treatment are at risk (Ruble & Matsuo 1999).
It is not easy to recognise cutaneous drug reaction at the onset. In general, cutaneous 
drug reactions are suspected in anyone who develops a rash during a course of drug 
treatment. Timing is important to determine the implicated drug reactions 
(Wolkenstein et al. 1998). Cutaneous drug reactions mostly occur within a few weeks 
of the introduction of the causative drug (Roujeau & Stern 1994; Schlienger & Shear 
1998; Rzany et al. 1999; Ruble & Matsuo 1999), so that if a drug has been used for 
many years without any skin disorder being reported then it is less likely to be 
responsible. It also has been suggested that symptoms of cutaneous reactions occur 
within 1-3 weeks after treatment (Wolkenstein et a l 1998). However, there are some 
exceptions; for example, cutaneous drug reactions to antibiotics (e.g. penicillin) can 
appear several weeks after discontinuing the treatment.
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Although timing is suggested as a practical tool to determine which drug is 
implicated, to identify the particular causative drugs confidently is difficult especially 
when patients have been exposed to several drugs at the same time. More than 100 
compounds have been reported to cause cutaneous drug reactions (Roujeau & Stern 
1994; Wolf et a l 2005). Table 9.1 presents a list of selected drugs which have been 
associated with cutaneous reactions (Roujeau & Stern 1994; Ruble & Matsuo 1999; 
Svensson et a l 2000). Many drugs have been implicated, but the most frequently 
reported drug groups were antibiotics (e.g. sulfonamides, and penicillin), 
anticonvulsants, nonsteroidal anti-inflammatory drugs (NSAIDs), and allopurinol 
(Kelly et al. 1995; Wolfe? al. 2005).
Table 9.1 Drugs associated with severe cutaneous reactions.
Drug causing cutaneous drug reactions
Allopurinol Lithium
Amithiozone Metronidazole
Aminopenicillins Naproxen
Amoxicillin Nevirapine
Amphotericin B Nitrofurantoin
Azole antifungals Oral contraceptives
Aminoglycosides Phenytoin
Barbiturates Phénobarbital
Benodiazepines Phenylbutazone
Benoxaprofen Piroxicam
Carbamazepine Primidone
Captopril Pseudoephedrine
Cephalosporins Salicylates
Chlormezanone Sulfadiazine
Cephalosporins Sulfdoxine
Co-tiimoxazole Sulfasalazine
Dapsone Sulindac
Diclofenac oxicam
Ethambutol Tetracycline
Fenbufen Thiazides
Fluoroquinolones Tiaprofenic acid
Gold Valproic acid
Hydantoins Vancomycin
Ibuprofen Ketoprofen
Isoxicam
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Mechanism of cutaneous reactions
The precise mechanism of cutaneous reactions is still unclear; this is because these 
reactions may be caused by several mechanisms. It has been suggested that the proper 
terminology to describe cutaneous reactions caused by drug is ‘idiosyncratic reaction’ 
(Svensson et a l 2000). In general, the cutaneous drug reactions are related to the 
immune system. There are two major types of reactions, in which T cells play an 
important role: immediate-type immune-mediated drug reaction, and delayed-type 
immune-mediated drug reactions (Svensson et a l 2000; Reilly et a l 2000). The 
mechanisms of these two types of reactions will not be discussed in detail as this is 
beyond the scope of this thesis. However, the model o f ‘haptoxic epidermal necrolysis 
hypothesis’ which has been studied for idiosyncratic drug reaction is presented in 
Figure 9.1. The concept of haptoxic epidermal necrolysis hypothesis is the imbalance 
of detoxification and bioactivation. Haptoxic epidermal necrolysis are formed by 
reactive metabolites which bind to cellular proteins irreversibly, these modified 
proteins then start targeting the immune system (Feeder 1998).
The conventional anticonvulsants such as phenytoin, carbamazepine and 
phénobarbital have been documented as having a high risk of developing cutaneous 
drug reactions (Svensson et a l 2000). This is because these drugs have an aromatic 
benzene ring which is metabolised into arene oxides. These arene oxides may either 
act as cytotoxic or haptoxic epidermal necrolysis, causing an immune reaction 
(Feeder 1998; Maria et a l 2001). It should be noted that although conventional 
anticonvulsants (i.e., phenytoin, phénobarbital) are notorious in terms of cutaneous 
adverse reaction, the concern that lamotrigine (newer anticonvulsant) induces this 
reaction also needs to be addressed.
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Figure 9.1 ‘Haptoxic epidermal necrolysis hypothesis’ of idiosyncratic drug reactions.
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As discussed previously, many drug groups such as antibiotics and NSAIDs can cause severe 
cutaneous reactions. Other factors can also cause these conditions such as virus infections- 
Herpes simplex, Mycoplasma pneumonia, Epstein-Bair virus, human immunodeficiency virus 
(HIV). A TEN-year study (1985-1995) retrospectively investigated the risk of erythema 
multiforme, SJS, TEN in children at the Hospital for Sick Children in Toronto. A total of 61 
children were identified with an average age of 4.8 years, the causes of the conditions 
included infections, drugs or both. Of these. Herpes simplex virus was the most commonly 
implicated infection (26%; n=16) causing these conditions, and sulphonamides and penicillin
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(both 26%; n=16) were the commonest drugs associated with these conditions. Of the 28 SJS 
cases, 7 cases were caused by drugs and the remaining were attributable to infection or both; 
all TEN cases (n=8) were attributable to drugs. The majority of erythema multiforme cases 
(14/30; 47%) were caused by infection. It needs to address that cases identification in this 
study only relied on the discharge notes without firm diagnosis. Also, the authors did not 
examine the causality between severe cutaneous reactions and drug use.
There are many different types of severe cutaneous drug reactions. The aim of this study was 
mainly to focus on the following severe cutaneous reactions: eiythema multiforme, Stevens - 
Johnson syndrome, TEN and exfoliative dermatitis.
Erythema multiforme, Stevens - Johnson syndrome, TEN, and exfoliative dermatitis
Erythema multiforme (EM) was originally described and named by Ferdinand von Hebra in 
his article in 1866 (Fabbri & Panconesi 1993). In 1922, Stevens and Johnson, American 
physicians, published an article to describe two boys aged 7 and 8 with the symptoms of 
‘generalized eruption, continued fever, inflamed buccal mucosa and conjunctivitis’. In both 
cases, erythema multiforme was excluded from diagnosis due to the presentation of skin 
lesions and continuing high fever. In the report, Stevens and Johnson suspected this condition 
was caused by an unknown infectious disease (Stevens & Johnson 1922). In 1950, Thomas 
divided erythema multiforme (EM) into two categories: ‘EM minor’ and ‘EM major’ which 
is known as SJS, based on the absence or presence of mucous membrane involvement. EM 
minor is in exclusively attributable to herpetic or mycoplasma infection without mucous 
membrane erosions, while the main difference of EM major is mucous membranes
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involvement (i.e. mouth, eyes, genital) such as SJS (Leaute-Labreze et a l 2000; Svensson et 
al 2000).
In 1956, Alan Lyell, an English dermatologist, first described four cases ‘whose skin 
appeared to have been severely scalded, although there had been no thermal burn’, and this 
appeared to be caused by drug, staphylococcus, and idiopathic causes. Lyell initially named 
this condition as ‘scalding disease’ for eight years. Once he found another three cases (two at 
Edinburgh, one at Aberdeen), he changed the name to ‘TEN (TEN) to describe this condition 
(Lyell 1988; 1991). As a result of being the first person to describe this condition, the name 
Lyell’s disease or Lyell’s syndrome is also used. It is interesting to note that, in fact, in 
Lyell’s initial report includes three entirely different types of condition: generalized fixed 
drug eruption, staphylococcal scalded skin syndrome (SSSS), and TEN (TEN) (Wolkenstein 
et a l 1998).
In 1993, Bastuji-Garin et a l  made an attempt to establish a classification to distinguish EM, 
SJS, and TEN. By viewing case history and a photograph of the patient, they proposed five 
categories to distinguish these three conditions (i) bullous erythema multiforme, less than 
10% of body skin detachment with localized ‘typical target’ or ‘atypical targets’ (ii) SJS, less 
than 10% skin detachment with widespread erythematous or purpuric macules (iii) overlap 
SJS-TEN, with 10%-30% skin detachment plus purpuric macules (iv) TEN with spot, more 
than 30% skin detachment plus widespread purpuric macules and, (v) TEN without spot, 
more than 10% of the skin detachment with epidermal and without puipuric macule. In recent 
years, it has now been widely accepted that these conditions are all in part of ‘EM spectrum’
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(Ruble & Matsuo 1999; Leaute-Labreze 2000). A summary of clinical feature of these 
conditions is presented in Table 9.2,
Table 9.2 A comparative features of erythema multiforme, SJS and TEN
(reference: Ruble & Matsuo 1999)
Feature Eiythema multiforme SJS TEN
Onset after drug exposure 1-3 weeks 1-3 weeks 1-3 weeks
Location of reaction Lesions confined to 1 
location, usually on 
trunk or extiemities
Lesions on > 2 locations, 
including trunk, extremities or 
face
Lesions on > 2 
locations, including 
trunk, extremities 
or face
Duration after drug 
discontinuation
1-3 weeks 2-4 weeks 3-6 weeks
Skin detachment 0% 1-15% >15%
Mortality 0% 5-10% 10-50%
EM is normally characterised an acute, feverish eruption with target cutaneous lesions. 
Lesions are rounded with three types of presentations: a central area of erythema or purpura, 
a middle paler zone of oedema and an outer ring of erythema with well-defined edge (Ruble 
& Matsuo 1999). The cause is mainly infection especially herpes simplex virus and 
mycoplasma (Roujeau & Stern 1994). EM usually spontaneous resolves within 1-3 weeks 
and has no mortality.
SJS presents as widespread skin lesions consisting of blisters arising on purpuric macules, 
and in about 80% of SJS patients the causes are attributable to drugs (Ruble and Matsuo, 
1999). Several drugs have been implicated as the cause of SJS, most frequently 
anticonvulsants (phenytoin, phénobarbital, carbamazepine, valproic acid), sulfonamides, 
certain nonsteroidal anti-inflammatory drugs (especially oxicams derivatives) (Roujeau and 
Stern, 1994). In SJS cases, epidermal detachment involves less than 15% of total body skin
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area. The cutaneous lesions of TEN appear within 1 to 3 weeks and may gradually resolve in 
up to 6 weeks. Mortality rate of SJS patients is much less than 5% (Roujeau & Stern 1994).
TEN is described as the skin disease with a burning and painflil eruption, and with mucous 
membrane involvement occurring before skin lesions. This eruption is symmetrically 
distributed from the face to the upper of body and the whole body especially trunk and 
proximal limbs, of TEN with confluent erythema Nikolsky’s sign (dislodgment of epidermis 
by lateral pressure) (Wolkenstein et al. 1998).
Comparing to erythema multiforme, SJS, and TEN, exfoliative dermatitis has gained less 
popularity. Exfoliative dermatitis is also known as erythroderma, a rare cutaneous condition 
but severe cutaneous reaction (Karakayli et al. 1999). It is difficult to establish diagnosis as 
exfoliative dermatitis is a complex condition with a variety of morphologic presentations 
(Rothe et al. 2005). The common causes are preexisting dermatoses, drugs and other 
idiopathic disorders (Karakayli et al. 1999; Rothe et al. 2005).
The main symptoms of EM, SJS, and TEN conditions include fever, conjunctivitis, 
pharyngitis and pruritus. The eruption of mucocutaneous is normally noted 1 to 3 days before 
skin lesions appear (Svensson et al. 2000; Wolf et al. 2005). The main symptoms in 
exfoliative dermatitis are malaise, pruritis and chilly sensation (Karakayli et al. 1999). The 
onset of exfoliative dermatitis is sudden and rapid if it induces by drug use (Rothe et al. 
2005). Table 9.3 presents clinical and laboratory findings which can assist evaluating 
cutaneous drug reactions.
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Table 9.3 Clinical and laboratory findings which may indicate 
drug-induced severe cutaneous reactions (reference: Roujeau & Stern 1994) 
Clinical findings 
Cutaneous 
Confluent erythema
Facial edema or involvement of central part of face 
Skin pain 
Palpable purpura 
Skin necrosis
Blisters or epidermal detachment 
Positive Nikolsky's sign*
Mucous membrane erosions 
Urticaria
Swelling of tongue 
General
High fever (temperature >40 degree)
Enlarged lymph nodes 
Arthralgias or arthritis
Shortness of breath, wheezing, hypoTENsion 
Laboratory results 
Eosinophil count > 1000/mm 
Lymphocytosis with atypical lymphocytes 
Abnormal results of liver function tests 
'The outer layer o f  the epidermis separates readily from the basal layer with lateral pressure.
In 1996, the American Academy of Dermatology has outlined the treatment 
recommendations for cutaneous reactions caused by drugs. This guideline provides detailed 
information on diagnostic criteria, medical treatment and patient education (Drake et al. 
1996). The treatment recommendations include: (i) topical and systemic corticosteroids (ii) 
antihistamines (iii) topical antipruritic agents (iv) baths with or without additives (v) 
emollients and, (vi) special treatments in severe reactions depending on the type of severe 
reaction. Other treatments such as fluid replacement, topical antiseptics (e.g. 0.5% silver 
nitrate, 0.05% chlorhexidine) or calamine have also been suggested (Ruble & Matsuo 1999; 
Wolkenstein et al. 1998; Wolf et al. 2005). Detailed diagnostic criteria for assessing 
cutaneous drug reactions were also given, including the thorough examination of medication 
history (i.e. onset of reaction, previous adverse drug reaction), and previous family or
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personal history of skin disease. Diagnostic tests such as skin biopsy, laboratory tests (e.g. 
drug levels, complete blood cell etc.), patch tests or skin cultures can also be carried out to 
distinguish between different cutaneous reactions.
Incidence of erythema multiforme^ SJS, TEN, exfoliative dermatitis
Many attempts have been made to establish the incidence rate of severe cutaneous reactions 
over the years. A systematic review of current literature was performed to determine 
published incidence rates of SJS, TEN, erythema multiforme, and exfoliative dermatitis. The 
MEDLINE search was performed to from January 1990 to December 2005 for studies 
investigated the incidence rate of SJS, TEN, erythema multiforme, and exfoliative dermatitis. 
A hand searching was also carried out to examine the reference lists o f identified studies. 
Only studies published in English were included. Studies that clearly did not meet eligibility 
criteria were rejected on initial abstract review. Studies marked for potential inclusion were 
than obtained electionically or in paper copy, and assessed again for inclusion. The search 
results were imported and managed in EndNote 9 (Thomson Reuters Corporation).
All studies of incidence rate of SJS, TEN, erythema multiforme, and exfoliative dermatitis 
were selected by MESH heading or text word; {SJS or TEN or eiythema multiforme or 
exfoliative dermatitis or erythroderma) AND {incidence or incidence rate) in the abstract or 
title.
The initial search identified 298 studies. Of these, only 6 studies were included after 
reviewing the abstracts. The reasons for excluding studies were: ineligible primary outcome 
(221), review article (58), case report (4), case series (7), clinical trial (1), letter (1). Table 9.4 
presents the summary of 6 studies.
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Table 9.4 Studies of incidence of SJS, TEN, erythema multiforme, and exfoliative dermatitis.
Study Counti-y N Study period Data source Incidence rate (per million person-years) 
SJS TEN EM ED*
Chau et al. (1990) USA 61 1972-1986 Computerised database” NA 0.5 NA NA
Roujeau et al 
(1990)
France 253 1981-1985 NA 1.2 NA NA
Strom et al. 
('1991)
USA 19 1980-1984 COMPASS'’ M icbigan:7.1
Minnesota:2.6
Florida;6.8”
< 1 NA NA
Schopf et al. 
(1991)
Germany 574 1981-1985 Hospitalised patients'' 1.1 0.93 NA NA
Rzaiiy et al. 
(1996)
Germany 353 04/1990- 12/ 
1992
Registry database for 
skin disorders"
1.17 1.53 1.89 NA
Sigurdsson et al. 
(2001)
NL 141 1997 Questionnaires'^ NA NA NA 0.9'
Abbreviation: N, number o f subjects; NA: not available; NL, the Netherland, SJS, Steven-Johnson syndrome; TEN. toxic epidermal necrolysis. 
* Exfoliative deniiatitis is also known as erythroderma. The terms o f erythroderma was used in Sigurdsson et al. study.
° computerised database: tire Group Health Cooperative (GHC).
data were obtained from computerised On-Line Medicaid Pharmaceutical Analysis and Surveillance System (COMPASS).
“ the incidence o f  SJS in Florida only reported in 1983.
patients were identified from hospital in Federal Republic o f  German.
' ‘Dokumentationszentrum schwerer Hautreaktionen’ (dZh): a population based registry for severe skin disorders in West Germany, 
incidence rate o f erythrodenna was calculated by cases divided by inhabitants (15,567,100) in Netherlands in 1997.
There is variation of incidence of SJS and TEN in the literature. Incidence of SJS is to be 1.1 
to 7.1 cases per million person-years, and incidence of TEN is fr om < 1 to 1.53 cases per 
million person-years (Table 9.4). This may be due to different inclusion criteria. Strom et a l 
(1991) identified patients with a diagnosis of erythema iris staphylococcal scalded skin 
syndrome (SSSS) along with SJS and TEN whereas other studies included patients only had a 
diagnosis of SJS or TEN, There was only one study investigated the incidence of exfoliative 
dermatitis (erythroderma) in the Netherlands. Study subjects were identified from 
dermatologist (n=258) through questionnaires. The response rate of questionnaires was 
deemed to be high (78%; 202/258). It should be highlight that this approach may 
underestimate as hospitalised patients may not being included in their study. There appear to 
be very few published incidence of erythema multiforme and exfoliative dermatitis. This may 
be due to differing diagnosis, clinical presentation, and definitions. In addition, the mortality 
rates in these two conditions are relatively low comparing to SJS or TEN. To date, there has 
been no population-based study carried out to estimate the incidence rate of EM, SJS, TEN,
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or exfoliative dermatitis in children, so the precise figures in the paediatric population remain 
unknown.
Many studies have conducted to assess the association of anticonvulsants and severe 
cutaneous reaction reactions. However, most of these study designs were descriptive. This 
approach does not control the confounding factors so the findings may be biased. To resolve 
this issue of confounding in the analysis is to have comparison group to patients who have the 
same level of confounding variables, so the case-control study design would be preferable 
and powerful. In order to have better understanding of cutaneous reactions associated with 
anticonvulsants use. A literature search was conducted to investigate the risk of cutaneous 
reaction associated with drug use in case-control study design.
The English literature was search using the MEDLINE from January 1990 to December 2005 
database. Only studies published in English were included. Studies that clearly did not meet 
eligibility criteria were rejected on initial abstiact review. Studies marked for potential 
inclusion were than obtained electronically or in paper copy, and assessed again for inclusion. 
The search results were imported and managed in EndNote 9 (Thomson Reuters Corporation), 
The search strategy employed the following MESH term: {anticonvulsant or antiepileptic 
drug) AND {case control study or nested case control study or matched case control study or 
case comparison study) in title or abstract.
The initial search identified 22 studies. Nineteen studies were excluding and the major reason 
for excluding studies was ineligible primary outcome. There were only 3 studies were 
included after reviewing the abstracts (Roujeau et al. 1995; Rzany et al. 1999; Lin et al. 
2005).
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The largest-scale study, severe cutaneous adverse reactions (SCAR), was an international 
collaborative case-control study carried out in four European countries: France, Germany, 
Italy, and Portugal. This study was aimed to quantify the association between specific drugs 
and SJS and TEN. The potential cases were those had a diagnosis of SJS or TEN in hospital 
admission. Diagnoses were validated by an international group of dermatologists. The control 
subjects were those admitted to the same hospital as potential cases for acute conditions. 
Additional information regarding medications use four week prior to hospitalisation was 
obtained through patient questionnaires. A total of 245 cases were included this study, of 
which 121 cases from France, 57 from Italy, 49 from Germany, and 18 from Portugal. In 
these potential cases, 89 patients were classified as SJS, 76 patients were overlapping SJS and 
TEN, and 80 patients had TEN. A total of 1147 patients were identified as controls. There 
was a strong association of sulfonamides and SJS or TEN, yielding a crude relative risk of 
172 (95%CI 75-396). Anticonvulsants, phénobarbital (multivariate relative risk, 8.7; 95%CI 
3.2-23), carbamazepine (multivariate relative risk, 12; 95%CI 3.5-38), phenytoin 
(multivariate relative risk, 8.3; 95%CI 1.5-45) and valproic acid (multivariate relative risk, 
8.3; 1.8-40), have all shown significantly associated with these conditions. This study was 
able to demonstrate the risk of developing SJS or TEN in each individual drug (Roujeau et al.
1995). However, the authors did not assess other confounding factors such as infection, or 
concomitant drug use. Without considering these factors in analysis, it should be caution to 
interpret their findings.
Following the SCAR study, a subgroup analysis was carried out. The authors specifically 
investigated the risk of SJS/TEN during the first 8 weeks of anticonvulsant treatment. This 
analysis was based on 352 cases with a diagnosis of SJS (n=136) or TEN (n=216) and 
matched to 1579 controls. The authors reported that SJS/TEM cases were associated with the
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short-term use of anticonvulsant. In each individual anticonvulsants the relative risk of 
developing SJS/TEN was 57 (95%CI 16-360), 91 (95%CI 26-oo) for phenytoin, 120 for 
carbamazepine (95%CI 34-oo), 25 (95%CI 5.6-oo) for lamotrigine, and 24 (95%CI 5.9-oo) for 
valproic acid. (Rzany et ah 1999). This study has obtained detailed information of each 
individual anticonvulsants use associated with SJS/TEN. However, it should be noted that the 
users of anticonvulsant were relatively low: 3 lamotrigine users, 13 valproic acid users, 21 
carbamazepine users, 14 phenytoin users, 36 phénobarbital users in four countries during 
February 1989-July 1995 (study period). In addition, many newer anticonvulsants were 
marketed over the past decade, it is questionable of how accurate their findings can generalise 
to current situation. In addition, these studies were included patients in all ages. It is difficult 
to extrapolate adult studies to children.
A case-control study conducted by Lin et a l (2005), investigated the risk of SJS and TEN 
with certain specific drugs (carbamazepine, phenytoin, allopurinol) in Taiwanese patients. A 
total of 35 cases and 105 controls were included in the analysis. The authors adjusted the 
potential confounders such as radiotherapy, collagen vascular disease, infections with HIV, 
recent herpes infection, and autoimmune disease. The multivariate relative risk in 
carbamazepine treated subjects was 301.8 (95%CI 13.6-6700.2), the risk in phenytoin treated 
subjects was 290.8 (95%CI 9.2-9239.3), and 186.7 (95%CI 6.4-5458.2) in allopurinol treated 
subjects. The confidence intervals in Lin et a l study and Rzany et a l were considerable 
wide, this may be due to the low number of cases with SJS and TEN. It is important to 
highlight that in Lin et a l study, the authors did not clearly stated whether controls were 
matched to cases or not. This makes it difficult to compare their findings with SCAR study.
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To date, there was only one population-based study carried out in paediatric population. 
Forman et a l (2000) reviewed patient charts retrospectively from 1985 to 1995 to identify 
SJS, TEN or EM patients in a tertiary care paediatric hospital in Toronto. There were 61 
children with EM, SJS, or TEN were identified from over 300,000 admissions during the 
period covered. This study apparently only described the clinical features, treatment, and 
possibly aetiology factors of these severe cutaneous reactions in children, no any causality 
assessment was conducted.
Despite the rarity of severe cutaneous reactions in children, the understanding this issue of 
anticonvulsants use in the paediatric population is still lacking. In 2005, Novartis 
Pharmaceuticals and the U.S. Food and Drug Administration (FDA) notified health care 
professionals about the new warning of oxcarbazepine use associated with severe cutaneous 
reactions which include SJS and TEN. This was due to the identification of several cases both 
in adults and children having been reported to the authority, and from these reported cases the 
average time of onset was 19 days. Oxcarbazepine was first introduced onto the market in 
2000 for the treatment of partial seizure, however, the severe cutaneous reaction were not 
detected until recently. This implies that the safety profile of a drug is incomplete at the time 
its license is granted. There has been no population-based study carried out to assess the risk 
of severe skin disorders in anticonvulsant-treated youths at the time of writing.
The high level of anticonvulsants use in children and adolescents has shown in our findings 
between 1992 and 2000 (see Chapter 5). In addition, in view of the steadily increase in the 
prescribing of newer anticonvulsants has steadily increased over the years (see Chapter 7). 
There is a need to better define the association of anticonvulsants use and severe cutaneous 
reactions and as well as predisposing factors in this population. There has been no
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population-based study carried out to investigate the risk of anticonvulsants and severe 
cutaneous reactions in paediatric population at this time. Hence, a matched case-control study 
was carried out to investigate the association of anticonvulsants and severe cutaneous 
reactions in children and adolescents. There were only four severe cutaneous reactions: 
erythema multiforme, SJS, TEN, and exfoliative dermatitis.
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9.3 Methods;
Study population
A matched case-control study was carried out. The study population comprised all 
children and adolescents aged 0-18 years at any point in the study period and 
permanently registered with practices contributing to the GPRD at any time between 1 
January 1992 and 31 October 2001. For each patient, at least 6 months’ up-to- 
standard data were required for entry into this analysis. Within this study population, 
children and adolescents with diagnoses of EM, SJS, TEN or exfoliative dermatitis 
were identified.
Identification o f EM, SJS, TEN, or exfoliative dermatitis
Children and adolescents with EM, SJS, TEN, or exfoliative dermatitis were selected 
by appropriate OXMIS and Read codes (Table 9.5), Owing to the nature of the 
conditions studied, a ‘study window’ period was defined for each patient from 2 
months prior to diagnosis to 1 month after diagnosis. The risk of cutaneous drug 
reactions is greatest within the first 2 months of introducing a drug; or other exposure 
using the 2 months period prior to the event date enabled the verification of causative 
drugs. As these conditions were severe and life-threatening, the month period after the 
event date was to confirm patients were given symptomatic treatment.
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Case identification
All children and adolescents with an OXMIS/Read code for EM, SJS, TEN, or 
exfoliative dermatitis were identified. The index date was taken as the date of the first 
recorded diagnosis of the event. In order to identify the potential cases, cases of EM, 
SJS, TEN, or exfoliative dermatitis were included along with at least one of the 
following supporting evidence during the study window:
(i) had diagnosis of symptom records: fever, skin rash, urticaria, itching, skin 
eruption, or conjunctivits.
(ii) had a record of at least one of the following prescriptions: oral or systemic 
corticosteroids, antihistamines, or skin preparations (e.g. emollient, topical 
corticosteroid, antipruritics, or calamine lotion).
(iii) Prescriptions for the treatment of cutaneous reactions continued up to at 
least 30 days after diagnosis.
(iv) A record of hospital admission. However, the following records were not 
accepted as supporting evidence: screening child development, 
development check, clinic development atTENdance, seen in development 
clinic, or child health examination; because these records did not suggest 
that cases had been admitted to hospital for cutaneous reactions treatment.
Potential cases who had a diagnosis without any other supporting evidence were not 
included. In order to distinguish if corticosteroid prescriptions were being issued for 
the treatment of EM, SJS, TEN, exfoliative dermatitis and not asthma, only systematic 
and skin preparations were included (BNF 06.03.02). Once cases with EM, SJS, TEN, 
and exfoliative dermatitis had been selected fi'om the database, the records for each 
case were scrutinised to confirm case status and establish an index date (event date). 
As discussed, several drug groups are frequently reported to cause severe cutaneous 
reactions. Thus, the use of sulfonamide, antibiotics, or NSAIDs during the study 
window was reviewed.
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Selection o f controls
For each identified case, four controls were randomly selected from the study 
population matched by year of birth, sex and general practice. It should be noted that 
cases could be selected as controls for other cases before their index date. Controls 
had to be registered on the database on the index date of the matched case. All 
conti'ols also needed to have at least 6 months up-to-standard data prior to the index 
date and 1 month after the index date. All records for each case and control were 
reviewed coded automatically. At this stage, case and control status as well as drugs 
exposure was blinded.
Establishing anticonvulsant exposure
All prescriptions for anticonvulsants were identified. The duration of anticonvulsant 
use was calculated by dividing the quantity and daily dose. Exposure to 
anticonvulsants prior to the index date (event date) was assessed during the study 
window. The use of anticonvulsant was described with reference to the index date as 
before. The exposure duration was stratified into three categories: < 60 days, > 
60days, and more than 1 year to investigate whether risk varied in relation to duration 
of use. In some patients, it was possible that cutaneous conditions occurred after the 
patients ceased taking prescribed anticonvulsants. Time since discontinuation was 
stratified into the same categories based on the end date of the prescription. Exposure 
status in cases was subject to the same criteria as the controls. Exposure status was 
blind to case status.
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Confounders
The medical records for all cases and controls were reviewed and various
characteristics defined. Amongst all study subjects these characteristics were:
Age
Recent infections within 60 days prior to the index date 
Use of antibiotics within 60 days prior to the index date 
Use of sulfa drugs within 60 days prior to the index date 
Use of NSAIDs/an NSAID within 60 days prior to the index date 
Vaccination within 60 days prior to the index date 
History of skin disease 
History of eczema and urticaria 
Confirm case status as indicated by hospital admission
Statistical analysis
Conditional logistic regression models were built to provide risk estimates for SJS, 
TEN, EM and exfoliative dermatitis associated with anticonvulsants and adjusted for 
potential confounding. Potential confounders included in the model were history of 
skin disorder, eczema, urticaria, infections {Herpes simplex, Mycoplasma 
pneumoniae, chicken pox etc.), and vaccination. We investigated whether risk varied 
in relation to duration of anticonvulsant exposure, time since stopping treatment and 
age (0-2,3-5,6-9,10-12,13-15, and 16-18 years). Analyses were carried out using 
Stata/SE, version 8 (Stata Corp, College Station, Texas). Odd ratios (ORs) with 95% 
confidence intervals were calculated and interaction between variables using 
conditional logistic regression. Backward and forward stepwise conditional logistic 
regression models were used to identify variables for inclusion in the full multiple 
conditional logistic regression model. The level of p<0.05 was used for inclusion and
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exclusion. Risk estimates for these severe cutaneous conditions were calculated and 
adjusted for other variables.
Table 9.5 Read and OXMIS medical codes for Stevens - Johnson syndrome, Toxic
Read/OXMIS code Read/OXMIS term
6951 Erythema multiforme
695IME Erythema multiforme exudativum
695IMJ Syndrome Stevens-Johnson
6951 NE Toxic epidermal necrolysis
695 INF Ritter’s disease
6959A Erythema N E C
6959B Erythroderma
6959E Erythema
6959N Exfoliative dermatitis
9779DE Erythema due medicine ingested
6959BN Nonspecific erythema
L7090LD Lyell’s disease
L7090NE Epidermal necrolysis
M15..00 Erythematous conditions
M150.00 Toxic erythema
M151.00 Erythema multiforme
M151.il Leyell’s syndrome
M151.12 Toxic epidermal necrolysis
M151500 Erythema urticatum
M151700 Stevens-Jolinson syndrome
M151800 Toxic epidermal necrolysis
M151812 Lyell’s syndrome
M151900 Nonbullous erythema multiforme
M151y00 Other specified erythema multiforme
M151z00 Erythema multiforme NOS
M15y.OO Other specified erythematous conditions
M15yOOO Ritter’s disease
M15y400 Other exfoliative erythema
M15yz00 Other erythematous conditions NOS
M15z.00 Erythematous conditions NOS
Myu4.00 [XlUrticaria and erythema
Myu4400 [XJErythema in other disease classified
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9.4 Results
4,756 patients were identified with a diagnosis of EM, SJS, TEN, or exfoliative 
dermatitis in the entire GPRD paediatric population aged 0-18 years. Of which, 2,617 
had their first diagnosis record at any time during the years 1992 to 2000. In this 
group, 1,576 patients were identified with supporting evidence (potential cases). Each 
of the 1,576 cases was matched by year of birth, sex, and practice to four controls 
(6,295). Characteristics of cases and controls were shown in Table 9.6.
An increased unadjusted risk for EM, SJS, TEN or exfoliative dermatitis associated 
most strongly with urticaria. Streptococcal and Measles infection, history of skin 
diseases, and prior use of antibiotics (within 2 months before event date). Other 
significant risk factors for EM, SJS, TEN or exfoliative dermatitis included recent 
infections (within 2 months prior to index date) of Chickenpox, Herpes, Rubella, 
eczema, prior use of sufa drugs, NSAIDs, vaccination (within 2 months before index 
date), and hospital admission. There was no significant difference in anticonvulsant 
exposure between cases and controls.
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Table 9.6 Characteristics of cases and controls^
Variable Cases (n = 
n
= 1,576) 
%
Controls (n = 
n
6,295)
%
unadjusted OR (95% CIs) P value^
Sex
Boys 780 49.5 3,114 49.7 - - -
Girls 796 50.5 3,181 50.3 - - -
Age group
0-2 367 23.3 1,463 23.2 - - -
3-5 372 23.6 1,490 23.7 . - -
6-9 342 21.7 1,367 21.7 - - -
10-12 220 12.7 877 13.9 - - -
13-15 152 9.6 606 9.6 - - _
16-18 123 7.8 492 7.8 - - -
Recent infections (within 2 months before the index date)
Chickenpox 187 11.8 467 7.4 1.79 (1.48-2.18) <0.001
Cytomegalovirus 0 0 0 0 - - -
Epstein-Barr 0 0 0 0 - - -
Herpes 211 13.3 591 9.3 1.55 (1.30-1.86) <0.001
Measles 20 1.3 37 0.6 2.95 (1.53-5.70) 0.001
Myocoplasma 2 0.1 0 0 - - -
Rubella 42 2.6 121 1.9 1.73 (1.09-2.75) 0.02
Streptococcal 29 1.8 33 0.5 3.81 (2.27-6.39) <0.001
Anticonvulsant exposure
<= 60 days before index date 9 0.6 37 0.6 0.9 (0.47-2.01) 0.94
> 60 days and < 1 yr before
index date 9 0.6 28 0.4 1.3 (0.61-2.72) 0.51
> 1 yr before index date 9 0.6 25 0.4 1.4 (0.67-3.08) 0.34
Use of any below drugs within 2 months before index date
Antibiotics 1,312 82.9 4,395 69.8 2.58 (2.20-3.03) <0.001
Sulfa drugs 181 11.4 566 8.9 1.37 (1.13-1.66) 0.001
NSAIDs 596 37.5 1,889 29.7 1.65 (1.43-1.89) <0.001
Vaccination* 243 15.3 801 12.6 1.51 (1.22-1.87) <0.001
History of skin diseases 794 49.9 1,484 30.0 3.25 (2.87-3.68) <0.001
Eczema* 365 22.9 933 14.8 1.80 (1.56-2.07) <0.001
Urticaria* 252 15.9 192 3.0 6.27 (5.11-7.70) <0.001
Hospital admission* 223 14.1 550 8.7 1.98 (1.64-2.40) <0.001
Abbreviation: Cl indicates confidence interval; OR, odds ratio.
Subjects prescribed these drugs 2 months prior to index date.
 ^Cases included subjets with a diagnosis o f  Stevens-Johnson syndrome, or toxic epidermal necrolysis, or erythema multiforme, or exfoliative 
dermatitis.
^Statistically significant OR (p< 0.05).
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Stepwise conditional logistic regression
The forward and backward conditional logistic regression was performed to identify all the 
variables where there were significant differences between cases and controls. Based upon 
the results of stepwise conditional logistical regression, Mycoplasma infection, vaccination, 
use of NSAID, sulfa drugs and anticonvulsants were dropped from this model, because these 
variables did not independently predict to the outcomes. Results of forward and backward 
stepwise conditional logistic regression are presented in Table 9.7.
Table 9.7 Stepwise conditional logistic regression.
Forward stepwise analysis (inclusion criteria p<0.05; number of obsi
Variables Adjusted OR 95%CIs t
Recent infections*^
Chickenpox 1.49 1.20-1.84
Herpes 1.31 1.08-1.59
Measles 2.78 1.31-5.91
Rubella 1.79 1.06-3.00
Streptococcal 2.95 1.67-5.21
History of skin disorders*^ 2.70 2.36-3.09
Urticaria*^ 5.95 4.79-7.44
Eczema*^ 1.47 1.25-1.72
Antibiotics*^ 2.06 1.73-2.44
Hospital admission*^ 1.75 1.42-2.16
Backward stepwise analysis (inclusion criteria p<0.05; number of observation=7871)
Variables Adjusted OR 95%CIs +
Recent infections*^
Chickenpox 1.49 1.20-1.84
Herpes 1.31 1.08-1.59
Measles 2.78 1.31-5.91
Rubella 1.79 1.06-3.00
Streptococcal 2,95 1.67-5.21
History of skin disorders*^ 2.70 2.36-3.09
Urticaria*^ 5.97 4.79-7.44
Eczema’^ 2.47 1.25-1.72
Antibiotics*^ 2.06 1.73-2.44
Hospital admission*^ 1.75 1.42-2.16
' Within the 2 months period before index date.
 ^Statistically significant odds ratio (OR) (p< 0.05).
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Thus the variables selected for the final model of the multivariate conditional logistical 
regression analysis included recent infections (within 2 months before index date), history of 
skin disorders, urticaria, eczema, vaccination (within 2 months before index date), hospital 
admission in the 2 months preceding the index date, and antibiotics use (within 2 months 
before index date). Result of the final model of conditional logistical regression is given in 
Table 9.8 The strongest predictors of EM, SJS, TEN, exfoliative dermatitis was recent 
diagnosis of urticaria (OR: 5.95; 95%CI: 4.78-7.44). The ORs for recent infections of 
Chickenpox, Herpes, Measles, Rubella, Streptococcal, eczema, prior skin disorders, 
vaccination (2 months prior to index date), and hospital admission in the previous 2 months 
were raised. There was no association of anticonvulsant use and EM, SJS, TEN and 
exfoliative dermatitis. But this variable was forced into the conditional logistical regression 
analysis. It yielded that an adjusted odds ratio for EM, SJS, TEN, exfoliative dermatitis risk 
associated with anticonvulsant in the previous 2 months use was 0.93 (95%CI: 0.48-1.79) in 
the final analysis. This apparent that no evidence of anticonvulsant use increased the risk of 
and severe cutaneous reactions as the odd ratos was below 1 and the lower bound of the 
confidence interval less than 1.
Table 9.8 Final conditional logistical regression analysis 
(number of observations^? 871)
Variables Adjusted OR 95%CIs
Recent infections*^
Chickenpox 1.49 I.2I-1.84
Herpes 1.31 1.08-1.59
Measles 2.79 1.31-5.92
Rubella 1.78 1.06-3.00
Streptococcal 2.95 1.67-5.21
History of skin disorders*^ 2.70 2.36-3.09
Urticaria*^ 5.96 4.78-7.44
Eczema*^ 1.47 1.25-1.72
Antibiotics*^ 2.06 1.73-2.44
Hospital admission*^ 1.76 1.42-2.16
Anticonvulsant exposure 0.93 0.48-2.05
Within the 2 months period before index date.
' Statistically significant odds ratio (OR) (p< 0.05).
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Table 9.9 presents the pattern of anticonvulsant use amongst cases and controls. 
Amongst anticonvulsant exposure cases, 9 cases have a diagnosis of EM and only 1 
case had a diagnosis of SJS. The most frequently prescribed anticonvulsant was 
sodium valproate, followed by diazepam (non-orally administered), lamotrigine, and 
phenytoin.
Table 9.9 Exposure to anticonvulsant drugs in study population*
Drug name Cases Controls Total users
Carbamazepine 0 4 4
Clobazam 1 2 3
Clonazepam 0 5 5
Diazepam (non-orally administered) 2 14 16
Ethosuximide 1 1 2
Gabapentin 2 1 3
Lamotrigine 2 9 11
Paraldehyde 0 1 1
Phénobarbital 0 1 1
Phenytoin 1 10 11
Sodium valproate 10 23 33
Topiramate 3 2 5
Vigabatrin 2 4 6
study subjects may receive more than one anticonvulsant.
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9.5 Discussion
We found there was no evidence to support the risk of anticonvulsant use and severe 
cutaneous reactions (EM, SJS, TEN, and exfoliative dermatitis) in paediatric population. The 
adjusted odd ratios (ORs) of this association was 0.93 (95%CI 0.48-2.25), the 95% 
confidence interval overlapped, indicating that there was no statistically significant in this 
association. Several risk factors for these severe conditions have shown, including a history 
of skin disorders, recent infections {Chickenpox, Herpes, Measles, Rubella, Streptococcal), 
eczema, urticaria, the recent hospital admission (within 2 months prior to index date), and the 
use of antibiotics within 2 months prior to index date. The study by Forman et al. reviewed 
10-year hospital chart review of EM, SJS, and TEN in children has demonstrated that 
infection was the major cause for these conditions (2002). It is important to highlight that 
Forman et al. study did not investigate causality assessment. In contract, we were able to 
control the confounding factors by matching cases and controls. Our findings have shown a 
strong and statistically significant association of recent infection {Chickenpox, Herpes, 
Measles, Rubella, Streptococcal) and severe cutaneous reactions.
To our knowledge this is the first large paediatric study to investigate the causality of severe 
cutaneous reaction and anticonvulsant use. However, there are several limitations need to be 
addressed. Firstly, we did not validate these cases through additional information such as 
questionnaire, hospital summary. This information can be obtained through the GPRD 
verification service via GP questionnaires. As we only identified potential cases through 
diagnosis codes along with supporting evidence (e.g. symptom, hospital admission, 
treatment) in the database, so misclassification should take into account. Secondly, we did not 
stratify our analysis by each cutaneous condition. This make it difficult to compare our 
results with other studies. In SCAR study and Lin et a l study, only cases of SJS and TEN
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were included whereas we included SJS, TEN, EM and exfoliative dermatitis cases. This may 
be the reason we did not report a wide confident interval as we had more cases included. 
Thirdly, we did not quantify the risk in each individual anticonvulsant. Concern has raised 
that some individuals may take two anticonvulsants concomitantly. As a result, it may give 
biased estimates in the multivariate case-control study. Fourthly, we found a strong 
association of antibiotics use and severe cutaneous reactions [adjusted OR: 2.06 (95%CI 
1.73-2.44)]. It is important to highlight that this risk factor may be confounding by indication. 
As antibiotics may prescribe to treat infection, and infection may possibly the cause to trigger 
severe cutaneous reactions. We did not have secondary data such as GP questionnaire to 
verify in this present analysis.
In this study, we used a matched case-control study to investigate the risk of severe cutaneous 
reactions and anticonvulsant use. The reason to use this design was because the rarity of these 
conditions, it would therefore be required to have thousands of cases in order to have useful 
results. So the case-control study design is deemed preferable and powerftil to assess the rare 
risk (Rothman & Greenland 1998), As discussed, the considerations of concomitant use of 
two anticonvulsants and confounding by indication in our analysis, case-crossover study 
design may be applied to reassure our findings. The case-crossover study design was 
originally developed to investigate the transient exposure in acute conditions (Maclure 1991). 
In this study design cases are treated as their own matched controls (self-matching). This 
design can avoid the limitations we discussed previously. It is suggested that further study 
should use case-crossover design to reassure our results.
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9.6 Conclusion
There is no evidence to show a risk of anticonvulsant use and severe cutaneous reactions. 
Several potential risk factors have identified to have strong association with severe cutaneous 
reaction. Since this study was undertaken, a new edition of the GPRD has become available 
which has a large number of person years than its predecessor. The version of GPRD 2000 
(data collected until October 2001) in the current study is relatively smaller than. As can be 
seen from Chapter 7, a steadily increase of lamoti'igine prescribing has taken place. If this 
trend continued, the number of lamotrigine exposure could expect larger than current analysis. 
It is worthy to use new edition of GPRD to reinvestigate this association in paediatric 
population. In addition, it is recommended to conduct case-crossover design to confirm our 
findings.
Despite no evidence to support an increased risk for cutaneous reactions with anticonvulsants 
in our study, the warning of an increased risk in children receive anticonvulsant for treatment 
has been mentioned in BNF Children (2005). Clinicians should be aware of the risk of severe 
cutaneous reactions associated with anticonvulsants during the early weeks of exposure as 
these conditions are unexpected and life-threatening.
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Chapter 10 Overall Discussion
This thesis presents three drug utilisation studies, one case-series study and one case-control 
study, together contributing to an understanding of psychotropic drug prescribing patterns 
and the risk of severe cutaneous reactions, and anticonvulsant use in children and adolescents. 
In this chapter the substantive findings from chapters 5 to 9 are discussed in five sections. 
The first section discusses methodological issues relevant to the computerised primary care 
database, while the second considers the issues regarding prescribing patterns of psychotropic 
drugs. The third section discusses safety issues relating to anticonvulsant treatment derived 
from two risk assessment studies: a case series study and a case-control study. The fourth 
section discusses the clinical implications and issues for future research.
10.1 Methodological considerations of computerised primary care database research
Computerised primary care databases have been used widely in pharmacoepidemiology in 
recent years. This thesis comprises a classical pattern of pharmacoepidemiological studies: 
drug utilisation studies and risk assessment studies. These studies achieve an in-depth 
understanding of psychotiopic drug use in young people which has not been previously 
reported in UK practice. Strengths and limitations apply throughout this thesis and 
implications for clinical practice are highlighted in the following section.
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Limitations
Several studies have validated the diagnoses recording in the GPRD (see Chapter 4); however, 
there is only one study by Nazareth (1993) that has validated the diagnosis of psychosis and 
schizophrenia. Other psychiatric disorders have not been fully evaluated. It should be noted 
that the data source in Nazareth’s study was drawn from the VAMP research database 
between April 1990 and September 1990, and only 16 general practices provided data for this 
validation study. To generalise Nazareth’s study is deemed inappropriate, as the current 
GPRD contains data from more than 400 general practices. In addition, the diagnoses of 
ADHD, HKD and epilepsy have not been validated at this time. As can be seen in the 
analysis of methylphenidate prescribing, many study subjects received methylphenidate for 
treatment without a definite diagnosis of ADHD and/or HKD, with only behavioural 
problems recorded in their medical records. The degree of severity and type of behavioural 
problems, such as inattention, hyperactivity or impulsiveness, were also not clearly recorded. 
Hence, it is not possible to establish severity of these conditions from routinely recorded data 
in the computerised primary care database. The first limitation of using a computerised 
database in our studies is that diagnosis may be inaccurate and there may be incompleteness 
o f recording.
Another example regarding diagnosis recording in the database is that children who received 
methylphenidate for treatment had a diagnosis of hearing problems, which also raises 
concerns regarding the reliability of diagnosis in the primary care database (see Chapter 6). 
“Does not seem to listen” is one of symptoms for ADHD/HKD in the ICD-10 and DSM-IV 
criteria (Swanson et al. 1998). As many methylphenidate-treated subjects had a record of 
hearing problems, questions have arisen: have these subjects taken a hearing test? Did these
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subjects simply not seem to listen, or did they actually suffer from hearing problems? These 
questions remain unclear in our present study.
There are other issues that need to be considered in a methylphenidate study. These include:
(i) the difficulty of reaching an accurate diagnosis of ADHD and HKD. Sayal and colleagues 
(2005) have noted that many parents of ADHD children do not openly discuss their concerns 
or anything associated with the condition itself. The authors also stated that many patients 
have not been consulted about this problem in the primary care setting, (ii) the GPRD 
contains data that is collected from day to day clinical practice, so GPs are unlikely to record 
any detailed symptoms associated with ADHD/HKD, (iii) complications of using predefined 
codes that may not cover the appropriate symptoms. All these lead to the possibility of 
inaccuracy of ADHD/ HKD diagnoses and behavioural problems in our studies.
This limitation is also seen in the analysis of anticonvulsant prescription (see Chapter 7). As 
children may have varying degrees of seizure type, the choice of epilepsy treatment will 
depend upon the type of seizure. Ideally, the specific type of seizure and adequate 
information related to epilepsy symptoms should be fully recorded. However, vague and 
unspecific diagnoses of epilepsy appear in the medical files. Consequently, it could not 
investigate the rationale of anticonvulsant treatment in detail. In addition, a lower rate of 
post-mortem examinations was recorded amongst anticonvulsant-treated subjects who died 
during the study period (Chapter 8). It may be that a post-mortem had been performed in 
hospital, but the relevant documents were not entered into the GPs records. Without a post­
mortem report to confirm the actual cause of death, it was difficult to draw any firm 
conclusion that these subjects were true SUDEP cases. The limitation of inaccurate diagnosis 
also raises the concern of co-morbidity diagnoses, as co-morbidities might be potential
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confounders in risk assessment study. As discussed, two questions arise: Firstly, are 
diagnoses valid in our study population? Secondly, have all cases (i.e. ADHD, HKD, epilepsy) 
been identified by the investigator or GPs/specialists? Omission of relevant information in the 
GPRD poses significant limitations in using a computerised primary care database.
In addition, it was not possible to investigate how appropriately the drug has been prescribed 
to children and adolescents. For example, did all subjects with behavioural problems require 
to be treated with methylphenidate? Similarly, due to non-specification of seizure types in the 
medical record, it is not feasible to investigate the rationale of anticonvulsant use in our study 
population. As a result, it is difficult to elucidate any differences between user groups, i.e. 
which anticonvulsants were commonly prescribed for particular seizure types in young 
people.
Although the diagnoses of ADHD/HKD and epilepsy were deemed inconclusive in the 
GPRD, it should be noted that these conditions were initially confirmed by specialists. In the 
GPRD, data is routinely collected from GPs in primary and not secondary care. Also, the 
GPRD is set up for clinical management purposes rather than to accommodate the demands 
of research. Therefore, there will be little obligation upon GPs who enter the data to be aware 
of any associated research needs. Nevertheless, it remains necessary to be aware of 
considerable diagnostic inaccuracy within this routine primary care database.
The second limitation in these studies is that vrescribbm information may be mireliable for 
certain druss. In the GPRD, the prescription data is not quite from a comprehensive list, even 
though all prescriptions issued by GPs are logged. Prescriptions issued during a hospital stay, 
over-the-counter (OTC) drugs or home visits are rarely recorded in the computerised primary
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care database. Prescribing information is important as it helps to measure the levels of 
compliance, to some extent, as well as assist in establishing exposure status for safety studies. 
For certain drugs, the data in the GPRD may be unreliable. This is can be seen in the 
methylphenidate study. Some children might stop taking methylphenidate during the 
weekend (sometimes referred to as a drug holiday) or when symptoms lessen (taken as 
needed). Because the reason for methylphenidate discontinuation was not recorded in the 
database, it is not possible to measure the exposure status. Consequently, this causes 
difficulty in mapping methylphenidate prescriptions for further risk assessment studies. The 
mapped exposure matrix for each individual subject on the database is applied to identify 
subjects who were exposed to methylphenidate on specific days and to calculate the numbers 
of patient years of exposure during each calendar year. In methylphenidate study, establishing 
exposure status using a computerised database is not feasible.
Exposure status of NSAIDs is another example. In the case-control study on severe cutaneous 
reactions (Chapter 9), we were able to identify the exposure status to NSAIDs prescriptions 
recorded in the GPRD, however, prescriptions issued during a hospital stay or over the 
counter (OTC) may be missed. As many NSAIDs can be easily obtained through OTC, it is 
likely that there was a misclassification in terms of exposure status. It should be noted that 
many published studies using GPRD to investigate safety issues in different drugs and the 
exposure status of their use were established. As discussed, it is not feasible to use GPRD to 
carry out risk assessment studies on methylphenidate use in this thesis.
Following on fiom the issue of prescription data, a third limitation associated with this thesis 
arises, that is ti^eatment compliance and non-compliance cannot be established. Compliance 
is particularly important, especially when patients receive anticonvulsants for epilepsy
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treatment, because this is the indicator commonly used to monitor seizure control and 
intolerability. Poor anticonvulsant compliance has been cited as one of the potential risk 
factors associated with SUDEP. It is problematic to establish compliance in our study 
because the recording of prescriptions on the GPRD reflects prescriptions issued by the GPs, 
rather than collection or uptake of the drug.
The socioeconomic status (SES) and ethnicity were reported as important factors associated 
with psychotropic drug use (Efron et al. 2003; Zito et al. 1998; Zito et al. 2000; Zito et al. 
2003; Skurtveit et al. 2005). However, these factors are not available fiom the GPRD version 
(2000) in this thesis, thus the fourth limitation in our studies is the lack o f  data on SES and 
ethnicity. As these factors are not contained in the GPRD, it could not investigate how these 
factors affect the prescribing patterns. Also, this limitation may have an impact on the risk 
assessment study, such as case-control study, with regard to confounding. In the case-control 
study (Chapter 9), we only matched controls for general practice, age and sex, but not 
socioeconomic status. We need to consider these factors when attempting to assess causality 
in risk assessment studies. This limitation could be resolved in a new edition of GPRD. At 
this time, a new link between practices and patients’ postcodes is being established which is 
based upon socio-economic status, derived by the Index of Multiple Deprivation (IMD). This 
can act as a proxy determinant of patient socio-economic status.
As discussed, inaccurate diagnosis and the absence of ethnicity and socio-economic status all 
need to be considered when assessing causality in risk assessment studies. The fifth limitation 
in our studies was issues o f  confoundim. The data in the GPRD is collected from day-to-day 
GP clinical practice, and is unlikely to record all symptoms and signs, as they are not all 
considered significant. As a result, using a computerised primary care database could be
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inadequately controlled for confounding due to insufficient or incomplete information. This 
raises concerns about inadequate controls for confounding in causality assessment. This is a 
particularly important issue in the risk assessment study, such as case-control study.
Although the GPRD contains referrals and hospital admissions information, which specialists 
confirmed the diagnosis and/or symptoms at time of onset and which specialists initiated 
administration of psychotropic drugs remains unclear in our analysis. In addition, other 
psychological interventions performed along with psychotropic drugs cannot be examined. 
This leads to the sixth limitation in our studies: lack o f information on specialists and 
vsvcholosical inteiyentions in the database. This information is especially important in 
paediatric psychiatric research. It has been suggested that investigation should take place into 
whether specialists influence the decision on using psychotropic drugs for treatment or 
psychological intervention in UK practice. The attitude of specialists toward treatment 
options needs to be taken into account when comparing the prescribing patterns between 
different countries.
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Strengths
Despite the limitations, several strengths are associated with using the GPRD in psychiatric 
research, and these include:
(i) Orimnalitv. To our knowledge, this is the first comprehensive study into psychotropic 
drug prescribing in children and adolescents in UK clinical practices. Although previous 
research (Wong et al. 2003) has reported an overall increasing use of psychotropic drugs in 
youths under the age of 19 in the UK, to what extent the individual drug groups were 
involved was not being investigated. This thesis is able to demonstrate prescription trends 
associated with each individual psychotropic drug groups. Research on methylphenidate and 
anticonvulsant utilisation also yielded in-depth understanding in terms of prescribing patterns 
and raised relevant safety issues, which had not been studied in UK practice.
(ii) The GPRD can be representative. The GPRD is a population-based database of primary 
health care in the UK. It provides a large source of longitudinal data from general practices, 
and it has the advantage of data collected at the time of the event, including demographic 
information, clinical events and prescriptions. There were over 3 million person years 
represented for most studies reported in this investigation, therefore the result of our analysis 
can be generalised to represent UK practices.
(iii) The GPRD can be used to investigate rare conditions. The large computerised database 
can be used broadly and efficiently for rare conditions such as SJS, TEN. As the GPRD can 
provide enough data retrospectively, this approach can shorten the time compared to a 
prospective design, which may require up to several years to recruit enough cases to obtain 
robust estimates.
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(iv) Research can be done comparatively quickly and inexpeiisivelv. There are several ways 
to investigate adverse reactions to drugs, such as field studies (collecting data individually) 
and randomized controlled trials (RCT). However, these study designs can add complexity 
with regard to ethical considerations, cost and feasibility. These study designs are also time- 
consuming tasks, whereas use of a large database can minimize time and expense.
(v) Drug utilisation studies can assist in the establishment o f  further risk assessment studies. 
This study design can provide in-depth understanding of drug prescribing trends and, 
consequently, to prioritise further risk assessment studies.
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10.2 Prescribing patterns
Prevalence o f  psychotropic drug prescribing
As there is limited information on psychotropic drug use in children and adolescents in the 
UK general practices, we carried out a cohort analysis to estimate the overall prevalence of 
psychotropic drug prescribing. There was a steadily increased use of psychotropic drugs in 
children and adolescents over the past decade (see Chapter 5). This is growing trend is 
particularly obvious with respect to the use of stimulants (mainly methylphenidate). The most 
common drug group prescribed to our study population was anticonvulsants. However, the 
levels of clonidine and lithium use were comparatively lower throughout the period covered. 
This growing trend has raised concerns, as most psychotropic drugs have not been authorised 
for use in children and adolescents. In addition, the diagnoses of ADHD, mood disorders and 
schizophrenia in children are often difficult (Coyle 2000). This means that some children 
might have received these drugs when indications, dosage and safety information had not 
been approved for use. Some individuals might even have started taking psychotropic drugs 
before accurate diagnoses had been made. Another concern about this rising trend is long­
term adverse effects. As psychotropic drugs are acting on CNS, how these drugs affect 
children in the long-term is still unclear at this time.
Compared with previous studies in North America and continental Europe, it is clearly 
demonstrated that there are marked differences in psychotropic drug prescribing. In the USA, 
the use of clonidine has massively increased (Zito et al. 2000; Zito et al. 2003) whilst its 
usage was comparatively lower in the UK. Although the use of stimulants has shown an 
increase in our analysis, the overall rate of increase was far behind the USA. There are some 
explanations for this situation: Firstly, it could imply that clinicians in the UK tend to use 
other interventions, i.e. psychosocial intervention for ADHD/HKD management, whereas in
216
practices in other countries, such as in the USA, drugs are more likely to be the first line of 
treatment. Secondly, differences in diagnostic criteria also need to be considered for these 
differences in prescribing patterns. It has been suggested that one child in 20 meets the 
diagnostic criteria for HKD in the USA, and about one in 200 does in Europe (Rutter & 
Taylor 2002). This is due to the European clinician using the narrower ICD-9 diagnosis of 
hyperkinetic disorders, while DSM-IV is commonly used in US practices. Consequently, this 
may lead to the use of stimulants (mainly methylphenidate) being less frequent in Europe. 
The differences between ICD-9 and DSM-IV diagnostic criteria are beyond the scope of this 
study, but this factor needs to be considered. Thirdly, cultural differences between countries 
may also play an important role with regard to mental health care (Rutter & Taylor 2000). 
Anticonvulsant use is an example. The majority of our study subjects were issued 
anticonvulsants along with an epilepsy diagnosis. This prescribing practice differs from the 
USA studies (Cooper et al. 1997; Zito et al. 2006). They reported that the increasing use of 
anticonvulsants was in part for the treatment of psychiatric disorders, such as bipolar disorder, 
rather than seizure control. In the UK, several anticonvulsants have been licensed for the 
treatment of psychiatric disorders. However, the majority of our subjects were being 
prescribed anticonvulsants for the treatment of epilepsy. Concomitant use is another example 
demonstrating the difference in prescribing patterns between countries. This is discussed in 
the following section.
Concomitant use o f psychoti^opic drugs
Concomitant use of psychotropic drugs is becoming increasingly prevalent in US practice 
(see Chapter 2). However, this prescribing trend is not evident in our analysis. Findings have 
shown that 80% of study subjects received only one type of psychotropic drug during the 
period covered (Chapter 5). The need to combine with another psychotropic drugs may either
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enhance the treatment efficacy or result in other psychiatric co-morbidities. Previous studies 
have suggested that there is an increase in the use of clonidine and antidepressants as an 
adjunct to methylphenidate (Guevara et al. 2002; Elia et al. 1999; Zito et al. 1999). 
Antidepressants and clonidine are not licensed for the treatment of ADHD, but clinicians 
frequently prescribe these drugs as adjuncts to methylphenidate (Safer et a l 2003). At this 
time, there is insufficient evidence to consider the effect of concomitant use of 
methylphenidate along with these drugs in terms of efficacy and adverse reactions 
(Markowitz & Patrick 2001). However, this prescribing pattern is becoming increasingly 
prevalent in clinical practice.
Concerns need to be addressed with regard to this concomitant prescribing pattern: Firstly, 
the efficacy and adverse reactions of psychotropic drugs concomitantly used is unclear 
(Besag & Berry 2006). For example, risperidone (an antipsychotic) is becoming more 
commonly prescribed along with methylphenidate for ADHD treatment in children. However, 
the efficacy of this concomitant use has not yet been studied (Rutter & Taylor 2002). This 
concern is primarily because of the fact that most psychotropic drugs are metabolised through 
the cytochrome P450 (GYP) system (enzyme inducer or inhibitor), and this may cause drug- 
drug interaction when these drugs are used concomitantly. Tables 10.1 and 10.2 present the 
GYP enzymes involved in the metabolism of psychotropic drugs. This is particularly 
important in patients undergoing anticonvulsant therapy for seizure control, along with other 
psychotropic drugs for the treatment of psychiatric disorders, because inappropriate drug 
combinations may lower the anticonvulsant therapeutic level and lead to poor seizure control 
or enhance toxicity (Monaco & Gicolin 1999). A detailed discussion of drug-drug interaction 
is beyond the scope of this investigation; however, it is another issue which requires to be 
addressed.
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Secondly, several studies have reported the frequency of concomitant use of psychotropic 
drugs, but there is a lack of consensus on concomitant use in terms of the definition of ‘time 
period’. This concern has also been addressed by Safer and colleagues (2003) in a review 
article. Consequently, it is difficult to make any direct comparisons between studies. Our 
major concern with this issue is that inappropriate time period definition would hinder 
plausible interpretations of exposure status in risk assessment studies. In addition, the rate of 
concomitant use might be over-estimated. An example of concomitant use is depicted in 
Figure 10.1 which can assist understanding of this concept.
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Table 10.1 Main CYP isoenzymes involved in metabolism of psychotropic drugs.
Antipsychotics Antdipressants Benzodiazepam Anticonvulsants
CYP2D6 Perphenazine
Haloperidol
Thioridazine
Risperidone
Olanzapine
Bromperidol
Zuclopentixol
Secondaiy and tertiary 
amines of tricyclic acid
CYP1A2 Olanzapine
Clozapine
Pimozide
Tertiary amines of 
tricyclic acid Alprazolam
Bromazepam
Diazepam
CYP3A4 Clozapine Alprazolam Carbamazepine
Pimozide Diazepam Valproic acid
Zotiepine Bromazepam Clonazepam
Ethosuximide
Lamotrigine
Topiramate
Tiagabine
CYP2C19 Imipramine Alprazolam
Diazepam
Zonisaniide
Phenytoin
Table 10.2 Some psychotropic drugs and their effect (inhibition - or induction +)
on CYP isoenzymes
Antipsychotics Antidepressants Benzodiazepam Anticonvulsants
CYP2D6 Olanzapine(-)
Sertindole(-)
Risperidone(-)
Clozapine(-)
Pimozide(-)
Paroxetine(-)
Fluoxetine(-)
Flunitrazepam(-)
CYP3A4 Sertindole(-) Fluoxetine(-) Phenytoin(+)
Risperidone(-) Fluvoxamine(-) Phenobarbital(+)
Primidone(+)
Carbamazepine(+)
Felbamate(+)
CYP2C19 Clozapine(-) Fluoxctine(-)
Fluvoxamine(-)
Felbamate(-) 
Topiramate(-) 
Valproic acid(-)
CYP1A2 Fluvoxamine(-)
No relevant action 
on CYP isoenzymes
Sertraline
Citalopram
Ethosuximide
Tiagabine
Vigabatrin
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Child A
Child B
Figure 10.1 An example of concomitant use patterns.
Concomitant use
ATD MPH MPH
Antipsychotic
ATD
+ + + +
MPH
+
Antipsychotic MPH _
+ + 4- +
Jan Feb Mar Apr May June July Aug Sept Oct Nov Dec 
(month)
A TD: antidepressant 
MPT: methylphenidate
Child A received his/her first methylphenidate prescription during April and June; the second 
methylphenidate prescription was issued from August to December. This child started 
antipsychotic treatment from September onward. According to our concomitant definition, 
Child A is categorized as a concomitant user during October and December whereas Child B 
is not a concomitant user. If the ‘time frame’ of concomitant use is defined as one year, both 
children will be categorised as concomitant users which would lead to over-estimation.
Although previous studies have investigated the concomitant use of psychotropic drugs in the 
paediatric population, the ‘time frame’ was not clearly defined. This can be seen from the 
studies of Safer (1997) and Schirm et al. (2001). Recently, the issue of the definition of 
concomitance has been examined by Tobi and colleagues (2006). They proposed three 
patterns with different time frames: co-prescribing (prescribed on the same day), concomitant
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medication (including same day, within 7 days, 15 days and 30 days), and possible 
concurrent medication (month, quartile, half year, year). Two different types of drug groups 
were investigated: concomitant use of anticonvulsants and antidepressants, and concomitant 
use of antihistamines and penicillin. Their results demonstrated a significant difference within 
three definitions. For example, the use of anticonvulsants and antidepressants, the percentage 
of co-prescribing (on same day) in the year of 2000 was 5.8% (95% Cl 4.99-6.80). The 
concomitant was 6.15 (95% Cl 5.27-7.12) within the 7 day interval to 9.8% (95 Cl 8.79-11.0) 
in the 30 day interval; possible concurrent use was 8.4% (95 Cl 7.35-9.48) in the month 
interval to 14.8% (95% Cl 13.17-15.86) in the year interval. Apart from the differences 
resulting from “time frame”, the combination between different drug groups also influences 
the results. For example, the use of antihistamines and penicillin ranged from 0.5% (95% Cl 
0.4-0.6) to 9.7% (95%C1 9.3-10.2), yielding a factor of 12, whilst the combination of 
anticonvulsant and antidepressants gave a 2.5 factor. The reason for this is that both 
antidepressant and anticonvulsant treatments are long term, whereas the use of antihistamine 
and penicillin are restricted to a short period of time. Their study provided an in-depth 
understanding of the impact of different ‘time frames’ related to concomitant use. However, 
it did not examine how these different definitions influence the prescription mapping.
The concept of prescription mapping is determining whether patients have been exposed to 
the drug of interest. This is particularly vital, especially for the case-control study, to evaluate 
the causality between drugs and adverse reactions. Without a clear definition of concomitant 
time frame, this may cause difficulty in measuring the drug exposure status. Although US 
studies have shown an increase of concomitant psychotropic drug use in the paediatric 
population, since no well-defined “time frame” of concomitant use has been established, 
whether this prescribing trend actually increases or has been over-estimated needs to be
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considered. In conclusion, there is a requirement for an international consensus on time 
period definition in concomitant drug use.
Co-morbidities
In our studies, the analysis of co-morbidities was not limited to psychiatric disorders, but all 
underlying conditions. However, this is not an appropriate to investigate co-morbidities. We 
did not make an attempt to compare the co-morbidity rate in treated group and control group 
or general population. It is difficult to generalise our findings is potentially limited as we only 
described the fi'equency of specific disorders in our study subjects. In addition, we were 
unable to investigate the association between co-morbidity and ADHD or/and Epilepsy: for 
example, whether head injury was the cause of ADHD or head injury was present before the 
development of ADHD. Nevertheless, our initial attempt was to investigate co-morbidities to 
identify any other issues relevant to drug prescribing. The appropriate design would be to 
conduct a study include a case group (outcome of interest) and a control group (patients 
without outcome of interest) to investigate the prevalence of co-morbidity. This result will be 
more informative than without a comparison group.
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10,3 Safety issues of anticonvulsants
As discussed, it is not feasible to conduct a risk assessment study on methylphenidate using 
the computerised primary care database. Hence, after completing the work on two drug 
utilisation studies, we conducted safety studies surrounding anticonvulsant use. Throughout 
the anticonvulsants utilisation study, a small number of cases of death were found in the 
medical record (see Chapter 8). As the SUDEP is commonly related to patients with epilepsy 
patients, and the causes for this phenomena remain unclear at this time, so a descriptive case 
series study was carried out to assess the risk of SUDEP within the anticonvulsant-treated 
subjects.
The SUDEP in children has been demonstrated as being rare in previous studies (Harvey et a l 
1993; Donner et a l 2001). We found that 4 cases out of 150 death subjects were considered 
as possible SUDEP according to Burroughs-Wellcome criteria. It is not easy to compare our 
findings with previous studies as the lack of secondary data (e.g. GP questionnaire, hospital 
summary) to support death of causes and diagnosis of SUDEP cases. In addition, information 
of anticonvulsant therapeutic drug levels and treatment compliance was not recorded in the 
database. These factors have been reported associated with SUDEP. In addition, the absence 
of death certificate was difficult for SUDEP case ascertainment. It needs to be noted that we 
did not send GPs questionnaires and/or hospital letters to confirm the causes of death as these 
information can be obtained through GPRD verification service.
To retrospective evaluate SUDEP cases in primary care database is not recommended. Our 
study has demonstrated an unsuccessful approach to investigate SUDEP. It is suggested that 
hospital based study would be appropriate, as information on diagnosis, treatment, relevant
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potential risk factors and death certificate can be obtained. This approach can avoid the 
limitation we present in our study.
After completing the investigation of SUDEP death, a case-control study was carried out to 
assess the risk of severe cutaneous reactions within anticonvulsant treated children and 
adolescents (see Chapter 9). The reason to investigate this adverse reaction is that during the 
anticonvulsant utilisation study, the level of lamotrigine use increased steadily during the 
study period (1992-2000). The major concern associated with its use in young people is 
severe cutaneous reactions (BNF Children 2005). To date, no population-based study has 
been conducted to investigate the association of this adverse actions and anticonvulsant use in 
children. In the literature, the overall incidence rates of SJS and TEN was from 1.2 cases per 
million to 6 cases per million person-years (Roujeau & Stern 1994). As these conditions are 
considered rare, the case-control study design is deemed to be feasible when a condition of 
interest is rare (Hennekens & Buring 1987). Hence, we carried out a case-control study to 
assess whether there is an increased risk of severe cutaneous reactions (Stevens-Johnson 
syndrome, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis) with 
anticonvulsants use in children and adolescents. We found no evidence to support an 
increased risk of severe cutaneous reactions with anticonvulsant use in children and 
adolescents. Several potential risks have been identified with statistical significant association 
such as recent infections of Chickenpox, Herpes, Measles, Rubella, Streptococcal (2 months 
prior to diagnoses occurred), eczema, prior skin disorders, antibiotics use and hospital 
admission (2 months prior to diagnoses occurred). These results may be informative to assist 
clinicians to evaluate children with cutaneous reactions in practices. It is suggested that 
different study design such as case-crossover should be performed to reassure our findings. In 
addition, it is informative to stratify analyses by each individual anticonvulsant products.
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10.4 What does this thesis contribute?
In recent years, paediatric psychiatric research is becoming important since it deals with 
issues of use of psychotropic drugs off label or unlicensed use. Studies present in this thesis 
are important as there is a paucity of data available in the area of prescribing in children and 
adolescents at this time. The optimisation of prescribing in this population is urgently 
required since it would lead to better outcomes for the child, family and carers.
We demonstrate that drug utilisation studies can be used as an initial approach to investigate 
prescribing trends. The results from drug utilisation studies provide an in-depth 
understanding of how these drugs have being prescribed to young people. In two drug 
utilisations (methylphenidate, anticonvulsants), several issues emerged, such as the definite 
ADHD diagnosis, seizure types and sudden death. These results from drug utilisation studies 
are informative and can enable us to prioritise further risk assessment study.
This thesis also demonstrates the limitations and strengths of using a computerised primary 
care database in this area of research. There are several unsuccessful approaches in this 
thesis, such as SUDEP study using descriptive case series study design. This is mainly due to 
the incomplete causes of death recorded in the database, so we were unable to show the 
actual cause of deaths or any risk factors associated with SUDEP. These unsuccessful 
approaches, however, can prevent future errors in relevant research using the computerised 
primary care database.
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10.5 Recommendations for research
The computerised primary care database has been widely used in pharmacoepidemiology in 
recent years. Since we conducted these studies using the GPRD, several unresolved issues 
surrounding paediatric psychiatric research still remain. The absence of clinical interpretation 
in this thesis needs to be addressed. It is advisable to have a multidisciplinary team 
comprising paediatrician, consultant child and adolescent psychiatrist, public health scientists, 
or neuropsychologists in the project. A clinical understanding of childhood psychiatric 
disorder and the reasons for using these drugs will enable interpretation of the findings to be 
given justice. This is not only limited to our studies present in this thesis; a multidisciplinary 
team should be applied to all studies using the computerised primary care database.
The data from GPRD is robust and the studies in this thesis are pertinent. However, 
paediatric psychotropic drug research has, so far, mainly focused on prescribing trends, 
efficacy and safety. Little attention has been paid to parents and young people’s perspective. 
Survey (interviews or questionnaires) of users’ attitudes to, and knowledge about, 
psychotropic drug is suggested. Combining quantitative results with qualitative results will 
assist us in implementing policy and evaluating educational material for young people and 
their families. The outcome would be to improve patient compliance to medication and 
improve patient satisfaction and understanding of their illness. This approach will enable us 
to “put research into practice”. For instance, it is suggested to use drug utilisation study 
investigating methylphenidate prescribing trends, along with an interview study for young 
people with ADHD which will explore the issues surrounding methylphenidate treatment 
cessation.
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Data from the UK primary care database is a useful starting point to prioritise paediatric 
research; however the uptake of psychotropic drug use in other European countries remains 
clear. Hence, there is a need to understand the extent of these drugs prescribing trends in 
young people at multinational level. Collaboration is advised with other European databases. 
The multinational prevalence comparison would be a useful means of elaborating further 
research on safety studies in this population.
The primary care database is widely used to investigate drug safety. In present study, we only 
used classical case-control study design to assess association between anticonvulsant use and 
the risk of severe cutaneous reactions. No significant association was found, suggesting that 
anticonvulsants use may not induce severe cutaneous reactions. It should be noted that we did 
not confirm the diagnosis of severe cutaneous reactions via GP questionnaire. This raises the 
concern of case validation. Approaches for validating cases from safety study should include 
obtaining additional information from hospital summary or letter and sending questionnaires 
to the GPs. This additional approach can reaffirm the frue cases.
Our approach on co-morbidity analyses is considered not to be an appropriate study design. It 
is suggested conducting a cohort study to compare co-morbidities prevalence in patients with 
epilepsy and patients without epilepsy: similarly, a study to compare co-morbidities 
prevalence in children with ADHD and children without ADHD. Findings from this study 
design will be informative in elaborating further studies surrounding psychiatric research. In 
addition, this information is important for planning health services.
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Chapter 11 Conclusions
We have described the psychotropic drug prescribing patterns for children and adolescents in 
UK practice, in particular methylphenidate and anticonvulsants. Increases may be due to 
several reasons: Firstly, the change of licence status for methylphenidate in 1995. Secondly, 
the availability of newer anticonvulsant drugs in the market during 1990s. Thirdly, 
recognition of these conditions have improved. Comparing this study with those from North 
America, there is variation of prescribing patterns between countries.
Unfortunately, due to the incomplete recording of deaths in the database, we did not provide 
any useful information on sudden death in children with epilepsy. In addition, we did not 
utilise the GPRD verification service to obtain clinical information to confirm actual cause of 
death. Hence, we are unable to draw any firm conclusion regarding sudden death in 
anticonvulsant treated children in our study. There is no evidence to show the association of 
anticonvulsants and severe cutaneous reactions in children and adolescents. Several potential 
risk factors have identified with statiscially significant association. However, suggestion is 
that case-crossover study should carry out to reassure our findings.
This thesis has also demonstrated the feasibility of carrying out epidemiological research 
using a computerised primary care database. Deficiencies of present methodologies are also 
highlighted in our studies. During the process of working on this thesis, the National Quality 
and Outcome Framework (QOF) was introduced as part of the new General Medical Service 
(GMS) contract in April 2004, This scheme does not have direct impact on studies presented. 
It should, however, be noted as the primary care database has recently gained popularity in 
both research and policy implementation. This scheme may have an impact on the quality of 
data entering the database which could probably resolve the limitations present in this thesis.
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In November 2005, a new NHS scheme, Connecting for Health (previously was known as 
National programme for IT), was implemented. This is a new IT delivering system to 
modernise the way the NHS delivers health care and the purpose of this new initiative is to 
provide electronic NHS Care Records for every patient in England. Patients can book 
appointments directly from their GP, and the prescriptions will be sent directly to the 
pharmacy of the patient’s choice. This new initiative is aiming to connect over 30,000 GPs in 
England and more than 300 hospitals over the next ten years. The advantage of this new 
initiative is that it can keep patient health records and pharmacy records electronically. Other 
data, such as patient characteristics (e.g. demographic information) and clinical information, 
will all be stored in the system. This new implementation will provide resources not only for 
better health care management, but within research as well (http://www.dh.gov.ulO. This 
database will be particularly useful in the futher paediatric research, as the records from 
specialists (e.g. hospitals) are linked with GPs, enabling one to frack down which specialist 
confirmed a diagnosis and what psychological interventions have been carried out, along with 
drug treatment.
Collaboration with other countries to document psychotropic drug prescribing patterns is 
suggested. Recently, attention has been drawn to multinational comparisons on prescribing 
patterns. This approach can lead to more understanding of the different prescribing trends 
between countries. Considerable work is still required to ensure that psychotropic drugs can 
be used both safely and appropriately in young people.
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Appendix I
Utilisation and safety of psychotropic drugs in children and adolescents: population- 
based foIlow-uD and case-crossover studies
A) Rationale for the study:
As psychotropic prescribing is uncommon in children and adolescents in primary 
care, to obtain insight in the utilisation patterns and associated risk for adverse clinical events 
a large population-based information source is needed with information from the general 
population regarding drug use, clinical characteristics and clinical events. The GPRD 
provides this population-based information on drug use, diagnoses and symptoms, hospital 
referrals, as well as characteristics such as height, weight, and smoking behaviour. The 
GPRD has been demonstrated to be representative for the population in England and Wales 
with respect to general statistics on disease, age and sex distribution and urban vs rural 
practice, in summary only GPRD can provide a cost effective and sufficient sample size to 
conduct an epidemiological study in children and adolescents with metal illness.
Bi Description of the Database:
The GPRD (previously known as the VAMP Research Database) was set up in 
1987 and is now held by the Medicines Control Agency. It contains complete prescribing and 
diagnostic information fi om a large number of general practices and is the largest database of 
anonymised and longitudinal patient data fiom general practices in the world. Over 200 
published (pharmaco)epidemiology studies have been completed using the database. 
Participating general practitioners enter clinical information, prescriptions, immunisations, 
referrals and test results in a standardised manner into their clinical computing systems. The 
general practices are broadly representative of all practices in the UK in terms of 
geographical distribution, size, age, and sex. The demographic distribution of the population 
covered by the GPRD are similar to the whole UK population. The data available directly 
from the database include all drug prescriptions, repeats and their indications, a record of 
every consultation leading to a diagnosis, prescription or hospital referral, diagnoses, test 
results requested by the GP, and referrals. At present, 270 million patients and a total of 24 
million person-years. The quality of the information in the database has been validated in a 
number of inadequate studies and has been found to be hight. In addition to the electronic 
health record, subject to ethical approval questionnaires can be sent to patients (or their 
parents) via general practitioners, and copies of letters relating to referrals and hospital care
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can be obtained where available with extra cost. The data are held anonymously in the central 
GPRD database, with patient identifiers removed.
The GPRD has been used to successfully identify risk factors for many diseases 
and apart fiom the identification of previously unknown risk factors, known risk factors are 
usually identified in these studies. For instance, in studying the association between AMI and 
exposure to certain drugs, smoking also came out as a risk factor, a high body mass index 
was identified as one of the risk factors for VTE, and antibiotics were associated with liver 
disease using this database. This suggests the GPRD is a valuable resource for drug safety 
research and provides us with a unique opportunity to study safety of drugs that are used in 
children but not commonly so, and to focus on rare but serious adverse events in association 
with these drugs. So far this database has been underused for paediatric drug research, we can 
only identify one other study currently being conducted and funded by the Medical Research 
Council. The Department of Health has endorsed the above view and fully funded the 
principal applicant’s post to explore the potential of the GPRD in paediatiic pharmaceutical 
public health.
Cl Methods:
II Drug Utilisation study;
To characterise prescribing patterns of psychotropic drugs by general practitioners 
to children and adolescents aged <18 in England and Wales.
Study population and data synthesis:
The study population will consist of all children and adolescents aged <18 in the 
GPRD who received a psychotropic between 1-1-1992 and 31-12-2000. The first six months 
of each individual in the study population will be used as a screening period. Subjects who 
did not receive psychotropics during this period but did thereafter will be classified as new 
users of drugs for the relevant psychotropic drug group. Subjects who receive psychotropics 
within these first six months will be classified as prevalent users. An individual will start 
contributing person-time to the study on the date on which they are registered with the 
practice, the practice started contributing data considered to be up to research standard, or 31- 
12-1991, whichever is the latest. An individual will stop contributing person-time to the study 
on the date they left the practice, their date of death, or 31-12-2000, whichever is the earliest.
All prescriptions for psychotropics will be retrieved from the GPRD, psychotropic 
drugs are defined as British National Formulaiy (BNF) Section 4.1-4.3, which includes
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hypnotics and anxiolytics (4.1), drug used in psychosis and related disorders (4.2) and 
antidepressant drugs (4.3). Of these prescriptions, the theoretical end date will be calculated 
fi‘om the amount of medication prescribed and the prescribed daily dosage. In cases where the 
prescribed daily dosage of a drug is not given, this will be estimated as the most commonly 
prescribed daily dosage of that drug in the rest of the database for children/adolescents of the 
same age. Overlapping prescriptions for different psychotropic will be considered to possibly 
indicate a switch fi'om one psychotropics will be considered to possibly indicate a switch 
from on psychotiopic to the other. Wliere probable switches are identified (e.g. 
discontinuation of one SSRI and uptake of another SSRI) the initial psychotropic script will 
be truncated to end on the day the second psychotropic is prescribed. Concomitant 
prescribing of drugs fi'om more than one of the identified categories will be reported as such.
Data analysis;
The following analyses will be presented by psychotropic drug class (anxiolytic 
and hypnotic benzodiazepines, TCAs, SSRIs, other antidepressants, phenothiazines, atypical 
anti-psychotics, and other anti-psychotics). They will be partitioned by age and sex, by new 
versus prevalent users, the indication for which the drugs have been prescribed, and co­
morbidity. Utilisation in neonates is not expected but will be described separately if it is 
identified.
21 Risk assessment studies:
To calculate risk estimates for the association between psychotropic drug use and 
serious adverse clinical events in the same study population.
Analysis;
Within the identified population of psychotropic drug users (refer to 1 Utilisation 
study), a series of risk assessment studies will be carried out using a case-crossover design. 
Following the case-crossover design, the study population consists of exposed individuals 
only. The event rate during their exposed person time is compared with the event rate in their 
unexposed person time. This has been demonstrated to be a valuable study design to identify 
transient and acute effects of drug use. One of the advantages of this design is that most 
confounding factors, such as socio-economic status, environmental factors, co-morbidity and 
to a certain extent confounding by indication, are controlled for. We have considered using a
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control group (i.e. patients without psychiatric exposure); however the case-crossover design 
is more powerful in controlling for such confounding factors.
The following exposure categories will be identified: anxiolytic and hypnotic 
benzodiazepeines, TCAs, SSRIs, other antidepressants, phenothiazines, atypical anti- 
psychotics, and other anti-psychotics. Individuals will be considered to be exposed for the 
duration of drug use (as defined above) plus 14 days. Subgroup analyses will be carried out 
for concurrent exposure to more than one psychotropic drug at a time.
Risk estimates with 95% confidence intervals will be established for all exposures 
and the association with the following outcomes: death, hepatic injury, blood dyscrasias, 
renal failure, cardiac morbidity, and hospital admissions. Only incident cases of each of these 
adverse clinical events will be considered for inclusion in the study. There is considerable 
experience within the Department of Pharmacoepidemiology, University of Surrey in 
identifying these outcomes from GPRD. The following procedure will be used. Initially, all 
potential cases are identified from the database. The medical records of all identified 
individuals are then scrutinised independently by two trained research staff, who will be blind 
to exposure status of the study subject, following carefully produced protocols for in- and 
exclusion. The protocols have been and, for non-existing protocols, will be designed with the 
input fi'om at least one general practitioner as well as at least one hospital consultant with the 
relevant medical background. At least one of these researchers who identified cases for in- 
and exclusion will be medically qualified. Any discrepancies in- or exclusion of cases are 
discussed and, where necessary, a hospital consultant will be asked for their input at this 
stage as well.
In addition, we shall screen the fiequency of adverse clinical events within this 
study population. Any serious adverse clinical event appearing at least 30% more frequently 
than expected from national statistics will be incorporated in the risk assessment studies 
following the same procedures as described above.
Sensitivity analyses will be carried out in which the washout period for 
psychotropic drugs will be changed from 14 to 0 and 28 days; the stability of the risk 
estimates will be reported. All risk estimates will be adjusted for age and, where relevant, 
they will be stratified by sex. Other potential confounders will be adjusted for through the 
case-control study design although the chance of residual confounding by indication cannot 
be ruled out.
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3) Sample size consideration:
The study population will be representative for England and Wales. Over 15,000 
psychotropic drug users aged <19 have been identified with the initial search. Updating of the 
database will be continuing and therefore the drug utilisation study will be adequately 
powered to characterise detailed drug utilisation patterns. Based on the initial number of users 
identified, the population size should enable use to identify at least a doubling in risk of the 
adverse events specified above with a type 1 error of < 5% and 80% power using the case- 
crossover design.
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Appendix II Psychotropic drugs list in GPRD (version 2000)
Stimulant products in GPRD.
Stimulants Formulation Strength
Amphetamine tablets 5mg
Caffeine tablets 15mg, 50mg, 300mg
Caffeine/Dextrose tablets 30mg
Dexamfetamine tablets 5mg
Dexamfetamine capusles 7.5mg, 20mg
Dexamfetamine+ Amphetamine capsules lOmg + lOmg
Dexamfetamine+ Amphetamine capsules 12.5mg
Dexamfetamine+ Amphetamine capsules 20mg
Dexamfetam ine+ Amphetamine capsules 3.75mg + 3.75mg
DexamfetamineH- Amphetamine capsules 6.25 mg + 6.2 5 mg
Dexamfetamine+ Amphetamine capsules 7.5mg
Dexamphetamine sulphate capusles lOmg, 15 mg
Dexamphetamine sulphate tablets 2.5mg, 5mg
Dextroamphetamine tablets 5 mg
Methylphenidate tablets 5mg,10mg, 20mg
Modafmil tablets lOOnig
Pemoline tablets 20mg
Clonidine in GPRD.
Clonidine Formulation Strength
Clonidine injection 150micrograms/ml
Clonidine modified release capsule 0.2 5 mg
Clonidine tablets 0.1 mg, 0.3mg
Clonidine tablets 25micrograms
Clonidine hydrochloride injection 15 meg
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Antidepressant products in GPRD.
Antidepressants Formulation Strength
Amiti'iptyline tablets 75mg, 100mg,200mg,300mg
Amitriptyline capsule 25mg,50mg
Amitriptyline capsule 75mg
Amitriptyline injection 1 Omg/ml
Amitriptyline modified release capsule 25mg
Amitriptyline modified release capsule 50mg
Amitriptyline modified release capsule 75mg
Amitriptyline sugar fiee mixture 10mg/5ml
Amitriptyline sugar free oral solution 10mg/5ml, 25mg/5ml, 50mg/5ml
Amitriptyline tablets 10mg,25mg
Amitriptyline capsule I2.5mg 4- 5mg
Amitriptyline capsule 25mg +1 Omg
Amitriptyline tablets lOmg + 2mg
Amitriptyline tablets 25 mg + 2m g
Amitriptyline S/R syrup 25mg
Amoxapine tablets 25mg,50mg, 1 OOmg, 15 Omg
Butriptyline tablets 25mg,50mg
Chlordiazepoxide+ Amitriptyline capsule lOmg + 25mg
Clilordiazepoxide+ Amitriptyline capsule 5mg + 12.5mg
Citalopram oral drops 40mg/ml
Citalopram tablets 10mg,20mg,40mg
Clomipramine capsule 10mg,25mg,50mg
Clomipramine injection 12.5mg/ml
Clomipramine modified release tablet 75mg
Clomipramine syrup 25mg/5ml
Clomipramine tablets 75mg
Clomipiramine hydrochloride Injection 25mg
Clomipiramine hydrochloride tablets 25mg
Desipramine tablets 25mg
Dibenzepin hydrochloride tablets 80mg
Dothiepin capsule 25mg
Dothiepin sugar fiee elixir 25mg/5ml
Dothiepin sugar fi-ee elixir 75mg/5ml
Dothiepin syrup 25 mg, 1 OOmg
Dothiepin tablets 75mg
Dothiepin hydrochloride elixir 5 Omg
Dothiepin hydrochloride syrup 25mg, 75mg, lOOmg
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Doxepin capsule 10mg,25mg,75mg
Doxepin hydrochloride tablets 15mg
Fluoxetine capsule 20mg,60mg
Fluoxetine liquid 20mg/5ml
Fluphenazine+ Nortriptyline tablets 500mcg + lOmg
Fluvoxamine tablets 5 Omg, 1 OOmg
Imipramine capsule 25mg
Imipramine syrup 25mg/5ml
Imipramine Tablets lOmg,
25mg,50mg,75mg,l OOmg
Imipramine hydrochloride Injection 12.5mg
Imipramine hydrochloride tablets 5 Omg
Iprindole hydrochloride tablets 15mg,30mg
Isocarboxazid tablets lOmg
Lofepramine sugar-free suspension 70mg/5ml
Lofepramine tablets 70mg
L-tryptophan capsule 500mg
Maprotiline tablets 10mg,25mg,50mg,75mg
Maprotiline hydrochloride tablets 75mg
Mianserin tablets 10mg,20mg,30mg
Mianserin hydrochloride tablets 60mg
Mirtazapine tablets 3 Omg
Moclobemide tablets 150mg,300mg
Nefazodone tablets 100mg,200mg
Nomifensine hydrogen maleate capsule 25mg,50mg,100mg
Nortriptyline capsule 10mg,25mg
Nortriptyline elixir lOmg
Nortriptyline liquid 10mg/5ml
Nortriptyline tablets 10mg,25nig
Nortriptyline+ Fluphenazine tablets lOmg + SOOmicrograms
Nortriptyline+ Fluphenazine tablets 3 Omg + 1.5mg
Paroxetine sugar-free suspension 20mg/10ml
Paroxetine tablets 20mg, 3Omg
Perphenazine+ Amitriptyline tablets 2mg + 1 Omg
Perphenazine+ Amitriptyline tablets 2mg + 25mg
Phenelzine tablets 15mg
Protriptyline tablets 5mg, I Omg
Protriptyline hydrochloride tablets lOmg
Reboxetine tablets 4mg
Sertraline tablets 5 Omg, 1 OOmg
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Antîdepressants Formulation Strength
Tranylcypromine tablets Imt, 5 mg, lOmg
Trazodone capsule 50mg,100mg
Antidepressants Formulation Strength
Trazodone controlled release tablet 15 Omg
Trazodone modified release tablet 15 Omg
Trazodone oral liquid 50mg/5ml
Trazodone sugar free liquid 50mg/5ml
Trazodone tablets 15 Omg
Tiifluoperazine+ Tranylcypromine tablets ling + lOmg
Trimipramine tablets 5 Omg
Trimipramine maleate capsule 5 Omg
Trimipramine maleate tablets 1 Omg,25 mg
Tryptophan tablets 5 OOmg
Tryptophan powder 6g
Venlafaxine modified release capsule 75mg, 15 Omg
Venlafaxine tablets 37.5mg, 5Omg, 75mg
Viloxazine hydrochiloride tablets 5 Omg
Zimeldine hydrochloride tablets 100mg,200mg
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Antipsychotic products in GPRD.
Antipsychotics Formulation Strength
Amisulpride oral solution lOOmg/ml
Amisulpride solution lOOmg/ml
Amisulpride tablets 5Omg, 200mg,400mg,
Benperidol tablets 250micrograms
Chlorpromazine injection 25 mg/ml
Chlorpromazine sugar free syrup 25mg/5ml, 100mg/5ml
Chlorpromazine suspension 25mg
Chlorpromazine suppository lOOmg
Chlorpromazine suspension 100mg/5ml
Chlorpromazine syrup 25mg/5ml, 50mg/5ml, 100mg/5ml
Chlorpromazine tablets 10mg,25mg,50mg, 100mg,200mg
Chlorpromazine injection lOmg, 5 Omg
Chlorpromazine mixture lOOmg
Chlorprothixene tablets 15mg,50mg
Clozapine tablets 25mg,100mg
Droperidol elixir 5mg
Droperidol injection 5mg/ml
Droperidol liquid 1 mg/ml
Droperidol sugar free liquid 1 mg/ml
Droperidol tablets lOmg
Flupentixol tablets 0.5 mg, ling
Flupentixol tablets 500 micrograms
Flupentixol decanoate injection 100mg/ml,20mg/ml,200mg/ml
Flupentixol decanoate injection 40mg/2ml
Flupentixol hydrochloride tablets 3mg
Fluphenazine tablets Img, 2.5mg,5mg
Fluphenazine decanoate conc. injection 1 OOmg/ml
Fluphenazine decanoate injection 12.5mg
Fluphenazine decanoate injection 25mg/ml, 1 OOmg/ml
Fluspilene injection 2mg/ml
Haloperidol capsules 0.5mg
Haloperidol capsules 500micrograms
Haloperidol injection 20mg
Haloperidol injection 5mg/ml,l Omg/ml
Haloperidol liquid 5mg
Haloperidol liquid lmg/ml,2mg/ml
Haloperidol oral liquid 1 mg/ml,2mg/m 1,1 Omg/ml
Haloperidol oral liquid concentr 1 Omg/ml
Haloperidol oral solution 2mg/ml
241
Haloperidol sugar free liquid 1 mg/ml,2mg/ml
Haloperidol sugar free oral solu Img/ml, 1.5mg/5ml, 1 mg/5ml,2mg/5ml
Haloperidol Tablets 1.5mg,5mg,10mg,20mg
Antipsychotics Formulation Strength
Haloperidol tablets SOOmicrograms
Haloperidol injection 1 OOmg/ml
Haloperidol decanoate injection 5 Omg/ml, 1 OOmg/ml
Loxapine capsules 10mg,25mg,50mg
Methotrimeprazine injection 25mg/ml
Methotrimeprazine tablets 25 mg
Olanzapine dispersible tablet lOmg
Olanzapine dispersible tablet 5mg,10nig
Olanzapine tablets 2.5mg,5mg,7.5mg, 10mg,40mg
Pericyazine syrup 10mg/5ml
Pericyazine tablets 2.5mg,10mg,25mg
Pericyazine elixir 2.5mg
Pericyazine injection 1%
Perphenazine injection 5mg/ml
Perphenazine sugar free syrup 2mg/5ml,4mg/5ml
Perphenazine tablets 2mg,4mg,8mg
Perphenazine F/C injection 8mg
Perphenazine F/C tablets 8mg
Pimozide tablets 2mg,4mg,10mg
Pipotiazine palmitate depot injection 50mg/ml
Prochlorperazine maleate modified release cap 10mg,15mg
Promazine injection 5 Omg/ml
Promazine sugar free syrup 50mg/5ml
Promazine suspension 50mg/5ml
Promazine syrup 12.5mg/5ml,25mg/5ml,50mg/5ml
Promazine tablets 25mg,50mg,100mg
Promazine hydrochloride tablets 25mg
Quetiapine tablets 25mg, 1 OOmg, 150mg,200mg
Remoxipride capsules 150mg,300mg
Remoxipride capsules 75mg
Risperidone liquid 1 mg/ml
Risperidone tablets 3mg
Risperidone tablets 0.5mg,lmg,3mg,4mg,6mg
Sertindole tablets 4mg, 12mg, 16mg,20mg
Sulpiride sugar free elixir 200mg/5ml
Sulpiride tablets 200mg,400mg,5 OOmg
Thiopropazate hydrochloride tablets 5mg,10mg
242
Thioproperazine mesylate tablets 5mg,10mg,25mg
Thioridazine sugar free syrup 25mg/5ml, 100mg/5ml
Thioridazine suspension 100mg/5ml
Thioridazine suspension 25mg/5ml
Thioridazine syrup 10mg/5ml
Thioridazine syrup 25mg/5ml
Antipsychotics Formulation Strength
Thioridazine syrup 50mg/5ml
Thioridazine tablets lOOmg
Thioridazine tablets lOmg
Thioridazine tablets 25mg
Thioridazine tablets 5 Omg
Thioridazine elixir 750mg/5ml
Thioridazine S/F syrup 50mg
Trifluoperazine concentrate 1 Omg/ml
Trifluoperazine injection 1 mg/ml
Trifluoperazine modified release cap 2mg,10mg,15mg
Trifluoperazine capsule 2mg,10mg,15mg
Trifluoperazine sugar free syrup 5mg/5ml
Trifluoperazine syrup 5mg
Trifluoperazine syrup lmg/5ml
Trifluoperazine tablets lmg,5mg
Trifluperidol tablets 0.5mg,lmg,2mg
Zotepine tablets 25mg,50mg, 1 OOmg
Zuclopenthixol oily injection 50mg/ml,200mg/ml,500mg/ml
Zuclopenthixol tablets 2mg,10mg,25mg
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Anticonvulsant products in GPRD.
Anticonvulsants Formulation Strength
Acetazolamide capsules 25 Omg
Acetazolamide modified release capsule 250mg,500mg
Acetazolamide powder
Acetazolamide syrup 40mg/ml
Acetazolamide tablets 25 Omg
Acetazolamide sodium injection 500mg/vial
Beclamide tablets 5 OOmg
Carbaniazepine liquid lOOmg
Carbamazepine suppository 125mg,250mg
Clobazam capsules 2.5mg, 5mg,7.5mg
Clobazam suspension Img
Clobazam tablets 5mg
Clomethiazole intravenous infusion 8mg/ml
Clonazepam injection Img
Clonazepam oral drops 2.5 mg/ml
Clonazepam sugar fiee oral solution 2mg/5ml
Clonazepam suspension 5 OOmicrograms/5 ml
Clonazepam tablets 0.5mg,2mg
Clonazepam tablets 500 micrograms
Diazepam injection 10mg,20mg
Diazepam injection 10mg/2ml, 5mg/nil
Diazepam injection (emulsion) 5mg/ml
Diazepam injection (solution) 5mg/ml
Diazepam rectal tubes 2.5mg,5mg, 10mg,20mg
Diazepam suspension 10mg/5ml
Diazepam suspension lmg/5ml,10mg/5ml,2.5mg/5ml
Diazepam syrup 2mg/5ml,5mg/5ml
Diazepam tablets 2mg,5mg,10mg
Diazepam 2ML injection 5 mg
Diazepam emulsion 
10mg/2ml injection lOmg
Diazepam rectal solution 2mg,4mg
Diazepam S/R capsules lOmg
Ethosuximide capsules 3 OOmg
Ethosuximide capsules 25 Omg
Ethosuximide syrup 250mg/5ml
Ethotoin tablets 5 OOmg
Fosphenytoin concentrate for injection 75mg/ml
Gabapentin capsules 1 OOmg,3 00mg,400mg
Gabapentin tablets 600mg,800mg
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Lamotrigine dispersible tablet 2mg,5mg,25mg, 1 OOmg
Lamotrigine tablets 25mg,50mg, 100mg,200mg
Levetiracetam tablets 250mg,500mg,1000mg
Lorazepam injection 4mg/ml
Lorazepam suspension Img
Lorazepam tablets 0.5mg, 5mg
Lorazepam tablets lmg',2.5mg
Methylphenobarbital tablets 30mg,60mg,200mg
Oxcarbazepine tablets 150mg,300mg,600mg
Paraldehyde injection 10ml
Paramethadoine capsules 3 OOmg
Phénobarbital elixir 15mg/5ml,50mg/5ml
Phénobarbital injection 15mg/ml
Phénobarbital injection 200mg/ml
Phénobarbital injection 3 Omg/ml
Phénobarbital injection 60mg/ml
Phénobarbital tablets 15mg,3 0mg,60mg, 1 OOmg
Phenobarbitone capsules 15mg,30mg,50mg,60mg, 1 OOmg
Phenobarbitone elixir 5mg,30mg
Phenobarbitone mixture 5 Omg
Phenobarbitone tablets 5mg,7.5mg, 1 Omg, 15mg,20mg,50mg, 1 OOmg
Phenobarbitione+Phenytoi
n
capsules 60mg
Phenytoin capsules 25mg,50mg, 100mg,300mg
Phenytoin paediatric tablets 5 Omg
Phenytoin sugar-free suspension 90mg/5ml
Phenytoin suspension 30mg/5ml
Phenytoin syrup 25mg
Phenytoin tablets 30mg,50mg,100mg
Phenytoin sodium capsules 25mg,5 Omg, 100mg,3 OOmg
Phenytoin sodium injection 5 Omg/ml
Phenytoin sodium tablets 5 Omg, 1 OOmg
Phenytoin+ phénobarbital capsules 1 OOmg + 5 Omg
Piracetam capsules 400mg
Piracetam film coated tablets 800mg,1200mg
Piracetam solution 33%
Primidone oral suspension 250mg/5ml
Primidone tablets 200mg,250mg
Sodium valproate crushable tablets lOOmg
Sodium valproate EC tablets 200mg
Sodium valproate EC tablets 5 OOmg
Sodium valproate enteric coated tablets 200mg,500mg
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Anticonvulsants Formulation Strength
Sodium valproate IV injection 400mg
Sodium valproate sugar free liquid 200mg/5ml
Sodium valproate sugar free oral solution 200mg/5ml
Sodium valproate syrup 200mg/5ml
Sodium valproate tablets 200mg,500mg
Sodium valproate C/R tablets 200mg
Sodium valproate controlled release tablet 200mg,300mg,500mg
Sodium valproate modified release tablet 200mg,300mg,500mg
Sultliiame mixture 50mg
Sulthiame suspension 5 Omg
Sulthiame tablets 50mg,200mg
Tiagabine tablets 5mg,10mg,15mg
Topiramate capsules 15mg,25mg,50mg
Topiramate tablets 25nig,50mg, 100mg,200mg
Troxidone capsules 300mg
Valproic acid
enteric coated soft gelatin 
capsules 150mg,300mg,500mg
Vigabatrin capsules 125mg
Vigabatrin sachets 5 OOmg
Vigabatrin sugar free powder 5 OOmg
Vigabatrin tablets 5 OOmg
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Lithium in GPRD.
Lithium Formulation Strength
Lithium capsule 25 Omg
Lithium liquid lO.mmol
Lithium tablets 800mg
Lithium chloride solution 400mg
Lithium carbonate modified release tablet 200mg,300mg,400mg,450mg
Lithium carbonate sustained release tablets 400mg
Lithium carbonate tablets 200nig,250mg,300mg,400mg,450mg
Lithium citrate CR tablets 564mg
Lithium citrate liquid 520mg/5ml
Lithium citrate modified release tablet 564mg
Lithium citrate solution 1018g/5ml
Lithium citrate solution 509mg/5ml
Lithium citrate sugar fiee liquid 1.018g/5ml
Lithium citrate sugar free liquid 509mg/5ml
Lithium citrate sugar free liquid 520mg/5ml
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Appendix III Codes used to identify epilepsy and seizure type based on ILAE 
classification (GPRD, version 2000)
Read/OXMIS code Read/OXMIS term Seizure types
F251200 Epileptic Seizuies-Clonic Generalized seizure
F250100 Pykno-epilepsy (childhood absence epilepsy) Generalized seizure
F253.00 Grand mal status Generalized seizure
F251100 Neonatal myoclonic epilepsy Generalized seizure
F250.00 Generalised nonconvulsive epilepsy Generalized seizure
F251300 Epileptic seizures-myoclonic Generalized seizure
F251400 Epileptic seizures-Tonic Generalized seizure
F251500 Tonic-clonic epilepsy Generalized seizure
F251600 Grand mal seizure Generalized seizure
F251y00 Other specified generalised convulsive epilepsy Generalized seizure
F251z00 Generalised convulsive epilepsy NOS Generalized seizure
F252.00 Petit mal status Generalized seizure
F251011 Tonic-clonic epilepsy Generalized seizure
2828 Absence seizure Generalized seizure
3450 Epilepsy nonconvulsive generalized Generalized seizure
3450A Seizure akinetic/myoclonic Generalized seizure
3450PM Petit mal Generalized seizure
3450T Epileptic absence Generalized seizure
3451 Grand mal epilepsy Generalized seizure
3459BA Idopathic epilepsy Generalized seizure
7802D Seizure dystonie Generalized seizure
F250011 Epileptic absences Generalized seizure
2823 O/E - petit mal fit Generalized seizure
F250000 Petit mal (minor) epilepsy Generalized seizure
2946.11 O/E - atonic muscle Generalized seizure
2979 O/E - myoclonus Generalized seizure
2993.11 O/E - ataxic gait Generalized seizure
F132.00 myoclonus Generalized seizure
F132y00 other specified myoclonus Generalized seizure
F132z00 Myoclonus NOS Generalized seizure
F132zl2 Myoclonic seizure Generalized seizure
F250z00 Generalised nonconvulsive epilepsy NOS Generalized seizure
2822 O/E - Grand mal fit Generalized seizure
3450AD Drop attack Generalized seizure
F258.00 Post-Ictal state Generalized seizure
F250400 Juvenile absence epilepsy Generalized seizure
7852P1 Post ictal state Generalized seizure
Fyu5000 [X]Other generalized epilepsy and epileptic syndromes Generalized seizure
3450TA Absence attack Generalized seizure
G65..11 Drop attack Generalized seizure
F256.00 Infantile spasms (West's syndrome) Generalized seizure
78031S Infantile spasm (West's syndrome) Generalized seizure
F392y00 Other specified myotonic disorder Generalized seizure
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Read/OXMIS code Read/OXMIS term Seizure types
F250500 Lemiox-gastaut syndrome Generalized seizure
3453P Epilepsy peripheral Partial seizures
F255311 Partial epilepsy with autonomic symptoms Partial seizures
F255400 Visual reflex epilepsy Partial seizures
F255z00 Partial epilepsy without impairment of consciousness NOS Partial seizures
F257.00 Kojevnikov's epilepsy Partial seizures
F255000 Jacksonian, focal or motor epilepsy Partial seizures
2824.11 O/E - Jacksonian fit Partial seizures
3453A Seizure Jacksonian Partial seizures
7G05411 Epilation NEC Partial seizures
721B500 Epilation of eyelash Partial seizures
E201500 Hysterical seizures Partial seizures
3453BC Epilepsy temporal benign centro childhood Partial seizures
2824 O/E - Focal (Jacksonian) fit Partial seizures
3453T Temporal lobe epilepsy Partial seizures
3459AB Abdomen convulsive equivalent (Epilepsy) Partial seizures
3459CL Epilepsy climacteric Partial seizures
Eu06013 [XJLimbic epilepsy personality Partial seizures
F255500 Unilateral epilepsy Partial seizures
2825 O/E - psychomotor fit Partial seizures
3001RE Seizure hysterical Partial seizures
F25y300 Complex paiital status epilepticus Partial seizures
282..13 O/E - a seizure Partial seizures
7803MJ Jerks myoclonic Partial seizures
3453AT Epilepsy automatism Partial seizures
F254000 Temporal lobe epilepsy Partial seizures
2932 Psychosis epileptic Partial seizures
F25y400 Benign rolandic epilepsy Partial seizures
2824.12 O/E - focal fit Partial seizures
F255011 Focal epilepsy Partial seizures
F255012 Motor epilepsy Partial seizures
F25y200 Locl-rlt (Foc)(part) idiop epilep&epilptic syn seiz loci onset Partial seizures
K1293 Epilation eyelash Partial seizures
F25yl00 Gelastic epilepsy Partial seizures
F254100 Psychomotor epilepsy Partial seizures
F254300 Limbic system epilepsy Partial seizures
F254400 Epileptic automatism Partial seizures
F255200 Somatosensoiy epilepsy Partial seizures
F254z00 Partial epilepsy with impairment of consciousness NOS Partial seizures
F255300 Visceral reflex epilepsy Partial seizures
F255.00 Par tial epilepsy without inipariment of consciousness Partial seizures
F254.00 Partial epilepsy with impairment of consciousness Partial seizures
F253.il Status epilepticus Status epilepticus
Fyu5200 pCJOther status epilepticus Status epilepticus
Fyu5900 [X] Status epilepticus, unspecified Status epilepticus
3452 Status epilepticus Status epilepticus
F25X.00 Status epilepticus, unspecified Status epilepticus
7802MA Neonatal convulsion Unclassified seizures
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7802A Febrile convulsion Unclassified seizures
7802FE Seizure febrile Unclassified seizures
7802MA Neonatal convulsion Unclassified seizures
SC20000 Traumatic epilepsy Unclassified seizures
3459N Nocturnal epilepsy Unclassified seizures
3459M Migraine epilepsy Unclassified seizures
667B.00 Nocturnal epilepsy Unclassified seizures
Q480.12 Seizures in newborn Unclassified seizures
Eu80300 [X]Acquired aphasia with epilepsy [Landau-Kleffner] Unclassified seizures
3459A Post-traumatic epilepsy Unclassified seizures
342 E Parkinsonian epilepsy Unclassified seizures
3032EP Epilepsy alcoholic Unclassified seizures
F25y000 Cursive (running) epilepsy Unclassified seizures
3459D Ischaemic epilepsy Unclassified seizures
7802A Febrile convulsion Not in ILAE classification
3459 Epilepsy convulsions Not in ILAE classification
3459F Fit epileptic Not in ILAE classification
3459C Epileptic coma Not in ILAE classification
3459R Epilepsy resolved Not in ILAE classification
7802 Convulsion Not in ILAE classification
6678 Epilepsy treatment changed Not in ILAE classification
F25y.OO Other forms of epilepsy Not in ILAE classification
F25yz00 Other forms of epilepsy NOS Not in ILAE classification
F25Z.00 Epilepsy NOS Not in ILAE classification
F25z.ll Fit (In known epileptic) NOS Not in ILAE classification
R003.00 [DJConvulsions Not in ILAE classification
R003000 [DJConvulsions, febrile Not in ILAE classification
ROOSzOO [DJConvulsion NOS Not in ILAE classification
R003zll [DjSeizure NOS Not in ILAE classification
F25..00 Epilepsy Not in ILAE classification
6671 Initial epilepsy assessment Not in ILAE classification
667Z.00 Epilepsy monitoring NOS Not in ILAE classification
667D.00 Epilepsy control poor Not in ILAE classification
6679 Epilepsy treatment started Not in ILAE classification
667A.00 Epilepsy tr eatment stopped Not in ILAE classification
7802E Seizure Not in ILAE classification
6677 Epilepsy drug side effects Not in ILAE classification
6674 Epilepsy associated problems Not in ILAE classification
667..00 Epilepsy monitoring Not in ILAE classification
6672 Follow-up epilepsy assessment Not in ILAE classification
2126000 Epilepsy resolved Not in ILAE classification
1473 H/0: Epilepsy Not in ILAE classification
13ZD.00 Eye witness to epileptic seizure Not in ILAE classification
1296 FH: Epilepsy Not in ILAE classification
7802LL SPELLS (meaning seizures) Not in ILAE classification
7802FT FIT (meaning seizure) Not in ILAE classification
7802F Convulsion febrile Not in ILAE classification
7802EA Epileptiform attacks Not in ILAE classification
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667C.00 Epilepsy control good Not in ILAE classification
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